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1. Introduction 
 
1.1. Biological medicinal products 
 
Recombinant monoclonal antibodies are currently rated as important and growing 
class of biological medicinal products. Many of them have been already approved 
and marketed, being used in different therapeutic areas such are oncology, auto-
immune and inflammatory disorders, cardiovascular disorders, organ transplants, etc. 
and many of them are undergoing different phases of clinical studies1, 2.  
Biological medicinal products, also known as biologics, are products for which the 
active substance has been made by or is derived from a living organism and often 
represent the cutting edge of medicinal science and research. They can be 
composed of sugars, nucleic acids, proteins or complex combination of these 
substances, or they may be living entities such as cells or tissues. In contrast to 
chemically synthesized small molecules, which have a well-defined structure and can 
be thoroughly characterized, biological products are complex in structure, and thus 
are usually not fully characterized3. 
Therapeutic biological products include wide range of medicinal products such as 
monoclonal antibodies and related substances designed as targeted therapies in 
cancer and other diseases, cytokines, growth factors, enzymes, immunomodulators 
and thrombolytics, therapeutic immunotherapies,  proteins intended for therapeutic 
use that are extracted from animals or microorganisms, including recombinant 
versions of these products, allergenic extracts, blood and blood components, gene 
therapy products, human tissue and cellular products used in transplantation, 
vaccines, devices and test kits3,4 
Often the term “biologics” is used more restrictively, referring to classes of 
medications that are produced by means of biological processes involving 
recombinant DNA technology.  
In addition, to represent a class of products produced by modern biotechnological 
techniques in 1980s originated other term known as “biopharmaceuticals”. 
Biopharmaceutical may be defined as proteins or nucleic acid based pharmaceuticals 
used for therapeutic or in vivo diagnostic purposes and produced by means other 
than direct extraction from a non-engineered biological source. 
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According this definition biopharmaceuticals comprise proteins based-products 
produced by genetic engineering, recombinant monoclonal antibodies, nucleic acid 
based drugs used in gene therapy and antisense technology. Proteins obtained by 
direct extraction from native sources and cell based products are excluded from this 
definition5.  
Biomedical research today focuses on cellular and gene-based biologics, given that 
they may make it possible to treat a variety of medical conditions, including diseases 
for which no other treatments are available. In the EU gene and somatic cell therapy 
medicinal products, as well as tissue engineered products, are summarized under 
the term advanced therapy medicinal products, and, as special expertise is needed 
for their development, EMEA will establish the Committee for Advanced Therapies to 
review their future marketing authorization applications6. 
Due to developments in targeted therapies, genomics and proteomics - amongst 
others - the recombinant therapeutic protein market has experienced great 
expansion. By 2003, 140 recombinant therapeutic proteins including recombinant 
mAbs, had gained approval for general human use in the EU and/or US with 
approximated global market of $30 billion, approximately double its global value in 
19997,8. However, in 2007, global prescription sales of biopharmaceuticals increased 
to more than $75 billion, while twenty-two rDNA derived products including targeted 
oncology therapies, autiomune agents antidiabetic agents and pure vaccines, 
generated sales exceeding $1 billion9.  
A small number of cell based products continue to gain marketing approval and one 
antisense based product; fromivirsen (Vitravene®, ISIS Pharmaceuticals) has been 
approved.  In 2003 the first gene therapy product, human adenovirus engineered to 
contain the human p53 tumor suppressor gene (Gendicine®), indicated for the 
treatment of head and neck squamos cell carcinoma, gained approval in China10.  
 
1.1.1. rDNA derived therapeutic proteins 
 
Over the past quarter century, advances in molecular biology, and genetic 
engineering led to rapid growth in the availability of recombinant protein products. 
Invention of restriction endonucleases and transformation of E.coli cells with 
recombinant plasmid by Boyer and Cohen in 1973 represented key events for the 
development of recombinant DNA technology11-13. Shortly after that, recombinant 
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human insulin, the first medicinal product obtained by rDNA technology, gained 
marketing authorization (1982, Humulin, Eli Lilly), followed by somatropin, rhGH, 
produced by Genentech under trade name Protropin® - the first recombinant 
pharmaceutical product to be manufactured and marketed by a biotechnology 
company14,15.   
These events set an entire industry into motion, to produce not only natural proteins 
for treatment of deficiency-associated diseases such as insulin or hGH, but also 
variety of products-from hormones and enzymes to receptors, vaccines, 
anticoagulants, cytokines, fusion proteins and monoclonal antibodies to treat a broad 
range of clinical indications thought untreatable just two decades ago16.  
There are many advantages of recombinant therapeutic proteins over traditional 
drugs consisting primarily on their improved safety, efficacy and cost issues. Unlike 
most low molecular weight pharmaceuticals, these proteins are developed not 
because of the novelty of their structures, but because of the novelty of their 
actions17. For the replacement therapy protein recombinant protein drugs are obvious 
choice, while when an agonist action is needed, they are generally preferred option.  
On the other hand, production of protein with identical sequence to its naturally 
produced counterpart reduces the possibility of complications resulting from antibody 
production against sequence variants resulting from species-to-species variation of 
molecular structure. Furthermore, innadequate preparation purity, for example of 
porcine or bovine insulin, can cause allergic reactions due to the presence of animal 
proteins. Recombinant human insulin is chemically identical to endogenous insulin 
and is free of pancreatic contaminants, therefore is less immunogenic than purified 
pork insuline18.  
Problems related to shortages and limited supplies, as well as iatrogenic Creutzfeldt-
Jakob disease (CJD) acquired after the use of growth hormone (GH) obtained from 
pituitary glands sourced from autopsy material are avoided with the replacement of 
NPA growth hormone with rhGH20. Furthermore, concerns regarding the infectious 
disease risk of plasma-derived concentrates such are HIV and hepatitis B and C, can 
be overcome by the development of recombinant clotting factors.  
Targeted bioengineering strategies are developed to improve functional activity, half 
life and immunogeneicity of exististing recombinant proteins, and this combined with 
advances in alternative recombinant protein production in transgenic animals could 
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result not only in improved clinical profile of these drugs, but it could yield to and 
affordable supply and increased availability to broader populations, as well21. 
Of the 32 new products, between 2002-2006, 12 have been re-engineered to have 
either an altered amino acid sequence or post-translational modification of parental 
structure, i.e. to ensure constant and prolonged release of insulin, long- acting insulin 
analog detemir (Levemir®) devoid of insulin B30 threonine residue and with a C14 
fatty acid attached to B29 lysine, was designed.  Substitution of 9 amino acid 
residues with additional pegylation in native hGH was needed, to obtain hGH analog 
pegvisomant (Somavert®).  This analog has antagonistic effect, and is used for the 
treatment of acromegaly while PEG-ylation increases its serum half life22, 23. 
Reduction or elimination of antibody immunogeneicity and enhancement of human 
effector functions were the primary goals of the antibody structure modification and 
numerous marketed rmAbs resulted form this strategy22. 
rDNA therapeutic proteins are large and hydrophilic molecules and they face 
numerous obstacles to entering bloodstream, such are biological membranes, 
stomach acid and enzymes. Therefore, they are administered parenterally. In order 
to avoid disadvantages of parenteral administration, nonparenteral delivery of rDNA 
proteins is being actively studied and some products reached commercialization, i.e. 
rh-Insulin inhalation powder was the first inhalable insulin product to be marketed24.  
In Table 1.1 a list of representative recombinant therapeutic proteins has been  
presented.  
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Therapeutic category rDNA product Trade name, Manufacturer Expression system Therapeutic indication 
Haemopoietic Growth factors 
 
 
 
 
 
Human Interferons 
 
 
 
Interleukin related molecules 
Epoetin alfa 
Epoetin beta 
Darbopoetin alfa 
Methoxy-PEG-Epoetin beta 
Filgrastim 
Pegfilgrastim 
Interferon alfa-2a 
Peginterferon alfa-2a 
Interferon alfa-2b 
Interferon beta 1-a 
Anakinra 
Oprelvekin 
Epogen®/Amgen 
NeoRecormon®/Roche 
Aranesp®/Amgen 
Mircera®/ Roche 
Neupogen®/Amgen 
Neulasta®/Amgen 
Ropheron A®/ Roche 
Pegasys®/Roche 
Peg-Intron®/Schering 
Avonex®/Biogen Idec 
Kineret®/Amgen 
Neumega®/Wyeth  
CHO 
CHO 
CHO 
CHO 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
CHO 
E.coli 
E.coli 
Anemia 
Anemia 
Anemia 
Anemia 
Chem. induced neutropenia 
Chem. induced neutropenia 
Cancer/Hepatitis 
Cancer/Hepatitis 
Cancer/Hepatitis 
Multiple sclerosis 
Rheumatoid arthritis 
Chem. induced thrombocytopenia 
rmAbs and fusion Proteins*     
 
 
 
 
Hormones of therapeutic 
interest 
 
Insulin human  
Insulin lispro 
Insulin aspart 
Insulin glargine 
insulin detemir 
Somatropin 
Follitropin alfa, r-hFSH 
Follitropin beta, r-hFSH 
Lutropin alfa, r-hLH 
Actrapid®/Novo Nordisk 
Humalog®/Eli Lilly 
NovoRapid®/Novo Nordisk 
Lantus®/Sanofi-Aventis 
Levemir® /Novo Nordisk 
Omnitrope®/Sandoz  
Gonal-F®/Serono 
Puregon®/Organon 
Luveris®/Serono 
S.cerevisiae 
E.coli 
S.cerevisiae 
E.coli 
S.cerevisiae 
E.coli 
CHO 
CHO-K1 
CHO 
Diabetes 
Diabetes 
Diabetes 
Diabetes 
Diabetes 
Growth disturbance 
Anovulation, IVF 
Anovulation, IVF/ET 
LH, FSH deficiency 
Blood coagulation factors Eptacog alfa, rFVIIa 
Moroctocog alfa, rFVIII 
Nonacog alfa, rFIX 
NovoSeven®/N.Nordisk 
Refacto®/Genetics Institute 
BeneFIX®/Wyeth 
BHK 
CHO 
CHO 
Hemophilia 
Hemophilia A 
Hemophilia B 
Thrombolitics and 
Anticoagulants 
Alteplase, r-tPA 
Tenecteplase 
Lepirudin 
Drotrecogin alfa,r-h APC 
Antitrombin alfa 
Activase®/Genetech 
TNKase®/Genetech 
Refludan®/Pharmion  
Xigris®/Eli Lilly 
aTryn®/LeoPharma 
CHO 
CHO 
S.cerevisiae 
HEK293 
Transgenic goat 
Acute myocardial infarction 
Acute myocardial infarction 
Anticoagulation 
Severe sepsis 
Venous thromboembolism 
Recombinant Enzymes Imiglucerase 
r-h a-galactosidase A 
Cerezyme®/Genzyme 
Fabrazyme®/Genzyme 
CHO 
CHO 
Gaucher disease 
Fabry disease 
r Vaccines r-HPV vaccine Gardasil®/Sanofi MSD S.cerevisiae HPV infection prevention 
Table 1.1. List of representative recombinant therapeutic proteins. 
*Comprehensive list of recombinant monoclonal antibodies and fusion proteins is presented in Table 1.2. 
CHO: Chinese hamster ovary. FSH: Follicle stimulating hormone. LH: Luteinizing hormone. IVF: in vitro  fertilization. ET: Embryo transfer. 
 rh: Recombinant human. BHK: Baby hamster kidney. tPA: Tissue plasminogen activator. APC: Activated protein C.HEK: Human embryonic kidney.  
HPV: Human papilloma virus 
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1.2. Therapeutic recombinant monoclonal antibodies and related products 
 
Among other therapeutic proteins, antibodies currently play an important role in the 
treatment of many diseases such are cancer, infectious diseases, allergy, 
autoimmune diseases, and inflammation. There are many reasons which make these 
molecules very attractive for commercial development. First, their action is specific, 
generally leading to fewer side effects. Second, in order to achieve efficient delivery 
to target site, and thus reduce potential side effects, antibodies can be conjugated 
with other therapeutic entities such are immunotoxins or chemotherapy agent. 
Furthermore, for specific diagnostic purposes they may be conjugated with 
radioisotopes. Finally, technology advancement has made complete human MAb 
available, which are less immunogenic25. 
 
1.2.1. Antibody structure and classification  
 
Naturally occurring antibodies (immunoglobulins) are roughly Y-shaped glycoprotein 
molecules and comprise four polypeptide chains, two identical heavy chains and two 
identical light chains (Fig. 1.1).  
One Fc (fragment crystallisable) and two identical Fab (fragment antigen-binding) 
fragments can be produced by papain proteolytic cleavage of the hinge in an intact 
antibody molecule. Papain cleaves IgG above the hinge region containing the 
disulfide bonds that join the heavy chains, but below the site of the disulfide bond 
between the light chain and heavy chain. This generates two separate monovalent 
Fab fragments and an intact Fc fragment. However, to produce an F(ab')2 fragment, 
IgG is digested with pepsin, which cleaves the heavy chains near the hinge region. 
One or more of the disulfide bonds that join the heavy chains in the hinge region are 
preserved, so the two Fab regions of the antibody remain joined together, yielding a 
divalent molecule, hence the designation F(ab')2. The light chains remain intact and 
attached to the heavy chain. The Fc fragment is digested into small peptides26.   
 
1.2.1.1.Classes of immunoglobulins 
 
Based on differences in the amino acid sequences in the constant region of heavy 
chains (γ, μ, α, δ and ε) immunoglobulins can be divided into five different classes, 
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B  
Amino- terminal 
Carboxy- terminal 
A  
C  
IgG, IgM, IgA, IgD and IgE, known as isotypes. Immunoglobulin isotypes differ as 
well in the number and localisation of disulfide bridges and in their glycosilation 
pattern, furthermore, no hinge region is present in IgM and IgE but they have an 
additional heavy chain constant region27.  
 
 
 
 
Most immunoglobulins are monomers, but IgA and IgM are respectively, dimmers 
and pentamers linked by J chains. IgGs are the most abundanta and widely used for 
therapeutic purposes. 
 
1.2.1.2. Immunoglobulin subclasses 
 
IgGs are further divided into several subclasses: IgG1, IgG2, IgG3, and IgG4 (in 
order of relative abundance in serum plasma)25. The four subclasses show more than 
Fig. 1.1. IgG antibody structure and fragmentation. A. Intact IgG molecule, B. Papain cleaves IgG 
above the hinge region but below the site of the disulfide bond between the light chain and heavy 
chain generating  two monovalent Fab fragments and an intact Fc fragment, C. Pepsin cleaves the 
heavy chains near the hinge region generating bivalent F(ab')2 fragment and degraded Fc fragment. 
Reference [26], slightly modified.  
 - 8 -
95% homology in the amino acid sequences of the constant domains of the γ-heavy 
chains but show marked differences in the amino acid composition and structure of 
the hinge region which determines the flexibility of the molecule. Hinge-dependent 
Fab-Fab and Fab-Fc flexibility may be important in triggering further effector functions 
such as complement activation and Fc receptor binding28.  There are two types of 
light chains: kappa (κ) and lambda (λ). In human immunoglobulins the average κ to λ 
ratio is 2:1. 
IgG1 hinge region has 15 amino acids and 2 disulfide bonds while IgG2 has a shorter 
hinge region, with 12 amino acid residues and 4 disulfide bridges which invokes 
restricted the flexibility of IgG2 molecule29. IgG3 differs from the other subclasses by 
its unique extended hinge region with 11 disulfide bridges, while the hinge region of 
IgG4 is shorter than that of IgG130,31.  In addition to differences among genes 
encoding the IgG subclass proteins, each with different amino acid composition and 
derived properties, mutations within these genes have led to variations of the 
composition of IgG subclass proteins within the population. The latter mutations 
provide the basis for genetic markers (called Gm allotypes) and correspond with 
minor differences in primary amino acid sequence between molecules of one IgG 
subclass that occur throughout a species. Among individuals, different allelic forms 
are expressed. Subclass IgG3 is the most polymorphic, with thirteen Gm3 allotypes, 
IgG2 has only one allotype, whereas no allotypes have been detected on the heavy 
chains of IgG432. In addition there are three allotypes of human κ light chains, Km(1), 
Km(2) and Km (3). There are four IgG1 allotypes located on the heavy chain: G1m 
(1); G1m (2); G1m (3) and G1m (17) based on amino acid residues at positions 356, 
358, 431 and 214. Substitution of Lys214 with Arg214 changes allotype G1m (17) to 
G1m (3) and a change of Asp356, Leu358 to Glu356, Met358 changes the allotype G1m 
(1) to the isoallotype nG1m (1) which is homologous to IgG2 in this region.  
There are several reasons to be concerned about immunoglobulin allotypes with 
regard to the engineering of antibodies for therapy, i.e.  when a patient has a different 
immunoglobulin allotype from the therapeutic monoclonal antibody then there is an 
increased potential for an antiglobulin response, directed to both the constant region 
and the variable region. One approach to avoid anti globulin response is to select the 
most common allotype for general use33.  
 
 
 - 9 -
1.2.2. Disulfide bonds 
 
IgG1 molecules have four interchain disulfide bonds-two connecting the two heavy 
chains at the hinge region and the other two connecting the two light chains to the 
heavy chains. Immunoglobulins have four intrachain disulfide bonds within each 
domain (two Fab and one Fc, domain), therefore overall, 12 intrachain bonds: each 
light chain two and heavy chain 4 disulfide bridges, respectively. Native IgG mAb's, 
with completely formed disulfide bonds, should not bear any free sulfhydryl 34.  
 
1.2.3. Oligosaccharides 
 
IgG has a single N-linked bianntenary complex oligosaccharide structure at Asn297 
which is buried between the CH2 domains, forming extensive contacts with amino 
acid residues within CH235.   
One of the most important structural features of recombinant monoclonal antibodies 
produced in mammalian cells is the N-linked oligosaccharide profile. These profiles 
impact recombinant therapeutics in a multitude of ways affecting distribution, efficacy, 
and immunogenicity36. Effector mechanisms mediated through FcγRI, FcγRII, and 
FcγRIII and C1q are severely compromised or ablated for aglycosilated or 
deglycosilated forms of IgG. It was documented that the interaction of effector ligands 
with IgG-Fc is through the protein moiety; however, generation of required IgG-Fc 
conformation is dependent of the oligosaccharide.37 
Carbohydrate heterogeneity introduced during fermentation of recombinant 
monoclonal antibodies can include differential addition of fucose, alternative 
mannose branching linkages, differential presence of terminal galactose residues 
(termed G0, G1, G1’ and G2, molecular species), and sialylation38.  
Differentially sialylated glycoprotein may display attenuated pharmacokinetics, owing 
to carbohydrate binding to asyalo-glycoprotein receptor and mannose receptor 
expressed in the liver where desialylated glycoproteins are sequestered and undergo 
rapid catabolism39. Presence of galactose residues in the non-reducing terminals of 
N-linked oligosaccharides affects antibody-dependent cellular cytotoxicity (ADCC) 
which is a major function of some therapeutic antibodies. ADCC was improved by the 
absence of fucose (fuc) residue at the innermost Glc-NAc of reducing end and by the 
presence of N-acetyl glucosamine38. It was demonstrated that and increased G0 
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oligosaccharide (lacking terminal galactose) level on the rituximab molecule is 
associated with a reduction in biological activity as measured by a complement 
dependent cytotoxicity (CDC) asay40.  On the other hand 10-fold increase in ADCC 
was observed for remodeled trastuzumab and rituximab With high (>80%) bisecting 
GlcNAc content41.High mannose, α-gal and other oligosaccharide species are highly 
immunogenic and in most cases should be minimized during antibody 
manufacturing36. 
 
1.2.4. Basic functions of antibodies 
 
There are two functional areas in immunoglobulin G molecules: variable (V) and 
constant (C) regions (Fig 1.1 and 1.2). Variable regions of the two heavy and light 
chains, composed of two beta sheets and loops connecting the beta strands, offer 
two identical antigen binding sites. Regions with highest variability values in a 
multiple alignment of antibody sequences or complementarity determining regions 
(CDRs) are responsible for antigen recognition and binding25, 42.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The remaining regions of V domain containing the two beta sheets and non CDR 
loops are referred as framework regions (FR). The CDRs in each chain are held in 
Fig. 1.2. IgG antibody structure. Acording reference [42]. 
A. IgG structure, showing two identical heavy (H) chains and two identical light chains (L) and their 
domains: VL, CL, VH, CH1, CH2, and CH3. The Fv fragment, indicated by a square, is the portion of 
the molecule that interacts with the antigen. It is composed by non-covalent pairing of VL and VH.  
B. Fv fragment shown from the antigen view indicating the placement of the hypervariable loops and 
CDRs. 
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close proximity by the framework regions and, with the CDRs from the other chain, 
contribute to the formation of the antigen binding site43. 
The constant domains are not involved directly in antigen binding, but are involved in 
various effector functions, which can be divided in two categories:  
1. Effector functions that operate after the binding of antibody to antigen 
(involve participation of the complement cascade or Fc receptor (FcR)- 
bearing cells), and 
2. Effector functions that operate independently of antigen binding (these 
functions confer persistence in the circulation and the ability to be 
transferred across cellular barriers by transcytosis) 44. 
The interaction of antibodies and antibody-antigen complexes with cells of the 
immune system effects a variety of responses including antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). ADCC 
functions are mediated by Fc receptors, which bind the Fc fregion of an antibody. 
Three subclasses of receptors for IgG antibodies are identified: FcγRI (CD64), FcγRII 
(CD32), and FcγRIII (CD16). The binding site on human antibodies for FcγR has 
been mapped to “lower hinge region” consisting of residues 233-23945. On the other 
hand, C1q and two serine proteases, C1r and C1s, form the complex C1, the first 
component of the complement dependent cytotoxicity pathway. It is suggested that 
the region comprising amino acid residues 318-337 might be involved in the 
complement fixation46.   
Another type of receptor is the neonatal Fc receptor (FcRn). This receptor, expressed 
in the liver, mammary gland and adult intestine plays key role in IgG homeostasis 
and half life. FcRn acts as salvage receptor binding and transporting pynocytosed 
IgGs in intact form within and across cells and rescues them from biodegradation. 
Furthermore, FcRn plays a role in the passive delivery of IgG from mother to young47. 
 
1.2.5. Polyclonal-derived antibody therapeutics 
 
Human or animal-derived polyclonal antibody therapeutics are today are widely used 
in medicine for viral and toxin neutralization and for replacement therapy in patients 
with immunoglobulin deficiencies48. Human plasma-derived hyperimune 
immunoglobulin is used for prophylaxis or therapy against infections with hepatitis B 
virus (Nabi-HB®), respiratory syncytial virus (RSV) (Respigam®), cytomegalovirus 
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(CMV) (Cytogam®) and rabies virus (BayRab®), as well as tetanus (BayTet®), 
botulinum intoxication  and Rhesus D (RhD) alloimmunization. The disadvantages of 
these products are that the limited range of infectious diseases could be treated, 
potential risk of infectious disease transmission and their high production cost. 
In order to overcome these limitations animal-derived immunoglobulins have been 
used. i.e, Rabbit and Equine anti-thymocyte immunoglobulins, Thymoglobulin® and 
Lymphoglobulin®, are used as immunosuppressivs for treatment or prevention of 
solid organ transplant rejection. 
As hyper-immunised serum contains a mixed population of antibodies, polyclonal 
antibody preparations are considered efficacious as they can neutralise multiple 
epitopes on the disease causing agents. However, due to the inherent risks 
associated to their use in humans such are hypersensitivity, anaphylaxis, anti-animal 
response and transmission of infectious pathogens including prions, their application 
is limited49.  
 
1.2.6. Development of recombinant monoclonal antibody therapeutics  
 
Monoclonal antibodies as a highly specific naturally evolved molecules that recognise 
and eliminate pathogenic and disease antigens, are widely used for the treatment 
and prophylaxis of diseases such as infection, cancer and autoimmune disorders50. 
Today monoclonal antibody technologies allow the development of an antibody 
against any target of choice and provide the ability for an unlimited supply of a single 
antibody of reproducible affinity and specificity49.  
The discovery of hybridoma technology by Kohler and Milstein in 1975 revolutionized 
the development of specific antibodies for clinical use51. This ingenious approach 
involves fusing antibody producing B-cells with an immortal, non-antibody secreting 
plasma cell (myeloma) line resulting in a population of hybrid cells, hybridomas that 
are selected for secretion of an antibody specific for an antigen of interest. Non-
antibody secreting plasma cell line is deficient in hypoxanthine phosphoribosyl 
transferase (HPRT) and when fused to B-cells and placed in medium containing 
hypoxanthine-aminopterin-thymidine (HAT), the aminopterine poisons the de novo 
purine synthesis pathway. Unfused cells die, and only the hybridomas survive in 
HAT, while the B-cell component of the hybridoma provide the purine salvage 
pathway and the plasma cells contribute unlimited in vitro proliferation52. 
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Supernatants of bulk cultures of hybridomas are then screened for the presence of 
antibodies of interest, usually by ELISA and finally monoclonal antibody is produced 
either in vivo in the rodent ascites fluid or in vitro in different bioreactors53. 
 
1.2.6.1. Murine monoclonal antibodies 
 
After the development of hybridoma technology, first murine monoclonal antibody, 
muromonab CD3 (OKT3), gained FDA approval in 1986 for clinical use in humans. 
Since then the number of approved antibodies, as well as mAbs in clinical trials, has 
steadily increased54. To date, three therapeutic murine mAbs have been approved by 
FDA or EMEA: muromonab-CD3 (Orthoclone OKT3®) used in transplant rejection 
therapy; antineoplastic, tositumomab-I131 (Bexxar®), and antineoplastic ibritumomab 
tiuxetan conjugated with Y90 or In111(Zevalin®).  
However, murine monoclonal antibodies have properties which limit their clinical 
utility:  
- Murine mAbs administered to humans induce an immunogenic response, 
referred to as human anti-mouse antibodies (HAMA) or human anti-globulin 
antibodies (HAGA)  
- Murine mAbs have reduced therapeutic efficacy (comparing to human mAbs), 
due to relatively faster clearance. 
- Murine mAbs exhibit weak effector functions: ADCC and CDC 
 
1.2.6.2. Chimeric recombinant monoclonal antibodies  
 
In order to overcome disadvantages of murine monoclonal antibodies, i.e. reduce 
immunogeneicity, extend half-life and increase effector functions, chimeric mAbs, 
consisting of rodent variable domains fused to human constant domains are 
designed using recombinant DNA technology 55.   
In 1997 FDA approved the first chimeric antibody against CD 20- rituximab 
(MabThera®) 56.  
Chimeric mAbs are less immunogenic than their fully murine counterparts. This is 
achieved by replacing of murine antibody with about 60-70% of human antibody. 
However, they are still immunogenic and administered to humans can elicit human 
anti chimeric antibody (HACA) response. Mechanism of action of chimeric 
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monoclonal antibodies is very complicated. The murine variable regions including 
Fab portion of molecule, are responsible for antigen recognition and binding. On the 
other hand, activation of complement system and the recruitment of killer cells can 
take place as a result of human Fc fragment mediated effector functions of rmAb.  
Half-lives of chimeric antibodies in humans range from about 4 to 15 days, 
somewhere between half-lives of human (around 24 day) and murine antibodies (1 to 
4 days) 57.   
 
1.2.6.3. Humanised recombinant monoclonal antibodies 
 
Due to relatively short half-lives of chimeric antibodies as compared to human 
antibodies, the assumption is that the their mouse variable regions are still antigenic 
to humans. Therefore, many mouse antibodies have been “humanized” for 
therapeutic use in humans.  
Antibody humanisation consist in grafting the complementarity-determining regions 
(CDRs) or hypervariable loops that can potentially interact with the target molecule 
from a non-human, parental antibody to a human acceptor antibody.  
In this process, which is known as “antibody reshaping” as well, human antibody is 
genetically engineered to contain only the antigen binding site from the murine 
antibody of desired specificity58. Humanised antibody contains only the CDRs of the 
murine antibody, but the framework regions (as well as constant regions) of a human 
antibody and is considered superior to chimeric antibodies because the murine 
contribution (and hence the immunogeneicity) is reduced to minimum.  
There is a delicate balance between specificity and humanization and in order to 
save the antibody specificity computer modelling is often used to overlay human 
amino acid sequences on mouse framework structures do determine what gene 
family of framework regions might least distort the CDRs52.  
Apart from CDR grafting, which is paradigm of humanisation and current standard in 
the field, other rational and empirical methods for antibody humanisation have been 
reported42.  
CDR grafting of both heavy and light chains of therapeutic antibody alemtuzumab 
was reported in 1988, while one year later was humanized the first FDA approved 
therapeutic monoclonal antibody daclizumab59. To date about half of approved 
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monoclonal antibodies in different therapeutic areas are humanized monoclonal 
antibodies (Table 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although humanized monoclonal antibodies are about 95 % human, they are still 
immunogenic. The marketed humanized monoclonal antibodies show a range of 
human anti human(ised) (HAHA) antibodies from 0 to 34 % of patients.   
The fact that the only currently marketed fully-human antibody, adalimumab directed 
against TNFα, shows significant HAHA response in patients61, documents that even 
so-called 100 % human biologicals are potentially immunogenic.  
 
1.2.6.4. Fully-human monoclonal antibodies 
 
Adalimumab, a human antibody selected by the phage display technique against 
tumor necrosis factor alfa (TNFα) was the first marketed fully-human monoclonal 
antibody62.  
In general there are two different approaches to make fully human monoclonal 
antibodies: in vivo and in vitro approaches.  
The in vivo process is based on the immunization of a transgenic mouse. Transgenic 
mice possess human IgG germlines instead of the normal murine germlines. The B 
cells harvested after immunization can be immortalized by fusion with a myeloma cell 
Fig. 1.3. Antibody engineering. According reference [60] 
Mouse monoclonal antibodies generated by mouse hybridoma technology 
Chimeric, humanised and human antibodies generated by recombinant DNA technology 
Fully human antoibodies can be generated human antibody library technology, transgenic mouse 
technology and  human hybridomas. 
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line, as in traditional hybridoma technology and resulting hybridomas can then be 
screened for specific antibodies. While only one antibody derived from this 
technology has been already marketed (panitumumab), a large number are in the 
development phase50, 54.  
The in vitro process is based on screening the library of antibodies against an 
immobilized target. The nonbinding phage antibodies are washed away and the 
recovered antibodies are amplified by infection in Escherichia coli. The antibody 
format for screening is either Fab or single-chain Fv. The antibody fragments 
themselves can be used as therapeutic agents, but they can also be converted into 
intact immunoglobulins by the cloning of the variable genes into plasmids 
incorporating the constant-region genes of immunoglobulins. The genes are 
transfected into cell lines and therefore produce fully human immunoglobulins. 
Human mAbs can also be produced from human hybroidomas or human B-
lymphocyte cell lines immortalized by Epstein-Barr virus63, 64. 
 
1.2.6.5. Immunoconjugates 
 
Recombinant mAbs currently approved for the treatment of malignancies exhibit   
varying levels of activity in several tumour types. However, efficient and prolonged 
intratumoral mAb uptake due to different biological and binding site barriers and 
antigen heterogeneity, remain problem for mAb therapeutic efficacy. In addition, even 
when accumulation of a mAb in the target tissue is achieved, therapeutic efficacy is 
often limited by the extent to which ADCC, CMC or induction of signalling events 
leads to cell death65. In order to increase therapeutic efficacy unmodified mAbs are 
armed with drugs, toxins and radionuclides. Already, three recombinant monoclonal 
antibody conjugates have been approved for cancer therapy:  two 
radioimmunoconjugates, ibritumomab tiuxetan, Zevalin® (a CD20-specific IgG1 κ 
radiolabeled with 90Y) and tositumomab, Bexxar® (a CD20-specific IgG2aλ 
radiolabeled with 131I) and one immunotoxin, gemtuzumab ozogamicin (Mylotarg®)65 
Immunoconjugates are examples of antibodies designed to specifically deliver their 
toxic load directly to cancer cells. Recombinant mAbs armed with various toxins such 
as doxorubicin, calicheamicin and maytansines, currently are being studied65. 
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1.2.6.6. Engineered antibody fragments 
 
Advances in biomolecular engineering i.e. phage display technique and in vitro 
human antibody library approach, allow efficient isolation of different antibody 
fragments such are single chain variable (scFv) and Fab fragments, diabodies, 
triabodies and minibodies. These engineered smaller fragments exhibit increased 
affinity and specificity to almost any kind of antigen, they are less immunogenic and 
have superior biodistribution and blood clearance properties and have great potential 
to be used as diagnostic and therapeutic agents. Another advantage of these 
techniques is the ability to select specific antibodies against toxins, drugs, cytokines 
and other targets that cannot, for various reasons, be injected into an animal to raise 
an immune response, one of which is that the target might kill the animal or that it 
might not be immunogenic at all50, 60. Currently there are two antibody fragments 
approved for therapeutic use: platelet aggregation inhibitor, chimeric Fab, abciximab 
(ReoPro®), and antiangiogenic agent, humanized Fab ranibizumab (Lucentis®) used 
for the treatment of macular degeneration. Many of these prooducts are currently in 
the clinical and preclinical development66.  
 
1.2.7. Fusion proteins 
 
Fusion proteins referred also as immunoadhesins are chimeric antibody like 
molecules that combine the functional domain of a binding protein, usually a 
receptor, ligand, or cell adhesion molecule, with immunoglobulin constant domains 
usually including the hinge, and Fc regions. The functional domain of protein 
(adhesin portion) determines target specificity and Ig- part confers IgG-like effector 
functions of molecule. Human fusion proteins are a novel class of biological agents 
and provide an alternative to human monoclonal antibodies as agents that recognize 
and neutralize proteins that possess pathological functions67. 
The simplest fusion protein design combines the binding region of the adhesin 
protein with the hinge and Fc regions of an IgG heavy chain (Fig. 1.4).  Resulting 
protein is a homodimer, which resembles an IgG antibody, but lacks CH1 domains 
and light chains. For human fusion proteins, IgG1 subclass has been used most 
frequently because γ1-immunoadhesins are amenable to purification by Protein A 
chromatography67, 68. 
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On the other hand, various binding proteins that react with ligands of interest can be 
used as adhesion partners. Such proteins are extracellular domain of human CTLA-
4, extracellular ligand-binding domain of the human TNF receptor, extracellular 
domain sequences of the Il-1 type 1 receptor and Il-1 receptor accessory protein, 
among others69-7.  
As human fusion proteins are based on human sequences of adhesin and Ig-part of 
molecule, there are minimally immunogenic to humans. This property is important 
advantage for indications that require multiple administrations. In addition, in contrast 
to chimeric or humanized monoclonal antibodies, construction of fusion proteins is 
straightforward and affinity for ligand is retained or even increased67. 
To date, four fusion proteins have gained approval for use in the different clinical 
settings: etanercept (Enbrel®), abatacept (Orencia®), alefacept (Amevive®) and 
rilonacept (Acralyst®). 
Fig. 1.4. Structure of prototype fusion protein. According reference [67]. 
ECD, TM, and CYT refer to the extracellular, transmembrane, and cytoplasmic domains, respectively 
The N-linked carbohydrate chain at Asn-298 within the CH2 domain is shown, as are the intrachain 
disulfide bonds. 
Receptor- and IgG1-derived sequences are indicated by shaded and unshaded regions, respectively. 
To construct the fusion protein, the receptor ECD is fused to the IgG hinge (DKTHTCPPCP sequence).  
In the fusion protein abatacept, hinge region cysteines are replaced with serines, therefore intrachain 
disulfide bonds are located in the receptor ECD part.
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1.2.8. Approved therapeutic recombinant monoclonal antibodies and fusion 
proteins  
 
Currently, the US Food and Drug Administration has approved 21 monoclonal 
antibodies and 4 fusion proteins for targeted cancer therapy, autoimune and 
inflamatory diseases, antiviral prophylaxis etc. About 400 pre-approval clinical 
studies are ongoing, so it is to expect that the increase in approval of antibody 
therapeuticals will not slow down in the near future72. 
 
1.2.8.1. Monoclonal antibodies targeting cancers  
 
Recombinant monoclonal antibody treatment of human malignancies today consists 
in two approaches: Specific or targeted antibody therapy in combination with 
classical chemotherapy is used for the destruction of cancer cell either by specifically 
targeting the tumour or the vasculature that nourishes the tumour. The most common 
cancer targets are HER2/ (c-erb-2) receptor, epidermial growth factor receptor 
(EGFR), vascular endothelial growth factor (VEGF) and CD20 and CD52.  Specific 
and highly cytotoxic immunoconjugates on the othert hand, target CD33 and CD 20. 
 
1.2.8.2. Anti-inflammatory monoclonal antibodies 
 
For the treatment of auto-immune diseases specific antibodies and fusion proteins to 
inhibit detrimental effect of cytokines, B and T cell receptors and modulate T-cell co-
stimulatory pathway, have been approved. Approved recombinant antoibodies and  
fusion protein for diferent  therapeutic indication are presented in Table 1.2.   
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Monoclonal antibody Trade name/ 
Manufacturer 
Approval status 
  FDA    EMEA 
Antibody type 
 
Specificity 
(Target antigen) 
Therapeutic indication 
Muromonab CD-3 Orthoclone OKT3® 
(Ortho Biotech) 
  1992      ― Murine IgG2a* CD3 complex on mature T-
lymphocytes 
Immunosuppressive therapy. 
Allograft rejection 
Rituximab  Mabthera® (Roche)   1997    1998 Chimeric IgG1** B-cell antigen CD20  Non-Hodgkin’s Lymphoma 
Rheumatoid arthritis 
Daclizumab Zenapax® (Roche)   1997    1999 Humanized IgG1 anti-
Tac antibody*a 
Alfa subunit of  
Interleukin- 2 receptor 
Prophylaxis of acute  
organ rejection 
Basiliximab Simulect® (Novartis)   1998    1998 Chimeric IgG1κ*a Interleukin-2 receptor α-
chain (CD25 antigen) 
Prophylaxis of acute  
organ rejection 
Palivizumab Synagis® (Abott)   1998     1999 Humanized IgG1κ*b Epitope of the fus. protein of 
res.syncytial virus RSV) 
Respiratory syncytial virus 
(RSV) disease prevention 
Infliximab Remicade® 
(Centocor B.V.) 
  1998     1999 Chimeric IgG1κ*a  TNFα, soluble and 
transmembrane form 
Rheumatoid arthritis, 
Crohn’s disease, psoriasis 
Trastuzumab Herceptin® (Roche)   1998     2000 Humanized IgG1κ** HER2/ (c-erb-2) receptor Breast cancer 
Gemtuzumab ozogamicin 
(calicheamicin derivative)  
Mylotarg® (Wyeth)   2000     2004# Humanized IgG4, 
immunoconjugate*c 
CD33 antigen Acute myeloid leukaemia 
(AML) 
Alemtuzumab 
 
MabCampath® 
(Genzyme) 
  2001     2001 Humanized IgG1κ** Lymphocyte cell surface 
glycoprotein (CD52). 
B-cell chronic lymphocytic 
leukaemia (B-CLL) 
Ibritumomab tiuxetan 
90Y-radiolabelled 
Zevalin® (IDEC)   2002     2004 Murine IgG1κ** 
(recombinant) 
B-cell antigen CD20 CD20+ follicular B-cell non-
Hodgkin's lymphoma  
Adalimumab Humira® (Abott)   2002     2003 Fully human IgG1** Cell surface TNF receptors 
 
Rheumatoid arthritis, 
Crohn’s disease, psoriasis 
Omalizumab Xolair® (Novartis)   2003     2005 Humanized IgG1κ** Immunoglobilin E Asthma therapy 
Iodine I131-Tositumomab Bexxar® (Glaxo SK)   2003     2005# Murine IgG2aλ*b B-cell antigen CD20  Follicular lymphoma 
Efalizumab Raptiva® (Serono)   2003     2004 Humanized IgG1κ** CD11a subunit of LFA-1 on 
activated T-lymphocytes 
Chronic plaque psoriasis 
Abciximab ReoPro®(Centocor)   2003       ― Chimeric Ab Fab 
fragment*a 
Glycoprotein (GP) IIb/IIIa 
receptor of platelets 
Cardiovascular disease 
Prevn. of cardiac ischaemia 
Table 1.2. Approved therapeutic monoclonal antibodies and fusion proteins. According references [73][74][75] #Orphane medicinal product designation (EMEA). 
 INN: International Nonproprietary Name. 
Expression system: *murine ascites; *amurine myeloma cell line SP/20; *bmurine myeloma cell line; *crecombinant murine plasmacytoma cell line ( KD1); 
 **Chinese Hamster Ovary (CHO) cells; **aSource: XenoMouse® Expression: CHO;  ***Escherichia coli. 
TNFR-IgG1: Extracellular ligand-binding portion of human tumor necrosis factor receptor (p75) fused to the Fc portion of human IgG1. 
LFA-3-IgG1: First domain of the human LFA-3 protein fused to the Fc portion of human IgG1. 
CTLA4-IgG1: Extracellular domain of human cytotoxic lymphocyte associated antigen 4 (CTLA-4) protein fused to the Fc portion of human IgG1. 
IL-1R1 IL-1RacP-IgG1:Extracellular domains of IL-1R1 receptor and IL-1 receptor accessory protein (IL-1RacP) fused to the Fc portion of human IgG1. 
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Cetuximab Erbitux® (Imclone)   2004     2004 Chimeric IgG1*b 
 
Human epidermal growth 
factor receptor (EGFR)  
Colorectal and squamous 
cell cancer of head and neck 
Bevacizumab Avastin® (Roche)   2004     2005 Humanized IgG1κ** 
 
Human vascular endothelial 
growth factor (VEGF)  
Metastatic colorectal, breast, 
lung and renal carcinoma 
Natalizumab Tysabri® (Biog Idec)   2004     2006 Humanized IgG4 κ*b α4β1 and α4β7 integrin Relapsing multiple sclerosis 
Ranibizumab Lucentis® (Novartis)   2006     2007 Humanized Fab  
fragment of  IgG1*** 
Human vascular endothelial 
growth factor A (VEGF-A) 
Neovascular age-related 
macular degeneration  
Panitumumab Vectibix® (Amgen)   2006     2007 Fully human IgG2**a Human epidermal growth  
factor receptor (EGFR) 
Metastatic carcinoma of the 
 colon or rectum 
Eculizumab Soliris® (Alexion Eu)   2007     2007 Humanized 
IgG2/4κ*a 
Human C5 complement 
protein 
Paroxysmal nocturnal 
haemoglobinuria (PNH) 
Certolizumab pegol 
 
Cimzia® (UCB Inc)   2008      ― Humanized, PEG*** 
conjugated Fab’ frag.  
TNF alfa Crohn’s disease  
Fusion protein, INN 
 
Trade name/ 
Manufacturer 
Approval status 
  FDA   EMEA 
Fusion protein type Specificity 
(Target antigen) 
Therapeutic indication 
Etanercept Enbrel® (Immunex)   1998    2000 TNFR-IgG** Human TNFα and 
Lymphotoxin (LTα) 
Rheumatoid arthritis, 
Psoriasis 
Alefacept Amevive® (Astellas)   2003      ― LFA-3-IgG** CD2 on T-lymphocytes Moderate to severe chronic 
plaque psoriasis 
Abatacept Orencia® (Bristol-
Mayers) 
  2005    2007 CTLA4-IgG** B7 molecules (CD80 and 
CD86 receptors) 
Rheumatoid arthritis 
Rilonacept Arcalyst® 
(Regeneron) 
 2008     2008# IL-1R1IL-1RacP-IgG** Interleukin IL-1β  
 
Cryopirin-Associated 
Periodic Syndromes 
 
 
Continued from the previuos page
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1.2.9. Nomenclature of monoclonal antibodies 
 
According the relevant guidelines for the assignment of the unique non-proprietary or 
generic names for medicines, the following scheme has been developed for 
monoclonal antibodies 76, 77:  
- General stem/suffix is used for mAbs antibodies and fragments, -mab 
- Sub-stems for source of product (product source identifiers): human (-u-); rat (-a-); hamster 
(-e-); primate (-i-); mouse (-o-); chimeras (-xi-); humanized; (-zu-); rat/mouse (-axo-); 
combination of humanized and chimeric chains (-xizu-). 
These identifiers are used as infixes preceding the -mab suffix stem, e.g.: -umab 
(human); -omab (mouse); -ximab (chimera); -zumab (humanized). 
- Sub-stems for disease or target class: bacterial (-ba(c)-); cardiovascular (-ci(r)-); 
immunomodulator (-li(m)-); infectious lesions (-le(s)-); viral (-vi(r)-); antifungal (-fun(g)-); 
interleukins (-ki(n)-) etc.   
 Tumours: colon (-co(l)- ); melanoma (-me(l)- ); testis (-go(t)-); ovary (-go(v)-); prostate 
 (pr(o)-); miscellaneous (-tu(m)- ) 
- Prefix should be random, e.g. the only requirement is to contribute to a euphonious and 
distinctive name.    
- Second word: If the product is radiolabeled or conjugated to another chemical such as a 
toxin, identification of this conjugate is accomplished by use of a separate, second word or 
other acceptable chemical designation. 
If a monoclonal antibody is used as a carrier for radioisotope, the latter will be listed 
first in the INN, e.g. Iodine I131-Tositumomab. 
 
1.2.10. Nomenclature of receptor molecules 
 
The stem for receptor molecules (native or modified) is -cept , while a preceding infix 
should designate the target, e.g. lymphocyte function-associated antigen 3 receptors 
-lefa- (alefacept); interleukin-1 receptors -na- (rilonacept); cytotoxic lymphocyte 
associated antigen 4 (CTLA-4) receptors -ta- (abatacept, belatacept). On the other 
hand, the common stem for tumor necrosis factor antagonists is -nercept. e.g. 
etanercept78. 
.  
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1.3. Quality of rDNA derived therapeutic proteins 
 
Quality, safety and efficacy are key components that need to be monitored 
throughout the lifecycle of any medicinal product79. Recombinant biological medicinal 
products, exhibit high degree of molecular complexity and their biological 
manufacturing process is highly complicated, involving cloning, suitable cell line 
selection, fermentation, purification and formulation. Therefore, quality control of 
these products addresses aspects related to the final drug product (its identification 
and purity, impurities, potency, stability and safety assessment) and production 
process (production organism characterization, monitorization of fermentation, cell 
culture processes and recovery/purification operations)80. 
rDNA derived therapeutic proteins are large, complex and folded macromolecules 
and their exact conformation is critical for their therapeutic action and adverse 
effects. Due to the biosynthetic processes involved in their production, an inherent 
degree of structure heterogeneity occurs, i.e. glycoforms.. 
Current analytical methodology to ensure comprehensive product characterization 
and identification, including determination of physicochemical properties, biological 
activity, immunochemical properties, purity, impurities; and product stability, employs 
different physicochemical, immunological and biological methods81, 82.  
In order to identify the nature and homogeneity of the amino-and carboxyl-terminal 
amino acids, N- and C-terminal amino acid sequence analysis, is performed. 
Edman degradation analysis is used to confirm the complementary DNA (cDNA)-
predicted amino acid sequence and to evaluate the potential extent of proteolytic 
clips80.  
Peptide mapping by HPLC is a highly specific identity method, and may serve as a 
confirmation of a genetic stability of proteins obtained by mammalian cell culture. It is 
used to compare the protein structure of a specific lot of material to that of reference 
standard, but lot-to-lot consistency of primary structure can be confirmed as well. It 
can provide additional information about product, i.e.glycosilation site, N- and C-
terminal peptides, and position of disulfide bonds. Therefore, this technique is 
particularly important in the quality control of rDNA derived proteins, especially 
rmAbs. Peptide mapping using an appropriately validated procedure is a method 
frequently used for the structure confirmation for lot release purposes83, 84. 
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1.3.1. Post-translational modifications 
 
Apart from the proteolytical processing, potential types of post-translational 
modifications are N- and O- glycosylation and acetylation, hydroxylation and 
gammacarboxylation. In addition, there are post-translational modifications that occur 
as degradation products such as deamidation and oxidation. 
 
1.3.2. Carbohydrate determination 
 
Glycosilation is characteristic of recombinant proteins expressed from eucariotic cell 
lines. Although polypeptide chain of a glycoprotein is synthesized under direct control 
of genetic code, oligosaccharides are not primary gene products; they are 
synthesized by enzymes glycosyltransferases. Glycosylation as a common co-and 
posttranslational modification of proteins may have profound effect on protein 
structure and function, including folding, trafficking and protein-protein recognition. 
One feature of protein glycosylation is that a single site can be occupied by any one 
of a number of glycan structures, and this can give rise to extremely heterogeneous 
glycoprotein populations, termed glycomorfs. The glycosylation pattern of a 
glycoprotein is not random but dependent on the cell-line, so glycoproteins with 
identical polypeptide chains made in different cell lines may have considerably 
different carbohydrate structures. 
For glycoproteins, regulatory authorities demand the determination of carbohydrate 
content, the study of structure, carbohydrate chains, the oligosaccharide pattern 
(antennary profile) and glycosylation site(s). 
The phenol-sulphuric acid method is the easiest and most reliable method for the 
determination of total neutral sugars, while free sialic acid content can be determined 
by thiobarbituric acid method after acid hydrolysis and periodate oxidation85, 86. On 
the other hand, individual sugars can be separated by high performance ion 
exchange chromatography (HPIEC) and quantitated as underivatized with pulsed 
amperometric detection (PAD). Once the glycans have been released from the 
glycoprotein, the glycan pool can be analyzed by MALDI-TOF mass spectrometry or, 
after fluorescent labeling, by either HPLC or MS, or both. This strategy can provide a 
“glycan profile” or a “glycosylation pattern” that is highly characteristic of the 
glycoprotein. The technology can be applied to compare glycan profiles of different 
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batches of recombinant protein products. High pH anion exchange chromatography 
with pulsed amperometric detector can be used with native glycans. Matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is the most 
widely used MS technique. MALDI-TOF MS and NP-HPLC are used for glycane 
sequencing after appropriate incubation of glycan with specific glycosidases83.   
Due to advantages, as short analysis time, ability to separate and quantify isomeric 
species and high sensitivity,  capillary electrophoresis  coupled with on-column laser 
induced fluorescence (CE-LIF) and hyphenated CE-MS with on-line LIF detection, 
are used for glycan profiling of glycoproteins (e.g. recombinant mAbs)87,88.   
Oligosaccharide mapping and monosaccharide content are required by European 
Pharmacopoeia for the demonstration of molecular identity and structural integrity of 
rmAbs89. 
For characterization of biotechnology derived therapeutic proteins, different analytical 
techniques are required by regulatory authorities81. Molecular weight or size is 
determined by size exclusion chromatography (SEC), SDS-PAGE, and mass 
spectrometry (MS); isoform pattern by isoelectric focusing (IEF); extinction coefficient 
by UV/VIS spectrophotometry; electrophoretic patterns and data on identity, 
homogeneity and purity by SDS-PAGE, Western-blot and CE; liquid chromatography 
pattern and data on identity, homogeneity and purity by SEC, IEC, and affinity HPLC; 
spectroscopic profiles by the determination of UV/VIS spectra and circular dichroism 
(CD) and NMR spectroscopy for examination of high-order structure. 
 
1.3.3. Determination of purity, impurities and contaminants in biotechnology 
derived therapeutic proteins 
 
The determination of absolute or relative purity of a biologics and biotechnology drug 
substance presents considerable analytical challenges, and the results generally are 
method dependent81. In biological therapeutics obtained by recombinant cell culture 
expression systems, a huge variety of impurities may be present, and their origin 
cannot be easily predicted. They can not only affect safety of the final product but 
also interact with the expressed protein and, then, alter its functionality90. The 
analytical procedure of choice should allow complete separation of the desired 
product and product-related substances from impurities and the purity of biologics 
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and biotechnology drug substances is generally assessed by a combination of 
analytical procedures91. 
 
 
 
 
 
Impurities or Contaminants Detection Method 
Impurities 
- Endotoxins 
- Host cell proteins 
- Host cell DNA 
- Other protein impurities (media) 
- Protein mutants 
- Formyl methionine 
- Oxidised methionins 
 
- Proteolytic cleavage 
 
- Aggregated proteins 
- Deamidation,isomerized, 
mismatched S-S linked, altered 
conjugated forms 
- Monoclonal antibodies 
- Amino acid substitutions 
 
Contaminants 
- Microbial (bacteria, yeast, fungi) 
- Mycoplasma 
- Viruses (endogenous and 
adventitious) 
 
Bacterial endotoxin test (LAL test), Pyrogen test 
SDS-PAGE, Immunoassays 
DNA hybridization, UV spectrophotometry 
SDS-PAGE, Immunoassays, HPLC 
Peptide mapping, HPLC, IEF, MS 
Peptide mapping, HPLC,MS 
Peptide mapping, HPLC, Amino acid analysis, 
Edman degradation analysis 
IEF, SDS-PAGE (reduced), HPLC, Edman 
degradation analysis 
SDS-PAGE, HP-SEC, CE 
IEF, MS, HPLC, CE, Circular Dichroism, Edman 
degradation analysis 
 
SDS-PAGE, immunoassays 
Peptide mapping, MS, Amino acid analysis, 
Edman degradation analysis 
 
Microbial limit tests, Sterility tests 
DNA binding fluorochrome test. Other tests 
CPE and HAD test, for exogenous virus only; 
reverse transcriptase activity, MAB 
 
Impurities in biotechnology derived therapeutic proteins can be of known structure, 
partially characterized, or unidentified, including: 
- Process-related impurities, derived from manufacturing process, i.e. cell 
substrates, cell culture or downstream processing (Table 1.3) 
Table 1.3. Potential immpurities and Contaminants in Biotechnology-derived Products. According 
references [81] and [83]. 
LAL: Limulus amebocyte lysate; EDA: Edman degradation analysis; SDS-PAGE: Sodium dodecyl 
sulfate-polyacrylamis gel electrophoresis; HPLC: High performance liquid chromatography; IEF: 
Isoelectric focusing; MS: Mass spectrometry; HP-SEC: High performance size-exclusion 
chromatography; CE: Capillary electrophoresis; CPE: Cryopathic effect; HAD: Hemadsorption; 
MAB: Murine antibody production  
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- Product related impurities, molecular variant arising during manufacture 
and/or storage, which do not have properties comparable to those of the 
desired product with respect to activity, efficacy and safety. 
- Contaminants, include all adventitiously introduced materials not intended to 
be part of the manufacturing process, such as chemical and biochemical 
materials (e.g., microbial protease), and/or microbial species81. 
 
When different source and manufacturing methods result in different impurity profiles, 
different sets of analytical procedures may be needed and for impurity identification 
and quantification.  
Choice and optimization of the analytical procedures should focus on the possibility 
to separate the desired product from the impurities, to identify and quantify all the 
possible impurities with suitable sensitivity, and to evaluate the biological activity of 
the product and related impurities90, 91.  
 
1.3.4. Biological activity testing 
 
Often, for complex molecules, the physicochemical information may be extensive but 
unable to confirm the high-order structure which, however, can be inferred from the 
biological activity. Assessment of biological activity constitutes an equally essential 
step in establishing a complete characterization profile of biotechnology derived 
products. Potency is the quantitative measure of biological activity based on the 
attribute of the product which is linked to the relevant biological properties. For the 
potency determination suitable validated procedures should be used, including: 
 
- animal-based biological procedures, which measure an organism’s biological 
response to the drug substance,  
- cell culture–based biological procedures, which measure biochemical and 
physiological response at the cellular level, 
- biochemical procedures, which measure biological activities or biological 
responses induced by immunological interactions, 
- ligand or receptor binding assays, which are based upon in vivo attribute(s) 
of the drug substance.  
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Activity-based procedures, such as enzyme assay, ligand binding, and cell culture–
based procedures can be stability-indicating. ELISA procedures may or may not be 
stability indicating, depending upon whether the modification affects the three-
dimensional structure of the antigenic epitope(s). Combining an applicable potency 
test procedure with a physicochemical or biological assay for the determination of 
content permits measurement of specific activity81, 91.  
 
1.3.5. Immunoassays 
 
Immunoassays are used either as active drug substance methods to identify and 
quantitate the protein of interest or as impurity profile methods to detect and 
quantitate known host cell protein impurities. Additionally, immunoassays may serve 
as potency assays for monoclonal antibodies using an appropriate antigen83.  
Immunoassays, including radioimunoassays (RIAs) and enzyme-linked 
immunosorbent assays (ELISAs), consist of a large group of assays that depend on 
specific high-affinity antibody: antigen interactions.  
 
1.3.6. Protein quantity determination 
 
Bicinchoninic acid assay (BCA) and Bradford method are generally used for the 
determination of protein concentration in rDNA products92. 
 
1.3.7. Stability testing of biotechnology-derived therapeutic proteins 
 
In the medicinal products obtained by rDNA technology, maintenance of molecular 
conformation and, hence of biological activity, is dependent on non-covalent as well 
as covalent forces. The products are particularly sensitive to environmental factors 
such as temperature changes, oxidation, light, ionic content, and shear. In order to 
ensure maintenance of biological activity and to avoid degradation, stringent 
conditions for their storage are necessary.  
The evaluation of stability may necessitate complex analytical methodologies, and 
appropriate physicochemical, biochemical and immunochemical methods for the 
analysis of molecular entity and the quantitative detection of degradation products 
are needed. Assays for biological activity should be part of stability studies, as well93.  
 - 29 -
There is no single stability-indicating assay or parameter that profiles the stability 
characteristics of biotechnology-derived therapeutic proteins. Consequently, a 
stability-indicating profile that provides assurance that changes in the identity, purity 
and potency of the product will be detected should be provided.  
Due to the effect of deamidation, glycosylation and other heterogeneities, the 
absolute purity of biotechnological products is extremely difficult to determine, 
therefore, the purity of these products should be determined by more than one 
method, and the purity value derived is method dependent. For purposes of stability 
testing, test for purity should focus on methods for determination of degradation 
products. Relevant physicochemical, biochemical and immunochemical methods 
should permit a comprehensive characterization of the drug substance and accurate 
detection of degradation changes that may result from deamidation, oxidation, 
sulfoxidation aggregation or fragmentation during the storage.  
The storage conditions for the real-time/ real-temperature stability studies may be 
confined to the proposed storage temperature. It is strongly suggested to conduct 
accelerated and stress conditions studies which  may provide data for establishing 
the expiration date, provide stability information for future product development, 
assist in validation of analytical methods for stability program and elucidation of the 
degradation profile. 
Studies under stress conditions may be useful in determining whether accidental 
exposures to other condition to those proposed are deleterious to the product and to 
evaluate which test parameters may be the best indicators for product stability. 
Influence of light, container/closure system and stability after reconstruction of 
freeze-dried products are studied, as well93, 94. 
 
1.3.8. Similar biological medicinal products (biosimilars) 
 
The recent and pending patent expirations for a number of recombinant therapeutic 
proteins have prompted the study and development of alternative versions of biologic 
products, referred to as similar biological medicinal products (biosimilars) 95. 
Biosimilar or similar biological medicinal products are biological medicinal products 
referring to existing ones which have been submitted to regulatory authorities for 
marketing authorization by an independent applicant after the time of protection of 
the data has expired for the original products. A biosimilar medicinal product can be 
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granted a marketing authorization provided that its similarity to a reference product is 
established in terms of quality, safety and efficacy (Comparability exercises). 
Biosimilars (term preferred by EMEA) or “follow-on biologics” (term coined by US 
FDA), are new biological therapeutics that are similar but not identical to reference 
product. This is unlike to the case with small-molecule generics, where the active 
substance of a generic is identical to the reference product. Therefore, the standard 
generic approach, applied to chemically derived medicinal products (demonstration 
of bioequivalence with a reference medicinal product by appropriate bioavailability 
studies), is scientifically not appropriate for biotechnology- derived products96, 97.  
 
1.3.8.1. Recombinant therapeutic proteins versus small-molecule drugs 
 
Biopharmaceuticals differ from low molecular weight drugs in a number of aspects 
(Table 1.4). While for small-molecule drugs their relatively simple structures render 
them easy to synthesize and produce identical molecular “copies”, therapeutic 
proteins, however, are much more complex in size and structure98. 
 
 
Therapeutic proteins versus small-molecule drugs 
• Large complicated molecules 
• Heterogeneity 
• Produced by genetically modified living cells 
• Complex mode of action mediated by large surface area 
• Complicated production and purification 
• Relatively unstable 
 
For low molecular weight drugs an arsenal of physicochemical techniques is 
available to fully characterize the active molecule along with its impurity profiles and 
contaminants. However, with the present toolbox of analytical techniques including 
the bioassays, it is very difficult to fully characterize proteins at the end of the 
downstream processing procedure95.  
Unlike low molecular weight drugs, there is a strong relationship between the 
manufacturing processes of therapeutic proteins and the characteristics of the final 
Table 1.4. Therapeutic proteins versus small-molecule drugs. According reference [98] 
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product. In this setting for therapeutic proteins one may say “the process is the 
product” or “process determines product”99. 
Biological manufacturing processes involve many steps from cloning the desired 
gene via selection of a suitable cell type, fermentation and purification to formulation 
of the end product. A variety of undesired chemical alterations to the drug product 
can occur during this time including oxidation, deamidation and the formation of 
protein aggregates100. Differences in manufacturing processes, protein source and 
extraction/ purification processes result in heterogeneity of the resulting therapeutic 
proteins. For example, the unique cellular-expression systems used in protein 
manufacture inherently produce a variety of isoforms. In addition, small changes in 
manufacturing process can produce alterations in the three-dimensional structure of 
the protein, folding, the quantity of charge variants and the glycosylation profile. Any 
change in the process can have profound effects on the biological activity and safety 
profile of the final product.  
The expression of the same genetic construct in different host cell expression 
systems has a great impact on the final structure of the protein. While due to the 
absence of glycosylation machinery Escherichia coli is not able to modify proteins by 
glycosylation, proteins manufactured Saccharomyces cerevisiea cells contain high 
levels of mannose sugar groups, rendering them more prone to degradation and 
thereby decreasing their half-life. On the other hand, use of cell lines derived from 
chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells and human 
fibrosarcoma cells, provide necessary (typically human- like) glycosylation in the 
production of many other therapeutically intended naturally glycosylated 
proteins101,102. 
Biosimilar manufacturers will not have access to the manufacturing processes of 
innovator products because this is proprietary knowledge. Thus, it will be impossible 
for biosimilar manufacturers to precisely replicate any protein product95.  
Based on the EU legistlation, European Medicines Agency (EMEA) is currently the 
only regulatory agency which has issued regulatory guidelines for the approval of 
biosimilars while guidance documents on the development of follow- on protein 
products and their approval might be issued by the FDA in the future96, 97,103,104. 
So far EMEA has developed three Guidelines applying to all biosimilars, and 
Annexes (product specific regulatory guidelines), i.e. for rh erythropoietin, rh G-CSF, 
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rh insulin, rh growth hormone. These guidelines advocate preclinical and clinical tests 
of biosimilars prior to marketing authorization. 
Because therapeutic biologic proteins are sometimes, although infrequently, 
associated with serious adverse events, EMEA guidelines also require 
immunogenicity testing and tailored pharmacovigilance plans to monitor the efficacy 
and safety of biosimilar products post-approval. 
The immunogenic potential of BMPs may differ between products and is influenced 
by several factors, such as the nature and structure of the active substance, 
impurities, excipients, manufacturing process, route of administration and target 
patient population. These differences may compromise the in vivo behavior of the 
product, resulting in undesired host immune responses to the drug that may abrogate 
efficacy and may give rise to potentially fatal adverse reactions, as an example the 
incidence of antibody mediated pure red cell aplasia (PRCA) in patients treated with 
epoetins, after replacing human serum albumin with polysorbate 80 as a stabilizer in 
erythropoietin formulations Eprex® and Erypo®105. 
Due to the aforementioned differences between biosimilars and reference products, 
automatic substitution based on the prescription of the international nonproprietary 
name (INN) of the active substance, does not appear reasonable95, 96.  
In order to facilitate clear identification, safe prescription and dispensing of 
biosimilars, and support their Pharmacovigilance monitoring, it is suggested that 
WHO assigns a different INNs for biosimilars and their reference products and since 
biological products cannot be identical, labels of originator and biosimilar products 
must be different106, 107. 
On April 2006 somatropin Omnitrope® received EMEA approval and being the first 
biosimilar medicinal product to granted the marketing authorization in EU. The 
reference medicinal product cited for Omnitrope was Pfizer’s Genotropin, which was 
originally authorized in the EU in 1988108,109. Omnitrope was quickly followed by a 
second EU biosimilar approval, for somatropin Valtropin®. Omnitrope® has been 
produced in Escherichia coli whereas Valtropin® in Saccharomyces cerevisiae. Under 
the EMEA guidelines a number of biosimilars are admitted to the European market 
such as growth hormones (Valtropin®, Omnitrope®), epoetins alfa (Binocrit®, 
Abseamed®, Hexal®) and zeta (Retacrit®, Silapo®), filgrastim (Tevagrastim®).  
Due to the structural complexity, remains uncertain whether the European rules 
would allow the development of a biosimilar rmAbs and whether current technology 
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would enable demonstration of their similarity. From an innovation perspective, 
development of new improved formats (or second-generation) of rmAbs replacing 
existing murine or chimeric antibodies is desired110. 
 
1.4. Two-dimensional electrophoresis (2-DE) as a straightforward method for 
the examination of recombinant drugs 
 
2-D electrophoresis is a powerful and widely used method for the analysis of complex 
protein mixtures. This technique separates proteins according to two independent 
properties in two discrete steps. In the first dimension, isoelectric focusing (IEF), 
proteins are separated according to their charge (pI); in the second dimension 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), separates 
proteins according to their molecular weights (Mr, relative molecular mass). Each 
spot on the resulting two-dimensional gel potentially corresponds to a single protein 
species in the sample and information such as the protein pI, the apparent molecular 
weight, and the amount of each protein can be obtained111, 112. 
Two-dimensional electrophoresis was first introduced by O’Farrell in 1975. In the 
original technique isoelectric focusing was performed in carrier-ampholyte-containing 
polyacrylamide gels cast in narrow tubes. However, pH gradient instability and 
susceptibility to cathodic drift, low resolution and intra- and inter- laboratory 2D-
pattern irreproducibility were main drawbacks of this technique113. These problems 
were overcome by the introduction of immobilized pH gradients (IPGs) generated by 
the co-polymerization of “immobilines” with acrylamide matrix. The replacement of 
carrier-ampholyte-generated pH gradients with immobilized pH gradients and tube 
gels with gels supported by a plastic backing, brought about superior resolution and 
reproducibility to first-dimension IEF114. The basic protocol of two-dimensional 
electrophoresis with immobilized pH gradients in the first dimension (IPG-DALT) was 
established by in 1988115. IPGs allow the generation of pH gradients of any desired 
range (broad, narrow and ultranarrow) between pH 3 and 12. Since the sample 
loading capacity of IPG-IEF is also higher than CA-IEF, 2-DE with IPGs is the method 
of choice for micropreparative separation and spot identification.  
In addition, development of new, sophisticated mass spectrometry techniques 
enables the identification and characterization of small quantities of proteins from 2-
DE spots and the availability of powerful computers and software, makes possible 
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the evaluation of highly complex 2-DE patterns. 2-D Electrophoresis not only 
provides information on protein modifications and/or changes in their expression 
levels, but also permits the isolation of proteins for further structural analyses by 
MALDI-TOF-MS, ESI-MS or Edman microsequencing. Due to the ability of this 
technique to separate large number of proteins simultaneously, 2-DE is widely used 
in proteome analysis. Recent advances and modernization (i.e. introduction of 
fluorescent 2D difference gel electrophoresis) make 2-DE currently the most 
widespread technique used for performing functional and differential proteomics116.   
This technique can detect post- and co-translation modifications of proteins which 
can not be predicted from genome sequence.  
Apart from proteome analysis, other applications of 2-D electrophoresis include, cell 
differentiation, detection of disease markers, monitoring therapies, drug discovery, 
cancer research, purity testing of biologics, and microscale protein purification112. 
Recently 2-DE has been proposed as a reliable method for the quality assurance of 
recombinant proteins and 2-DE electrophoresis in combination with MS for the 
detection of recombinant proteins in biological fluids for antidoping purposes117, 118. 
 
1.4.1. General principles of gel electrophoresis 
 
Under the influence of an electrical field charged particles dissolved or dispersed in 
an electrolyte solution migrate in the direction of the electrode bearing the opposite 
polarity. In gel electrophoresis, the movements of the particles are retarded by 
interaction with surrounding gel matrix, which acts as a molecular sieve. The 
opposing interactions of the electrical force and molecular sieving result in a 
differential migration rates according to sizes, shapes and charges of particles. 
Because of their different physico-chemical properties, different macromolecules of a 
mixture will migrate at different speeds during electrophoresis and will thus be 
separated into discrete fractions. Electrophoresis separations can be conducted in 
system without support phases (e.g. free solution separation in capillary 
electrophoresis) and in stabilizing media such as thin-layer plates, films or gels119.   
The fundamental driving force of electrophoresis is the voltage applied to the system. 
The speed of a molecule is directly proportional to the surrounding voltage gradient. 
Two basic electrical equations are important in electrophoresis. The first is Ohm’s 
Law (Equation 1) which relates voltage (U) measured in volts (V), current (I) 
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measured in amperes (A), and resistance (R) measured in ohms (Ω). The second 
fundamental equation in electrophoresis is the power equation, which describes the 
amount of heat produced in a circuit (Equation 2): 
 
 
 
 
P is power, measured in watts (W). This heat is also referred to as Joule heat. In the 
electrophoresis circuit, voltage and current are supplied by a DC power supply; the 
leads, electrodes, buffer, and gel all act as simple resistors. 
Power supplies used for electrophoresis hold one electrical parameter (current, 
voltage, or power) constant. The resistance of the electrophoresis circuit, however, 
does not remain constant during a run. Buffer resistance declines with increasing 
temperature caused by Joule heating. Resistance also changes as discontinuous 
buffer ion fronts move through a gel; in the case of discontinuous denaturing 
polyacrylamide gel electrophoresis (SDS-PAGE), resistance increases as the run 
progresses. For discontinuous SDS-PAGE, running at constant current leads to 
increasing heat generation and may require active heat removal. Whenever 
overheating is a potential problem, a method of heat removal should be supplied (a 
circulating thermostated bath or cold tap water). Conventionally, protein gels are run 
at constant current. Most protein isoelectric focusing experiments use constant power 
because the resistance of the gel becomes very high as the separation nears 
completion112. 
 
1.4.2. First-dimension isoelectric focusing (IEF) 
 
Isoelectric Focusing is an electrophoretic method that separates proteins according 
to their isoelectric points (pI). Proteins are amphoteric molecules; they carry either 
positive, negative, or zero net charge, depending on the pH of their surroundings. 
The net charge of a protein is the sum of all the negative and positive charges of its 
amino acid side chains and amino- and carboxyl-termini. The isoelectric point is the 
pH at which the protein has an overall net charge of zero. Proteins are positively 
charged at pH values below their pI and negatively charged at pH values above their 
pI. 
R
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R
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The presence of a pH gradient is critical to the IEF technique. In a pH gradient and 
under the influence of an electric field, a protein will move to the position in the 
gradient where its net charge is zero. A protein with a net positive charge will migrate 
toward the cathode, becoming progressively less positively charged as it moves 
through the pH gradient until it reaches its pI. A protein with a net negative charge 
will migrate toward the anode, becoming less negatively charged until it also reaches 
zero net charge. If a protein should diffuse away from its pI, it immediately gains 
charge and migrates back. This is the focusing effect of IEF, which concentrates 
proteins at their pIs and allows proteins to be separated on the basis of very small 
charge differences. Because the degree of resolution is determined by pH gradient 
slope and electric field strength, IEF is performed at high voltages (typically in excess 
of 1 000 V) and when proteins have reached their final positions in the pH gradient 
there is very little ionic movement in the system, resulting in a very low final current 
(typically in the μA range) 112. 
IEF performed under denaturing conditions gives the highest resolution and the 
sharpest results. Complete denaturation, disaggregation, unfolding and solubilization 
is achieved with a mixture of urea, one or more detergents, and reductant (i.e.), 
ensuring that each protein is present in only one conformation with no aggregation, 
therefore minimizing intermolecular interactions. Composition of sample solution and 
other reagents employed for the first dimension, IEF can be found in the 
experimental part of this work. 
As mentioned above, in the original method for the first dimension a continuous pH 
gradient was achieved applying carrier-ampholytes in cylindrical polyacrylamide gels 
cast in glass rods or tubes113. When a voltage is applied across a carrier ampholyte 
mixture (small, soluble, amphoteric molecules with a high buffering capacity near 
their pI), the carrier ampholytes with the highest pI (and the most positive charge) 
move toward the anode; those with the lowest pI (and the most negative charge) 
move toward the cathode. The other carrier ampholytes align themselves between 
the extremes according to their pIs, and buffer their environment to the 
corresponding pHs. The result is a continuous pH gradient. As a result of limitations 
and problems associated with carrier ampholyte pH gradients, immobilized pH 
gradients (IPG) were developed114. An immobilized pH gradient is created by 
covalently incorporating a gradient of acidic and basic buffering groups (immobilines) 
into a polyacrylamide gel at the time it is cast. Immobiline buffers are a set of well-
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characterized molecules, each with a single acidic or basic buffering group linked to 
an acrylamide monomer. 
Immobilized pH gradients are formed using two solutions, one containing a relatively 
acidic mixture of acrylamido buffers and the other containing a relatively basic buffer 
mixture. The concentrations of the various buffers in the two solutions define the 
range and shape of the pH gradient produced. Both solutions contain acrylamide 
monomers and catalysts. During polymerization, the acrylamide portion of the buffers 
copolymerizes with the acrylamide and bisacrylamide monomers to form a 
polyacrylamide gel (Polyacrylamide T = 4%, C = 3%).  
For reproducible performance and simplified handling different companies produce 
IPG gels in form of dry strips, precast onto plastic backing, supplied with protective 
cover foil120, 121. Sigma-Aldrich Co. and GE Healthcare produce trademarks 
ProteoGelTM  IPG Strips and ImmobilineTM DryStrips, respectively.  
IEF is performed with the Immobiline DryStrip gels using a flatbed electrophoresis 
unit because this setting allows efficient cooling by using the aluminum oxide ceramic 
strip holder and allows meeting safety standards required to operate at high voltages, 
as well. 
The advantages of Immobiline dry strip gels are higher reproducibility of the first 
dimension separation (no cathodic drifting), easier handling, useful pH range on any 
single immobiline dry strip gel, higher protein loading capacity and in precast gels the 
need to handle toxic acrylamid monomers is eliminated.   
ImmobilineTM DryStrips are available in different formats of their pH ranges and 
lengths. Shorter strips, i.e. up to 13 cm are commended for fast screening of the 
most abundant proteins, provided that, the sample load is limited. On the other hand, 
maximal resolution and loading capacity can be achieved with longer strips i.e. 18 cm 
and 24 cm length, but require longer times in both the first- and the second-
dimension separations. 
Immobiline dry strip gels allow effective IEF over a wide pH range, from very acidic 
proteins at pH 3 to extremely basic proteins at pH 11. These varied pH intervals allow 
fine-tuning of each separation strategy to increase first dimension loading and 
resolve a greater number of spots from crowded areas. Both aspects will improve 
later protein identification and characterization. In order to achieve maximal 
resolution, linear (L) and nonlinear (NL) pH ranges are employed.  
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In this study, broad range pH 3–11 NL 18 cm strips were used to overview total 
protein distribution, of recombinant monoclonal antibody therapeutics, trastuzumab 
and rituximab and fusion protein abatacept. For more details, however, recombinant 
monoclonal antibodies were studied with pH 6–9 L strips and abatacept with 3–6 and 
4–7 L strips, both 18 cm length. 
For the first dimension, immobiline dry strip gels are rehydrated in a solution 
containing the necessary components including solubilizators, detergents, reductants 
IPG buffers and the sample proteins. IPG Buffers are ampholyte-containing buffer 
concentrates used to produce more uniform conductivity along dry strip gels during 
IEF and to eliminate potential high background staining. IEF is performed at high 
voltage (Rehydration solution and experimental conditions are described in detail in 
Experimental section). After IEF, Immobiline DryStrip gels were stored at -60 °C. 
 
1.4.3. Second dimension: Sodium dodecyl-sulfate polyacrylamid gel 
electrophoresis (SDS-PAGE) 
 
SDS-PAGE is an electrophoretic method for separating polypeptides according to 
their molecular weights (Mr). Denaturing polyacrylamide gel electrophoresis using 
sodium dodecyle sulfate (SDS-PAGE) is the most common mode of electrophoresis 
used in the pharmaceutical quality assessment of protein products. Typically, SDS-
PAGE is carried out under conditions that ensure dissociation of the proteins into 
their individual peptide subunits and that minimize aggregation. The strongly anionic 
detergent SDS is used to dissociate the proteins before they are loaded on the gel 
and the intrinsic electrical charge of the sample proteins due to its presence is not a 
factor in the separation. SDS is an anionic detergent and in water solutions forms 
globular micelles composed of 70–80 molecules with the dodecyl hydrocarbon 
moiety in the core surrounded by a hydrophilic shell, formed by the hydrophilic and 
amphiphilic stretches of the polypeptide chain, and by the sulphate head groups of 
the detergent122. The denatured polypeptides bind to SDS (in a ratio of approximately 
1.4 g SDS/g protein), become negatively charged and exhibit a consistent charge-to-
mass ratio regardless of protein type. Because the amount of SDS bound is almost 
always proportional to the molecular mass of the polypeptide and is independent of 
its sequence, SDS-polypeptide complexes migrate through polyacrylamide gels with 
mobilities dependent on the size of the polypeptide.  The electrophoretic mobilities of 
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the resultant SDS-polypeptide complexes all assume the same functional relationship 
to their molecular masses. Migration of SDS complexes is toward the anode in a 
predictable manner, with low-molecular-mass complexes migrating faster than larger 
ones. The molecular mass of a protein can therefore be estimated from its relative 
mobility in calibrated SDS-PAGE.  Modifications of the polypeptide backbone, such 
as N-or O-linked glycosylation, however, have a significant impact on the apparent 
molecular mass of a protein since SDS does not bind to a carbohydrate moiety in a 
manner similar to a polypeptide. Thus, a consistent charge-to-mass ratio is not 
maintained. The apparent molecular mass of proteins having undergone post-
translational modifications is not a true reflection of the mass of the polypeptide 
chain119.  
In 2-DE setting, second dimension (SDS-PAGE) is performed under reducing 
conditions. Complete denaturation and dissociation of proteins by treatment with 
dithiothreitol (DTT) results in the disruption of protein three-dimensional structure by 
reducing disulfide bonds, unfolding and subsequent complexation with SDS.  In these 
conditions the determination of molecular mass is more straightforward. 
The most popular electrophoretic method involves the discontinuous buffer system 
gel electrophoresis, established by Laemmli in 1970123. This system consists of two 
contiguous, but distinct gels: a resolving or separating (lower) gel and stacking 
(upper) gel. The two gels are cast with different porosities, pH and ionic strengths. 
The resolving gel is buffered with Tris by adjusting it to pH 8.8 with HCl. The stacking 
gel is also buffered with Tris but adjusted to pH 6.8 with HCl. In addition different 
mobile ions are used in the gel and electrode buffers. The buffer discontinuity acts to 
concentrate large volume samples in the stacking gel, resulting in improved 
resolution.  When power is applied, a voltage drop develops across the sample 
solution which drives proteins into the stacking gel. Glycinate ions from the electrode 
buffer (glycine pI 5.97), follow the proteins into the stacking gel. A moving boundary 
region is formed with the highly mobile chloride ions in the front and the relatively 
slow glycinate ions in the rear. A localized high voltage gradient forms between the 
leading (chloride) and trailing (glycinate) ion fronts, causing the SDS-protein 
complexes to form into a thin zone (stack) and migrate between chloride and 
glycinate phases. Within broad limits, all SDS proteins condense into a very narrow 
region and enter the resolving gel as a well-defined, thin zone of high protein density. 
At the interface of stacking and resolving gel, the proteins experience a sharp 
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increase in retardation due to the restrictive pore size of the resolving gel. Once in 
the resolving gel, proteins continue to be slowed by the sieving of the matrix. The 
glycinate ions overtake the proteins, which then move in a space of uniform pH 
formed by the tris(hydroxymethyl)aminomethane and glycine. Molecular sieving 
causes the SDS-polypeptide complexes to separate on the basis of their molecular 
masses119, 124.   
 
1.4.4. Characteristics of polyacrylamide gels 
 
The sieving properties of polyacrylamide gels are determined by the three-
dimensional network of fibers and pores which is formed as the bifunctional NN’-
methylenebisacrylamide cross-links adjacent polyacrylamide chains. Polymerization 
is catalyzed by a free radical-generating system composed of ammonium persulfate 
(APS) and tetramethylethylenediamine (TEMED). Atmospheric oxygen is a free-
radical scavenger that can inhibit polymerization. For consistent results the 
acrylamide monomer solution must be deaerated.  
The effective pore size of a gel is operationally defined by its sieving properties; that 
is, by the resistance it imparts to the migration of macromolecules. As pore size of gel 
decreases the migration rate of a protein through the gel decreases. By adjusting the 
pore size of a gel, through manipulating the acrylamide concentration, the resolution 
of the method can be optimized for a given protein sample. Thus, a given gel is 
characterized by its respective composition in acrylamide and bisacrylamide. 
The size of the pores in a polyacrylamide gel is determined by two parameters: total 
solids content (%T) and the ratio of cross-linker to acrylamide monomer (%C) 
(Equations 3 and 4). 
 
  
 
 
 
 The %T is the ratio of the sum of the weights of the acrylamide monomer and the 
cross-linker in the solution, expressed as % w/v. For example, a 20%T gel would 
contain 20% w/v of acrylamide plus bisacrylamide. As the %T increases, the pore 
size decreases. The %T ranges from 5-30 %. 
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The second way to adjust pore size is to vary the amount of cross-linker. The %C is 
the weight/weight percentage of total cross-linker weight in the sum of monomer and 
cross-linker weights. Thus, a 20%T, 5%C gel would have 20% w/v of acrylamide plus 
bisacrylamide, and the bisacrylamide would account for 5% of the total solids weight. 
The %C ranges from 2.5-5%.125 
 
1.4.5. Detection of proteins in 2-DE gels 
 
Protein detection techniques applied to gel electrophoresis must meet the basic 
requirements such are high sensitivity, wide linear dynamic range, reproducibility and 
low toxicity. In addition, visualization methods should be fully capable of interfacing 
with modern proteomic analysis tools. Since two-dimensional (2D) gel 
electrophoresis is increasingly being used for the separation and isolation of proteins 
destined for characterization by mass spectrometry, it is now expected that protein 
visualization methods be validated with respect to their compatibility with this 
technology. For the determination of total protein in 2-DE gels, general methods such 
as conventional colloidal Coomassie blue and silver staining are employed. Specific 
detection methods suitable for revealing protein post-translational modifications have 
been devised and are available. In addition, difference gel electrophoresis (DIGE), 
multiplexed proteomics (MP) and isotope-coded affinity tagging (ICAT) as principal 
approaches to differential display proteomics, have been developed126.  
 
1.4.6 General protein detection methods 
 
1.4.6.1. Silver staining techniques 
 
Silver staining techniques are a sensitive, non-radioactive methods based upon 
saturating gels with silver ions, washing the less tightly bound metal ions out of the 
gel matrix and reducing the protein-bound silver ions to form metallic silver. Silver 
ions bind to the amino acid side chains, primarily to the sulfhydril and carboxyl 
groups of proteins. The protein bands are visualized as spots where the reduction 
occurs and, as a result, the image of protein distribution within the gel is based on the 
difference in oxidation-reduction potential between the gel’s area occupied by 
proteins and the free adjacent sites127. 
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Silver staining methods permit detection of as little as single nanogram of protein, but 
the linear dynamic range of the stain is restricted to a 10-fold range. Silver staining is 
a complex, multi-step process that must be stopped at some arbitrary time point in 
order to avoid over development. Consequently gel-to-gel reproducibility is 
problematic and variations of 20 % in spot intensity have been reported128. 
Though the best silver stain methods use aldehyde based fixatives prior to silver 
impregnation, this prevents subsequent protein analysis by Edman sequencing or 
mass spectrometry. The utilization of glutaraldehyde for example, causes the cross-
linking of two lysine residues within protein chain thus, strongly affecting two most 
crucial steps for the MS analysis: hampering the trypsin digestion and highly reduces 
the protein extraction from the gel129.  By omitting the aldehydes in the fixatives, the 
method becomes compatible with mass spectrometry analysis, although at the 
expense of sensitivity and uniformity of background staining130.  
In addition destaining procedures aiming sensitivity enhancement for subsequent 
mass spectrometric identification of gel separated, silver stained proteins, have been 
esblished131.   
 
1.4.6.2. Organic dye-based methods. Coomassie staining 
 
 
Although 50-fold less sensitive than silver staining, Coomassie staining is a relatively 
simple method and more quantitative than silver staining. The advantage of 
Coomassie blue dyes (R250 or G250 type) is their low cost, ease of use and 
compatibility with downstream characterisation methods; therefore, almost any 
protein that can be visualized using Coomassie will yield interpretable mass 
spectrometric data. Traditional Coomassie R250 or G250 dyes are used in 
regressive staining approach where gels are saturated with dye that has been 
dissolved in an aqueous solution containing methanol and acetic acid, followed by 
destaining in a similar solution devoid of dye. Since the proteins have a higher affinity 
for the dye molecules than the gel matrix a point is reached where the background 
staining is minimal but protein bands are well labeled.  
Colloidal G250 stains (progressive staining approach) have the benefit of very low 
background staining and the need for little or no destaining. The limits of detection for 
conventional Coomassie Blue and colloidal Coomassie Blue stains are 8–10 and 30–
100 ng, respectively. Both dyes provide a linear response with protein amount over a 
 - 43 -
10–30-fold range of concentration. Thus, the principal limitations associated with 
Coomassie Blue-based staining methods are the poor detection sensitivity and small 
linear dynamic range obtained with the dyes126. 
 
1.4.6.3. Radioactive labeling methods 
 
Radiolabeling is commonly accomplished by in vivo incorporating 3H, 14C, 35S, 32P, 
33P, or 125I into proteins. After electrophoresis signal detection may be accomplished 
either by autoradiography (γ-emitting isotopes) or by fluorography (β-emitting 
isotopes). Though sensitive detection is readily achieved (down to 200 fg of protein), 
radiolabeling is both hazardous and expensive120, 126.  
 
1.4.6.4. Reverse stain methods 
 
A number of reverse staining methods for visualizing proteins in SDS–PAGE have 
been described, including methods that employ potassium chloride, copper chloride, 
zinc chloride, cobalt acetate nickel chloride and zinc chloride–imidazole126.  
Zinc chloride–imidazole is the most sensitive reverse stain method to date. Negative 
Zinc-Imidazole staining has a detection limit of approximately 15 ng protein/spot and 
is compatible with mass spectrometry, but is a poor quantitation technique120, 132. 
 
1.4.6.5. Fluorescence-based staining methods 
 
 
Fluorescence-based staining methods provide significant advantages over 
Coomassie blue or silver staining. Fluorescent detection offers increased sensitivity, 
simple, robust staining protocols, and quantitative reproducibility over a broad 
dynamic range.  
Different dyes have been for this purpose, including Nile red dye (detection sensitivity 
20-100 ng), SYPRO Red, SYPRO Orange and SYPRO Tangerine dyes (detection 
sensitivity 4-8 ng). However the most suitable method for the modern proteomic 
applications employs SYPRO Ruby dye, which is a proprietary ruthenium-, based 
metal chelate stain. The linear dynamic range of the dye extends over three orders of 
magnitude thus surpassing both Coomassie and silver staining in performance133.  
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1.4.7. Immobilized pH gradient/MALDI-TOF MS and surface-enhanced laser 
desorption-ionization MS (SELDI-MS) 
 
In order to overcome fundamental limitations of the 2-DE method for detecting 
specific classes of proteins, including those of low abundance, poor solubility, very 
small or large size and extreme pI replacing of one or both gel electrophoresis 
dimensions in proteome projects with alternative separation methods was 
reported134.  In 1999 group of scientists replaced the SDS-PAGE dimension of 2DE 
by scanning IEF gels directly with a MALDI–TOF mass spectrometer, thus generating 
a ‘virtual 2D gel’ image in which the protein mass is measured by mass spectrometry. 
Analytical data may be presented as a computer-generated image of that is similar to 
a classical 2D gel in appearance135.  
Surface-enhanced laser desorption-ionization MS (SELDI-MS) involves retaining 
proteins based on their physico-chemical characteristics on a solid phase 
chromatographic surface (ProteinChip Array) and direct detection of the retained 
proteins by time-of-flight mass spectrometry (TOF-MS). 
SELDI technology has been applied in recent years to investigate a variety of 
biological phenomena, due to the increasing need for high-throughput technology 
that allows the detection, purification, and identification of proteins at high speed and 
with high sensitivity. The application of this approach for biomarker analysis has been 
reported136.  
 
1.4.8. Specific detection of protein posttranslational modifications 
 
The most common posttranslational modifications include phosphorilation, 
glycosylation, lipidation, and proteolytic modifications. These chemical modifications 
of proteins are crucial to modulating their function. 
Glycoproteins can be detected by autoradiography after incorporation of 3H or 14C 
sugars into cultured cells or tissues. However, nonradioactive methods using a 
periodic acid Shiff base chemistry are more preferred. These methods include 
colorimetric procedure with acid fuchsin and a fluorescent alternative of acid fuchsin 
dye, dansyl hydrazine that can be used for the detection of glycoproteins in 
polyacrylamide gels. 
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Other fluorescence-based method for detection of glycoproteins is sensitive green-
fluorescent glycoprotein specific stain Pro-Q Emerald 300 dye. Gels labelled with this 
dye may be post-stained with SYPRO Ruby dye, allowing sequential two-color 
detection of glycosylated and nonglycosylated proteins120. 
 
1.4.9 Difference gel electrophoresis (DIGE) 
  
Although 2-DE is well-established technique for protein analysis, it is time consuming 
and labor-intensive. Additionally, the system variability arise due to the lack of 
reproducibility between gels. In order to overcome these limitations, 2D difference gel 
electrophoresis (DIGE) that enabled more than one sample to be separated in a 
single 2D polyacrylamide gel was devised. This technique involves fluorescent 
labeling of as many as three different complex protein samples with succinimidyl 
esters of the cyanine dyes, Cy2, Cy3 and Cy5, prior to mixing them together and 
running them simultaneously on the same 2D gel120,137,138. The different protein 
extracts labeled with different dyes can then be visualized separately by exciting the 
different dyes at their specific excitation wavelengths.  
This technique is more sensitive than silver staining. Sensitivities are 0.075 ng, 0.025 
ng, and 0.025 ng for Cy2, Cy3 and Cy5 dye, respectively. The dynamic range is 
above 3.6 orders of magnitude and most critically, effects of gel to gel variation on 
the quantitation of a protein spot on a gel is substantially reduced. 
 
1.4.10. Isotope-coded affinity tagging (ICAT) 
 
 
Isotope-coded affinity tag (ICAT) peptide labeling is predicated upon distinguishing 
between two populations of proteins using isotope ratios. Isotope-coded affinity tags 
are reagents consisting a thiolate-reactive group to enable selective labelling of 
cysteinyl residues, an isotopic ethylene glycol linker containing either eight hydrogen 
atoms (d0, light reagent) or deuterium atoms (d8, heavy reagent), and an a biotin 
affinity tag. A reduced protein mixture from one protein specimen is derivatized with 
the isotopically light version of the ICAT reagent, while the other reduced protein 
specimen is derivatized with the isotopically heavy version of the ICAT reagent. The 
labelled peptides are typically detected and quantified using electrospray ionization 
microcapillary μRP-HPLC-MS/MS. The ratio of the isotopic molecular mass that 
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differs by 8 Da provides a measure of the relative amounts of each protein from the 
original samples139. 
 
 
1.5. Matrix-assisted laser desorption ionization mass spectrometry (MALDI-TOF 
MS) 
 
The incorporation of new technologies has resulted in fundamental change in the 
drug development paradigm. Mass spectrometry (MS) is the bioanalytical technique 
which provides key attributes relevant to modern pharmaceutical analysis: sensitivity, 
selectivity, speed, and high throughput and it is an essential component of the 
modern pharmaceutical laboratory as well as an important complement to traditional 
methods of analysis140. 
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-TOF MS) was 
introduced in 1987-1988 by Tanaka et al141 and Karas et al142, reporting the UV-laser 
desorption of large biomolecules for the first time. This is a rapid and sensitive 
technique for the characterization of peptides and proteins. Used in a variety of 
modes, MALDI-MS provides information such as the molecular weight of an intact 
protein, peptide mass mapping from a tryptic digest, and peptide sequencing.  
The schematic set-up of MALDI-TOF instrument is shown in Figure 1.5. 
 
 
 
 
 
 
 
 
 
 
 
MALDI-TOF MS as a “soft” ionization technique is suitable for thermolabile, non-
volatile compounds, especially those of high molecular mass and is used 
successfully in biochemical and biotechnological areas for the analysis of therapeutic 
proteins, peptides, glycoproteins, complex carbohydrates and oligonucleotides. It is 
Fig. 1.5. Schematic set-up of a MALDI-TOF MS instrument. According reference 
[140] 
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relatively straightforward to use and reasonably tolerant to buffers or other additives. 
The lower mass limit of MALDI TOF MS is around 500 Da due to signals arising from 
molecular, fragment and adduct ions of the matrix. Ions generated by MALDI can be 
routinely mass analysed in a TOF instrument in picomole (pmol = 10-12 mol) down to 
low femtomole (fmol = 10-15 mol) amount with mass resolution of over 20000 
(FWHM). However, attomole (amol = 10-18 mol) sensitivity has also been 
demonstrated using a MALDI TOF MS143. The mass accuracy depends on the type 
and the performance of the analyser of the mass spectrometer, but most modern 
instruments are capable of measuring masses with an accuracy of ± 0.01-0.05% up 
to 25 kDa, and ±0.05-0.3% up to 300 kDa125.  
MALDI-TOF samples are prepared with a matrix that contains a small organic 
molecule capable of absorbing ultraviolet light. Most commercially available MALDI 
mass spectrometers now have a pulsed nitrogen laser of wavelength 337 nm. A laser 
is used to desorb ions from the sample plate, ionized matrix molecules transfer a 
proton to the sample molecules in the gaseous phase, and the resulting ions are 
forced into the flight tube (typically 1-4 m long, maintained at a high vacuum) by 
application of the acceleration voltage from extraction grids.  
Separation is based on mass with lighter ions traveling faster than heavier ions.  
In the source of a linear TOF analyzer, a packet of ions is formed by a very fast (ns) 
ionization pulse. These ions are accelerated into the flight tube by an electric field 
(typically 2-25 kV) applied between the backing plate and the acceleration grid. Since 
all the ions are accelerated across the same distance by the same force, they have 
the same kinetic energy. Because velocity (v) is dependent upon the kinetic energy 
(Ekin ) and mass (m) lighter ions will travel faster. Ekin is determined by the 
acceleration voltage of the instrument (U) and the charge of the ion (e x z), (eqs 5 
and 6). 
 
 
 
After the ions accelerate, they enter flight tube. The ions drift through this field free 
region at the velocity reached during acceleration. At the end of the flight tube they 
strike a detector, such as microchannel plate (MCP). The time delay (t) from the 
formation of the ions to the time they reach the detector dependents upon the length 
2
2mvEkin = Uez
mv ××=
2
2
(Eq.5) 
(Eq.6) 
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of the drift region (L), the mass to charge ratio of the ion, and the acceleration voltage 
in the source (eq. 8). 
 
 
 
 
Eq. 8 can be inverted to eq. 9, which shows that that low m/z ions will reach the 
detector first.  
 
 
 
The mass spectrum is obtained by measuring the detector signal as a function of 
time for each pulse of ions produced in the source region. Because all the ions are 
detected, TOF instruments have very high transmission efficiency which increases 
the S/N level144, 145. 
In linear TOF mass spectrometers MALDI ions of slightly different kinetic energy are 
extracted from their desorption plume with an initial velocity distribution which causes 
ions of same mass to arrive at slightly different times at the detector. This initial 
velocity distribution which leads to a corresponding distribution of arrival times of ions 
of the same mass results in the reduction of mass resolution, and the peak 
broadening becomes worst for the larger ions because the energy distribution is 
mass dependent. In linear TOF mass spectrometers the energy distribution and its 
influence in the mass resolution could be reduced only increasing acceleration 
potential but considerations of handling very high voltages in the laboratory 
instruments limit this approach 125,146. 
Two elegant means to improve the resolution are to use an ion mirror (a reflectron) 
and/or pulsed-ion extraction, commonly called delayed extraction (DE) or time-lag 
focusing144. The reflectron, located at the end of the flight tube, has an applied 
voltage slightly higher than the accelerating voltage at the source. It acts as an 
energy-focusing device correcting for small kinetic energy differences between ions 
of the same mass resulting in improved resolution and mass accuracy. 
Second way to improve mass resolution is to use the delayed extraction (DE). In this 
system the ions formed by MALDI are produced in a weak electrical field, and 
subsequently extracted by application of a high voltage pulse after a predetermined 
t
Lv = Uez
t
Lm ××=⎟⎠
⎞⎜⎝
⎛ 2
2
1
eU
L
z
mt
2
×=
(Eq.7) (Eq.8) 
(Eq.9) 
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time delay. Decrease in energy spread of the ions and consequently increase in 
mass resolution is achieved by the adjustment of the field magnitude and direction 
during and immediately following ion production, the magnitude of the extraction field, 
and the time delay between the laser pulse and application of the extraction field147.  
 
1.5.1. MALDI sample preparation and presentation 
 
In a typical UV-MALDI sample preparation small volumes of an analyte solution (ca 
10-6M) and near-saturated (ca 0.1M) solution of matrix are mixed; the solvent is then 
evaporated before the sample can be introduced into the vacuum of mass 
spectrometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Matrix                                      Structure                           Wavelength    Major applications
Nicotinic acid
2.5-Dihydroxybenzoic acid
  (plus 10% 2-hydroxy-5-
  methoxybenzoic acid) 
  
Sinapinic acid
α-Cyano-4-
  hydroxycinnamic acid
  (CHCA)
3-Hydroxy-picolinic acid
6-Aza-2-thiothymine
k,m,n-Di(tri)hydroxy-
acetophenone
Succinic acid
Glycerol
N O
OH
O
OH
HO
OH
O
HO
O O
OH
O
OHHO
N
N
O
HO
HO
NH
SN
H
O
N
O
XX
X
X X
O
OH
O
HO
HO
OH
HO
UV
266 nm
UV
337 nm 353 nm
UV
337 nm 353 nm
UV
337 nm 353 nm
UV
337 nm 353 nm
UV
337 nm 353 nm
UV
337 nm 353 nm
IR
2.94 μm, 2.79 μm
IR
2.94 μm, 2.79 μm
Proteins, peptides
adduct formation
Proteins, peptides
carbohydrates
synthetic polymers
Proteins, peptides
Peprides,
fragmentation
Best for nucleic
acids
Proteins, peptides
non-covalent
complexes;
near-neutral pH
Proteins, peptides
non-covalent
complexes;
near-neutral pH
Proteins, peptides
Proteins, peptides
Liquid matrix
IR = infrared; UV = ultraviolet.
Table 1.5. A list of commonly used MALDI matrices. According reference [146] 
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Upon solvent evaporation, the matrix co-crystallizes with analyte to form a bed of 
crystals of different sizes depending of on the matrix type and sample preparation 
details. Typical analyte: matrix molar ratio ranges from 10-2 to 10-5 depending on the 
analyte, matrix and solvents. There is no single MALDI matrix or sample preparation 
protocol which is suited to all analytes in MALDI-TOF MS. There are different 
matrixes of first choice for different classes of analytes. For example CHCA is used in 
proteomics for the peptide mass fingerprint analysis (Table 1.5). 
For the determination of molecular mass of labile compounds “cold” matrices are 
used. They form mainly single charged ions. However, for PSD fragment ion analysis 
“hot” matrices, which form significant amounts of multiple charged ions, are optimal.  
In this study peptides obtained from the tryptic digestion of proteins separated with 2-
DE were co-crystallized with α-Cyano-4-hydroxycinnamic acid (CHCA).  
 
1.6. Peptide-mass fingerprinting 
 
Peptide mass fingerprinting (PMF) is the most common mass spectrometry technique 
used for the identification of proteins separated by two-dimensional gel 
electrophoresis.   
After the introduction of sensitive ionization techniques, MALDI and electrospray 
ionization (ESI), which allowed accurate mass measurement of peptides, different 
groups of authors described the use of MALDI-TOF data for correlating peptide 
masses generated from a digestion of a protein with sequence databases. This 
technique allowed a rapid identification of a sample protein before committing it to 
protein sequence analysis148-152.  The term “peptide mass fingerprinting” was first 
used in the paper of Pappin and al148.  This technique is most simply described as a 
method to identify proteins already contained within a sequence database using an 
algorithm to match a set of peptide masses generated using specific cleavage 
reagents (either enzymatic or chemical) from the protein of interest, with theoretical 
peptide masses calculated from each sequence entry in the database if the database 
sequences had been cleaved with the same specificity as the reagent in the 
experiment125.  
There are a number of advantages of using PMF for protein identification: 
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- Using MALDI-TOF instruments of improved analytical performance, PMF 
gained speed, high specificity for protein identification and the ability to 
identify individual components in simple protein mixtures 
- Direct correlation between the m/z value of the singly charged ions and mass 
of a peptide 
- Simplicity, high mass accuracy and sensitivity, analysis of femtomolar levels 
of proteins 
- Unlike automated Edman degradation, there is no requirement for a free 
amino terminus of protein 
- Mass differences between the measured and predicted peptides may provide 
evidence for the identity of peptide modifications 
- Possibility to increase the confidence of peptide mass searching through the 
incorporation of orthogonal approaches 
- Tolerance toward contaminants 
- Method is easily automated and there are available robotic workstations for 
high throughput operation  
 
There are limitations to protein identification by peptide mass mapping: 
 
- The protein sequence must be present in a database, 
- Proteins that have extensive post-translational modifications may fail to yield 
good matches 
- The individual components from mixtures of more than three or four proteins 
are difficult to identify 
- It is not a method for protein characterization, only for identification125, 146, and 
152.  
For successful peptide mass searching the possible highest molecular mass 
accuracy should be employed, ideally using internally calibrated monoisotopic 
masses. If this option is not available, when average masses are used, high mass 
accuracy should be achieved with an appropriate internal calibration.  
In addition to the importance of mass accuracy, the specificity of cleavage is also 
critical. 
Trypsin is the most commonly used protease for peptide mass searching.  This 
serine protease has high cleavage specificity, efficiency and is stable under a wide 
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variety of conditions. Trypsin specifically cleaves at sites C-terminal to basic amino 
acid residues Lys or Arg (if not followed by a Pro). The distribution of Lys and Arg 
residues in proteins is such that trypsin digestion yields peptides of molecular 
weights typically within the range of 500 to 2500 Da that can be analyzed by mass 
spectrometry. Furthermore, basic Arg or Lys residues located at the C-terminus help 
to localize the positive charge of resulting ions153.  For MS analysis trypsin of high 
specificity is required, because the native trypsin is subject to autolysis, it generates 
pseudotrypsin, which exhibits a broadened specificity. Consequently, nonspecific 
and/or incomplete cleavages may result. While so called missed cleavages are 
included as a parameter for PMF analysis in search programs, nonspecific cleavages 
is difficult to accommodate in search algorithms. On the other hand trypsin autolysis 
derived peptides can be used for the internal calibration.  
In order to increase sequence coverage of studied proteins often additional enzymes 
are used in PMF analysis i.e.  endoproteases AspN and LysC (cleave N-terminus of 
Asn and C-terminus of Lys, respectively), chymotrypsin (cleaves C-terminus of Phe, 
Tyr, Trp, Leu and Met), pepsin (cleaves C-terminus of Phe, Trp, Leu and Met) and 
S.auresus V8 DE and V8E (cleave C-terminus of Glu and C-terminus of Glu and Asp, 
respectively) 154. 
Several computer programs and algorithms have been described in literature for 
protein identification by searching sequence databases using mass spectrometry 
data. A number of such programs can be found on World Wide Web and most 
include examples to guide their users.  For PMF analysis the following programs are 
most commonly used. 
 
- MS-fit (ProteinProspector, University of California, San Francisco, USA; 
http://prospector.ucsf.edu/mshome.htm) 
- Aldente (ExPASy Molecular Biology server, Suiss Institute of Bioinformatics, 
Switzerland; http://www.expasy.ch/tools/aldente/) 
- Profound [(Prowl), The Rockefeller University, USA; 
http://prowl.rockefeller.edu/prowl-cgi/profound.exe)] 
- Mascot (Matrix Science Ltd. UK; 
http://www.matrixscience.com/search_form_select.html) 
Mascot is a powerful search engine that that it integrates all of the proven methods of 
searching: peptide mass fingerprint (experimental data are peptide mass values), 
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Sequence query (combination of peptide mass data with amino acid sequence) and 
MS/MS Ion Search (uses MS/MS data from one or more peptides). 
The sequence databases that can be searched on Mascot server are: 
 
1. MSDB ( a comprehensive, non-identical protein sequence database designed 
specifically for mass spectrometry applications) 
2. NCBInr (a comprehensive, non-identical protein database. The entries 
compiled from GenBank CDS translations, PIR, SWISS-PROT, PRF, and 
PDB. 
3. SwissProt (a high quality, protein database, uses non-redundant sequences, 
recommended for peptide mass fingerprint searches) 
4. dbEST [contains "single-pass" cDNA sequences, or Expressed Sequence 
Tags (EST), from a number of organisms]. 
 
In this study peptide masses obtained by MALDI-TOF-MS after in gel tryptic digestion 
of therapeutic proteins trastuzumab, rituximab and abatacept were searched in 
search engines Profound (Prowl) and Mascot using open access databases MSDB, 
NCBInr and Swiss Prot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6. Sheme of protein identification and characterisation using database searching. 
According reference [156] 
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Mascot incorporates a probability-based scoring with implementation of the Mowse 
algorithm. The fundamental approach is to calculate the probability that the observed 
match between the experimental data set and each sequence database entry is a 
chance event. The match with the lowest probability is reported as the best match 
and the total score is the absolute probability that the observed match is random 
event. However, reporting probabilities directly can be confusing because they 
encompass a wide range of magnitudes, and because a "high" score is a "low" 
probability, which can be ambiguous. Therefore, scores are reported as -10log10 (P), 
where P is the absolute probability155. In Fig. 1.6 a scheme of protein identification 
using sequence databases is presented. 
 
1.7. Search for the new quality parameters of recombinant monoclonal 
antibodies and their related substances 
 
As indicated, rmAbs are highly complex molecules with primary and higher order 
structure amenable to post-translational and chemical modifications; hence these 
substances and their final pharmaceutical formulations are highly heterogeneous. 
rmAbs often include subtle variations (microheterogeneity), including post-
translational (different glycosilation pattern) and chemical variations (i.e. disulfide 
shuffling, deamidation, Met-oxydation, N-terminal Glu cyclization and Lys truncation). 
These variations can affect antibody product quality and thus its clinical efficacy and 
safety. Therefore, development of appropriate analytical methodologies to study the 
quality of these complex medicinal products remains a challenging task. 
Regulatory agencies already have published guidelines concerning the production 
and quality control of rmAbs157, 158. In the European Pharmacopoeia two monographs 
related to the production and quality testing of rmAbs are available: Monoclonal 
antibodies for human use and Products of recombinant DNA technology159, 160.  
Principles concerning characterization of biotechnological products, discussed in 
Chapter 1.3 apply to rmAbs as well, although for this product class there are some 
specific requirements. For the biochemical/physico-chemical and 
biological/immunological characterization of rmAbs at least the following parameters 
should be determined: 
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- Class, subclass and light-chain composition, glycosylation pattern (G0,G1, 
G2 glycan structures and degree of sialilation), integrity of the molecule by 
analysis of the ratio heavy/light chain, microheterogeneity, molecular weight, 
N- and C terminal amino acid sequence, and secondary and tertiary structure 
of the antibody, 
- The total protein content, the degree of aggregation and molecular 
fragmentation of the immunoglobulin, 
- Especially for engineered and humanised antibodies sufficient sequence 
information to characterize the gene product adequately should be obtained 
by peptide mapping or amino acid sequencing. 
 
A wide range of analytical techniques exploiting different physico-chemical properties 
of the molecule should be used i.e. SDS-PAGE (under reducing and non reducing 
conditions), IEF, IEC, CE, HPLC, peptide mapping, amino acid analysis, circular 
dichroism (CD) and carbohydrate mapping94,161. European Pharmacopoeia requires 
different tests, including peptide mapping, IEF, IEC, HIC, oligosaccharide mapping, 
monosaccharide content and mass spectrometry, to be used for the demonstration 
molecular identity and structural identity of rmAbs. For the purity testing, suitable 
validated methods such are SDS-PAGE or CE can be used 159.  
Today very sensitive analytical methods are employed for the physico-chemical 
characterization of rmAbs, including CE-LID, MALDI-TOF MS, ESI-MS) or NMR. For 
the characterization of antigen-antibody interaction surface plasmon resonance has 
been used, whereas Circular Dichroism in near and far UV spectra makes possible 
the determination of antibody secondary structure110.  
On the other hand, two-dimensional gel electrophoresis  (2-DE) has been widely 
accepted technique for the quality evaluation of rDNA derived medicinal 
products160,162, suited for in-process, bulk and/or final product testing, i.e. identity, 
purity (testing  for product related and foreign protein impurities) and stability testing.  
Concerning planar electrophoresis methods, European Pharmacopoeia monograph 
(Monoclonal antibodies for human use), for the demonstration of product molecular 
identity and structural integrity suggests isoelectric focusing whereas for purity testing 
one dimensional SDS-PAGE. Since 2-DE is able to efficiently separate protein 
mixtures in two dimensions: according protein pI (1st dimension, IEF) and according 
their molecular masses (2nd dimension, SDS-PAGE), after sensitive staining 
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procedure, the map of all proteins present in a sample can be detected. Thus this 
method which allows estimation of both pI and molecular mass of sample 
components provides an essential advantage versus IEF and/or SDS-PAGE 
performed separately. In addition, comparison of 2-DE protein spot patterns of 2-DE 
separated proteins with reference protein product allows the determination of product 
heterogeneity and isomorf pattern. Moreover, on the basis of pI and molecular mass 
difference of 2-DE protein spots obtained after the treatment of glycoprotein products 
such are monoclonal antibodies and fusion proteins, with specific glycosiades, the 
important information on the glycan pattern can be obtained, as well. On the other 
hand, 2-DE separated proteins can be downstream analyzed with complementary 
MS methods, especially with relatively fast, cheap and simple technique of MALDI-
TOF MS analysis: whether for more detailed study of glycosylation (glycan profiling, 
glycosylation site) and for chemical modification (deamidation, isomerisation etc) or 
for the identification of resulting peptides after in gel tryptic digestion. Summing up, 
possibility for efficient separations of proteins in two dimensions, high detection 
sensitivity, and possibility to complement with MALDI-TOF MS analysis make 2-DE 
method suitable technique for the study of the quality of recombinant monoclonal 
antibodies not only for the in-process control, but this technique might be suitable for 
the testing of identity and purity of these products in Pharmacopoeia environment as 
well.  
 
1.8. Basic information about the chemistry, manufacturing and mechanism of 
action of recombinant biological products studied in this work  
 
1.8.1. Trastuzumab 
 
1.8.1.1. Nomenclature 
Trastuzumab [FDA, USAN INN], Herceptin [Trade name], Synonyms:  huMAb 4D5-8; HER2 receptor 
monoclonal antibody, recombinant [BIO]; anti-p185, rhuMab HER2; c-erbB2 monoclonal antibody. 
Drug Bank ID: DB00072; CAS-180288-69-1 
 Trastuzumab is a recombinant DNA-derived humanised monoclonal antibody 
glycoprotein that selectively targets the extracellular domain of the human epidermal 
growth factor receptor 2 protein (HER2). The antibody is an IgG1 kappa that contains 
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human framework regions with the complementarity-determining regions (CDR) of a 
murine anti-p185HER2 antibody that binds to HER2163, 164.  
 
    Heavy chain 
 
     10         20         30         40         50         60  
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY  
        70         80         90        100        110        120  
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS  
       130        140        150        160        170        180  
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS  
       190        200        210        220        230        240  
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG  
       250        260        270        280        290        300  
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN  
       310        320        330        340        350        360  
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE  
       370        380        390        400        410        420  
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW  
       430        440        450  
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 
 
    Light chain 
 
 10         20         30         40         50         60  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS  
        70         80         90        100        110        120  
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP  
       130        140        150        160        170        180  
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT  
       190        200        210  
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC 
 
 
 
 
The active substance trastuzumab is produced in recombinant Chinese Hamster 
Ovary cells using a serum free medium. Primary sequences and complementarity 
determining regions of trastuzumab heavy and light chains are presented in Fig. 
1.7165,166.  
Trastuzumab (rhumAb4D5-8) has been engineered by grafting the CDRs of the 
parental murine antibody mumAb4D5 into the consensus framework of a human 
IgG1167. Parental murine mumAb4D5 directed against the ECD of human epidermal 
growth factor receptor (p185HER2), specifically inhibited the growth of tumour cell lines 
overexpressing p185HER2. However, antigeneicity and lack of effector functions 
limited its efficacy. Therefore, aiming to reduce anti globulin response and increase 
Fig. 1.7. Primary sequences of trastuzumab heavy and light chain. Complementarity determining 
regions are highlighted. The heavy chain N300 glycosilation site is indicated by underlined boldface. 
According references [165] and [166]. 
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the effector functions (ADCC and CMC) with retention of high affinity for antigen, 
humanised antibody version (humAb4D5) was constructed. In the humanised version 
only complementarity determining regions (antigen binding loops) have murine origin. 
The rest of molecule, including IgG1 constant domains and variable region 
framework residues, is human 167-169. Trastuzumab was generated by the 
immunization of Balb/c mice with cells expressing HER-2 on their surface and 
partially purified membranes containing p185HER2 according to standard hybridoma 
techniques.  Hybridomas were either screened by an ELISA or a nude mice breast 
cancer xenograph model, resulting in muMAb 4D5. 
Humanisation of muMAb 4D5 was performed using “gene conversion mutagenesis”. 
The mumAb4D5 VLand VH gene segments were first cloned by PCR and sequenced 
There were 24 simultaneous amino acid changes required to humanize  mumAb4D5 
VL and 32 amino acid change mumAb4D5 VH, respectively. In this way humAb4D5-5 
was encoded. Additional humanized variants were constructed by site directed 
mutagenesis of humAb4D5-5167. In general, framework region residues were chosen 
from consensus human sequence and CDR residues from mumAb4D5.  The most 
potent humanised variant designed by molecular modeling, humAb4D5-8, contains 
five FR residues from mumAb4D5 (the most murine variant). 
This antibody binds p185HER2 ECD three fold more tightly than does mumAb4D5 
itself. In addition it has potency comparable to the murine antibody in blocking SK-
BR-3 cell proliferation and is more efficient in supporting ADCC against SK-BR-3 
cells. In contrast, humAb4D5-1 is the most humanised but least potent variant, binds 
p185HER2 80 fold less tightly and has no detectable antiproliferative activity (Table 
1.6.).   
 
 
 
  VH residue      VL residue   
mAb4D5 
variant 
72 
(FR3) 
74 
(FR3) 
79 
(FR3) 
97 
(FR3) 
109 
(CDR3 
 55 
(CDR2) 
66 
(FR3) 
Kd 
nM 
Relative cell 
proliferation 
humAb4D5-1 R D L A V  E G 25 102 
humAb4D5-2 Ala D L A V  E G 4.7 101 
humAb4D5-3 Ala Thr Ala Ser V  E G 4.4 66 
humAb4D5-4 Ala Thr L Ser V  E Arg 0.82 56 
humAb4D5-5 Ala Thr Ala Ser V  E Arg 1.1 48 
humAb4D5-6 Ala Thr Ala Ser V  Tyr Arg 0.22 51 
humAb4D5-7 Ala Thr Ala Ser Tyr  E Arg 0.62 53 
humAb4D5-8 Ala Thr Ala Ser Tyr  Tyr Arg 0.1 54 
mumAb4D5 Ala Thr Ala Ser Tyr  Tyr Arg 0.3 37 
 
Table 1.6. mAb4D5 variants designed by molecular modeling. According reference [167]. 
Human and murine residues are shown in one-letter and three-letter amino acid codes. 
Bold face: the most potent variant humAb4D5-8 (trastuzumab)  
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The resulting constructs were designed to express the human Fc γ1 (IgG1) isotype to 
maximally support CDC and ADCC167, 171.  
The human IgG1 heavy chain constant regions are identical with those reported in 
literature expect for mutations in CH3 domain of heavy chain: E359D and M361L 
which were installed to convert the antibody from the naturally rare A allotype to the 
much more common non-A allotype (Fig 1.7, ...359EEM361...  Gm(non-1) variant). In 
contrast, this mutation is not installed in the molecules of abatacept and rituximab 
therefore their sequence at corresponding amino acid positions is ...DEL.... and not 
... EEM. Therefore, abatacept and rituximab heavy chains belong to IgG1 Gm 
variants172, 173. 
 
1.8.1.2. Chemical information 
 
Trastuzumab (rhumAb4D5-8) is a recombinant monoclonal antibody of IgG class. It is 
composed of 1,328 amino acids and has a molecular weight of ~148 kDa164. Like all 
immunoglobulins of class IgG, it contains two identical heavy and two identical light 
chains linked via disulfide bonds. Each heavy chain contains 450 amino acids, with 
theoretical molecular mass calculated from the amino acid sequence derived from of 
cDNA 49284.65 Da and pI 8.49. Each light chain contains 214 amino acids with 
theoretical molecular mass of 23443.1 Da and pI 7.76.  Therefore theoretical 
molecular mass of nonglycosilated trastuzumab is 145455.5 Da173. 
The apparent molecular mass of tratuzumab is higher ~148 kDa, due to the presence 
of N-linked oligosaccharides174.  Based on the length of the hinge region and the 
number and location of interchain disulfide bonds trastuzumab belongs to 
immunoglobulin IgG1 subtype with γ1 heavy chain. The light chain is of κ subtype167. 
Heavy chain variable region (VH) covers the first 120 amino acids and variable region 
of light chain (VL) covers the first 107 amino acids, respectively. Variable regions VH 
+ VL together with respective CH1(121A-218V) and CL (108R-214C) domains form the 
antigen-binding (Fab) regions, whereas the remaining sequences of heavy chain, 
CH2 (231P-343K) and CH3 (344G-450K) linked with hinge region (219E-230P) form Fc 
(fragment crystallizable) regions responsible for effector recognition and binding175.  
Heavy chains are linked via two interchain disulfide bonds at the flexible hinge region 
( C229 -229’ and C232-232’). Heavy and light chains are linked with disulfide bridge 
involving heavy chain C223 and light chain C214.  
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Intrachain disulfide bonds reside in each domain of the H and L chain, stabilizing 
these domains174. In heavy chain there are four intrachain disulfide bonds: VH: 22C-
96C; CH1: 147C-203C; CH2: 264C-324C; CH3: 370C-428C. In light chain, however, there are 
only two intrachain disulfide bonds: 23C-88C and 134C-194C. In correctly folded 
immunoglobulin molecule all cysteine (C) residues are involved in disulfide bond 
formation, therefore no free sulfhydril groups should be present176. 
Like other IgG1 molecules trastuzumab has one N-linked biantennary 
oligosaccharide on the conserved asparagine 300N, buried between the CH2 domains 
(Fig 1.7). 
 
1.8.1.3. Clinical formulation 
 
Trastuzumab (Herceptin®, Roche) is a sterile, white to pale yellow, preservative-free 
lyophilized powder for intravenous (IV) infusion.  
In EU is marketed as single-dose formulation, each vial contains 150 mg 
trastuzumab with excipients histidine hydrochloride, histidine, α,α-trehalose dihydrate 
and polysorbate 20. Reconstitution with 7.2 mL of sterile water for injection (SWFI) 
yields 7.4 mL of a single-dose solution containing approximately 21 mg/mL 
trastuzumab, at a pH of approximately 6.0. The reconstituted solution is physically 
and chemically stable for 48 hours at 2°C – 8°C. 
On the other hand, in USA trastuzumab is approved as multi-dose formulation, each 
multi-use vial of Herceptin® contains 440 mg trastuzumab.  Reconstitution with 20 mL 
of the appropriate diluent (BWFI or SWFI) yields a solution containing 21 mg/mL 
trastuzumab. Herceptin® reconstituted with Bacteriostatic Water for Injection (BWFI), 
containing 1.1% benzyl alcohol is stable for 28 days after reconstitution when stored 
refrigerated at 2−8°C.  As the use of preservative benzyl alcohol is contrary to the 
European Pharmacopoeia requirements, in EU countries only single dose formulation 
has been merketed171. 
 
1.8.1.4. Therapeutic indications 
 
A paradigm shift in the management of metastatic cancer has occurred with the 
development of targeted therapies177. As the first targeted therapy approved for the 
treatment of metastatic breast cancer, trastuzumab has revolutionized the 
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management of this disease due to its clear efficacy, limited toxicity as a single agent 
and synergistic antitumour activity in combination with other chemotherapeutic 
drugs177, 178.  
Trastuzumab is most effective when combined with cytotoxics such as the taxanes 
and vinorelbine, provided that, other combinations such are those with other HER2 
signalling pathways modulators are being investigated. This includes combination 
with HER2 dimerization inhibitor, pertuzumab; HER1 (EGFR) inhibitor, cetuximab and 
tyrosine kinase inhibitors, gefitinib, orlitinib and lapatinib179, 180.  
Numerous clinical trials are ongoing to test the safety and effectiveness of 
trastuzumab for breast and other types of cancer. The Adjuvant Lapatinib And/Or 
Trastuzumab Treatment Optimisation study, (ALTTO), is an international, phase III 
clinical trial of two targeted therapies for HER2-positive breast cancer, trastuzumab 
and lapatinib. It will enrol 8000 participants, in 50 countries, on six continents181. 
Targeting multiple signalling pathways in breast cancer with angiogenesis inhibitor 
bevacizumab is under study, as well. This approach is used to overcome primary or 
acquired resistance to trastuzumab in breast cancer. Additionally, antibody drug 
conjugate (ADC), trastuzumab-DM1 (T-DM1) is being investigated for this purpose. 
This investigational ADC has a proposed dual mechanism of action: anti HER2 
activity and targeted intracellular delivery of DM1, a maytansine derivative that is a 
potent antimicrotubule agent. By targeting HER2 expression on cancer cells, 
trastuzumab-DM1 is designed to deliver chemotherapy to tumour cells in a precise 
manner177, 182. 
Currently, trastuzumab has been approved for the treatment of metastatic and 
adjuvant breast cancer as a single agent or as a combination therapy 183,184. 
In adjuvant setting, trastuzumab has been approved as combination therapy with 
other antineoplastic agents:  
- doxorubicin, cyclophosphamide, and paclitaxel 
- doxorubicin, cyclophosphamide, and docetaxel 
- docetaxel and carboplatin 
 
For the treatment of metastatic breast cancer trastuzumab can be used as single 
agent (monotherapy) in patients who have received one or more chemotherapy 
regimens for metastatic disease and in combination with paclitaxel, docetaxel or an 
aromatase inhibitor183, 185. Herceptin is indicated for the treatment of patients with 
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HER2 positive early breast cancer following surgery, chemotherapy (neoadjuvant or 
adjuvant) and radiotherapy. 
Trastuzumab is well-tolerated but associated cardiotoxicity makes use with 
anthracyclines and in patients with cardiac dysfunction problematic. A further adverse 
observation is that the rate of development of cerebral metastases is 2.8-times higher 
in patients who have received trastuzumab as part of their treatment regimens182. 
 
1.8.1.5. Determination of HER2 status and patient selection 
 
Trastuzumab should only be used in patients whose tumors have HER2 
overexpression or HER2 gene amplification. HER2 overexpression should be 
detected using an immunohistochemistry (IHC)-based assessment of fixed tumor 
blocks. HER2 gene amplification should be detected using fluorescence in situ 
hybridization (FISH) and chromogenic in situ hybridization (CISH). Trastuzumab 
treatment is only appropriate if there is strong HER2 overexpression, as described by 
a 3+ score by IHC or a positive ISH result. For patients with an intensity score of 2+ 
on IHC, confirmation of HER2 positive status by ISH is mandatory. It is also 
recommended for patients with 3+ staining by IHC  
Over the last decade, the (HER2) became established not only as a prognostic 
marker but also as a predictive factor for early-stage and metastatic breast cancer. Its 
clinical utility as a predictive marker to identify candidates for therapy with 
trastuzumab, assumes the availability of high-quality testing and accurate 
determination of HER2 status. Appropriate selection of patients is quite important 
when one considers the potential cardiotoxicity of trastuzumab, and its high cost186. 
 
1.8.1.6. Mechanism of trastuzumab action 
 
As indicated above, humanised recombinant monoclonal antibody trastuzumab is 
directed against the extracellular domain of the tyrosine kinase receptor HER2. 
HER2 or erbB2 is a member of the ErbB protein family, more commonly known as 
the epidermal growth factor receptor family163. 
The HER2 (or c-erbB2) proto-oncogene encodes for a single transmembrane 
spanning, receptor-like protein of 185 kDa, which is structurally related to the 
epidermal growth factor receptor. Overexpression of HER2 is found in 20–30% of 
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human breast cancers, and correlates with more aggressive tumours shortened 
disease-free survival and a poorer prognosis 164,187. When epidermal growth factor 
and its relatives bind the ErbB family of receptors, they trigger a rich network of 
signaling pathways, culminating in responses ranging from cell division to death, 
motility to adhesion. The network is often dysregulated in cancer and lends credence 
to the mantra that molecular understanding yields clinical benefit: over 420,000 
patients have been treated with trastuzumab since its FDA approval over a decade 
ago187, 188.  
A unique feature of human epidermal growth factor receptor 2 (HER2), is the 
absence of a known ligand. Its activity is subsequent to homo- or heterodimerisation 
with the other family members. HER2 levels strongly correlate with carcinogenesis, 
and HER2 overeexpression is an adverse prognostic factor in patients with breast 
cancer. Furthermore, the level of HER2 in human cancer cells is much higher than in 
normal tissues which invoke potentially less sensitivity of latter to the toxicity of 
HER2-targeting drugs. In addition, HER2 overexpression is found in both, primary 
tumor and metastatic sites indicating that anti-HER2 therapy may be effective at all 
disease sites. These features make HER2 ideal target for breast cancer treatment189. 
The proposed mechanisms of action of trastuzumab includes down regulation and 
enhancement of HER2 degradation, inhibition of angiogenesis, inhibition of cell cycle 
progression via inhibition of the mitogen-activated protein kinase pathway, and 
suppression of the antiapoptotic phosphatidylinositol 3-kinase and Akt (PI3K-AKT) 
resulting in apoptosis promotion and the arrest of proliferation. In addition, there is 
evidence supporting a role for trastuzumab in mediating antibody dependent cellular 
cytotoxicity (ADCC) mainly due to the activation of natural killer cells (NK), 
expressing the Fc gamma receptor, which can be bound by the Fc domain of 
trastuzumab 189,190. 
 
1.8.2. Rituximab 
 
1.8.2.1. Nomenclature 
 
Rituximab [FDA USAN INN], Rituxan; MabThera [Trade names]; Synonyms: CD20 Mab, rDNA; anti-
CD20 monoclonal antibody; IDEC-C2B8; CD20 monoclonal antibody, recombinant; DrugBank ID: 
DB00073; CAS : 174722-31-7. 
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Rituximab is genetically engineered chimeric mouse/human monoclonal antibody that 
is produced in mammalian cell culture using Chinese Hamster Ovary (CHO) cells. 
This IgG1-κ antibody contains murine light and heavy chain variable regions, and 
human gamma 1 heavy chain and kappa light chain constant regions1. Rituximab 
binds specifically to the antigen CD20 (human B-lymphocyte restricted differentiation 
antigen Bp35)1 which is found on the surface of normal and malignant B-
lymphocytes191, 192  
    Light chain 
 
     10         20         30         40         50         60  
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIHWFQQKPG SSPKPWIYAT SNLASGVPVR  
        70         80         90        100        110        120  
FSGSGSGTSY SLTISRVEAE DAATYYCQQW TSNPPTFGGG TKLEIKRTVA APSVFIFPPS  
       130        140        150        160        170        180  
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL  
       190   200        210  
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC 
 
     
   Heavy chain 
  
      
   10         20         30         40         50         60  
QVQLQQPGAE LVKPGASVKM SCKASGYTFT SYNMHWVKQT PGRGLEWIGA IYPGNGDTSY  
        70         80         90        100        110        120  
NQKFKGKATL TADKSSSTAY MQLSSLTSED SAVYYCARST YYGGDWYFNV WGAGTTVTVS  
       130        140        150        160        170        180  
AASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS  
       190        200        210        220        230        240  
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKAE PKSCDKTHTC PPCPAPELLG  
       250        260        270        280        290        300  
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY  
       310        320        330        340        350        360  
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD  
       370        380        390        400        410        420  
ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR  
       430        440        450  
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K 
 
 
 
 
 
 
As all antibodies of IgG1 class, rituximab contains four polypeptides linked via 
disulfide bonds: two light and two heavy chains. Each light chain consists of 213 
amino acids and heavy chain of 451 amino acids, respectively194, 195. Amino acid 
sequences of rituximab light and heavy chain are presented in Fig.1.8.  
 
 
Fig. 1.8.  Sequence of rituximab light (up) and heavy (down) chains. Murine variable domain 
highlighted. Complementarity determining regions underlined in italicized face. The heavy 
chain N301 glycosilation site is indicated by underlined boldface. According reference [193]. 
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 1.8.2.2. Clinical Formulation 
 
Rituximab is a sterile, clear, colourless, preservative-free liquid concentrate for 
intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/ml 
in either 100 mg (10 ml) or 500 mg (50 ml) single-use vials. The product is formulated 
for intravenous administration in 9.0 mg/ml sodium chloride, 7.35 mg/ml sodium 
citrate dihydrate, 0.7 mg/ml polysorbate 80, and Sterile Water for Injection. The pH is 
adjusted to 6.5196. 
It was recognized that murine 2B8 antibody specifically bound to CD20 receptor of B 
lymphocytes, however its immunogeneicity, lack of effector functions and short half-
life limited its clinical application. Therefore a reduction of immunogeneicity and 
production of human anti murine antibodies (HAMA) was needed. Additional aim was 
to increase antibody effector functions and half- life, while retaining the binding 
capacity and specificity of CD20 receptor recognition. In this way, chimeric 
recombinant monoclonal antibody rituximab (C2B8) was obtained by the 
chimerization of parent murine antibody 2B8. During the chimerization process 
murine variable domain of heavy and light chain was cloned into the human IgG1 
immunoglobulin framework190. In the chimerised version only variable domains have 
murine origin (around 30 %). The rest of molecule is human (around 70 %). 
 
1.8.2.3. Construction and expression of C2B8 
 
After amplification by the polymerase chain reaction ,he light- and heavy-chain 
variable regions of murine 2B8 were cloned into a cDNA expression vector that 
contained human lgG1 heavy chain and human kappa-light chain constant regions. 
Transfection into CHO cells is performed with electroporation, and the chimeric anti 
CD20 antibody was purified with protein A chromatography. High-level expression of 
chimeric-2B8 antibody (C2B8) was obtained in Chinese hamster ovary cells191. 
Rituximab is produced in cell suspension culture by a CHO transfectoma containing 
the TCAE 8 expression vector in a nutrient medium containing antibiotic gentamicin, 
added to the culture as a final prophylactic measure against mycoplasma 
contamination. Following production of the formulated bulk drug substance is 
aseptically filled into 100 mg and 500 mg glass vials196. 
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1.8.2.4. Chemical information 
 
Recombinant chimeric monoclonal antibody rituximab (IDEC-C2B8) contains 1328 
amino acids. Molecular weight calculated from the primary sequence of the reduced, 
non- glycosylated form of this antibody is 144.544 kDa. 
As all immunoglobulins of class IgG1, it contains two identical heavy and two 
identical light chains linked via disulfide bridges. Each heavy chain contains 451 
amino acids, with theoretical average molecular mass calculated from the amino acid 
sequence derived from of cDNA 49214.50 Da and pI 8.67. Each light chain contains 
213 amino acids with theoretical molecular mass of 23056.69 Da and pI 8.26197.The 
apparent molecular mass of rituximab is higher kDa, due to the presence of N-linked 
oligosaccharides174.   
Heavy chain variable region (VH) includes the first 121 amino acid residues while light 
chain (VL) first 106 residues, respectively. Variable regions of both chains comprise 
complementarity determining regions (CDR1-3), therefore are responsible for antigen 
recognition and binding. On the other hand human Fc γ1 (IgG1) fragment is 
responsible for ADCC and CDC. The human IgG1 heavy chain constant region 
belongs to IgG1 Gm allotype variant172. 
Rituximab heavy chains are linked via two interchain disulfide bonds at the flexible 
hinge region while heavy and light chains are linked with disulfide bridge involving 
heavy chain C-224 and light chain terminal C-214. Intrachain disulfide bonds reside 
in each domain of the H and L chain. In heavy chain there are four intrachain 
disulfide bonds while in light chain there are only two of them. In correctly folded 
immunoglobulin molecule all cysteine (C) residues are involved in disulfide bond 
formation, therefore no free sulfhydril groups should be present176. Like other IgG1 
molecules, rituximab contains only one N-glycosylation site at conserved asparagine 
301N where neutral biantennary oligosaccharides are attached.  
 
1.8.2.5. Therapeutic indications 
 
Rituximab is the first approved targeted biologic therapy for the treatment of 
haematological malignancies and it took very short time from its first description until 
the approval and clinical application. On the other hand, this recombinant antibody is 
a valuable therapeutical option not only for the treatment of blood neoplasms but the 
rheumatic arthritis, as well. Moreover, further clinical studies are being conducted for 
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the treatment of several other indications. Approved clinical indications of rituximab 
include: 
Non-Hodgkin’s Lymphoma 
 
For the treatment of patients with stage III-IV follicular lymphoma rituximab is 
used as monotherapy (second line therapy for chemoresistant patients) and 
combination therapy with CVP* chemotherapy (first line therapy). In addition, in 
combination with CHOP** chemotherapy rituximab is indicated for the treatment of 
patients with CD20 positive diffuse large B cell non- Hodgkin’s Lymphoma. In EU 
and other countries (excluding USA), rituximab maintenance therapy has been 
approved, as well195, 198. 
*cyclophosphamide, vincristine, and prednisolone,  
**cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine, and prednisone 
For the treatment of Non-Hodgkin’s lymphoma rituximab is often combined with 
radioimunoconjugate ibritumomab tiuxetan (Zevalin). Zevalin (IDEC Y2B8) is  an 
immunoconjugate in which the murine IgG1 kappa mAb ibritumomab is covalently 
bound to tiuxetan, linker-chelator for the radioisotopes Yttrium-90 (Y-90) or 
Indium-111 (In-111). The antibody moiety of Zevalin is directed  against the CD20 
antigen. The tiuxetan chelator provides a stable linkage between the antibody and 
the radioisotope, permitting radiation to be directed against antigen-positive cells. 
The beta emission from Y-90 induces cellular damage by the formation of free 
radicals in the target and neighboring cells199. 
 
Rheumatoid Arthritis 
Rituximab in combination with methotrexate is indicated for the treatment of adult 
patients with severe active rheumatoid arthritis who have had an inadequate 
response or intolerance to other disease modifying anti-rheumatic drugs including 
one or more tumour necrosis factor (TNF) inhibitor therapies198. 
 
The efficacy and safety profile of rituximab has been studied in numerous clinical 
trials for other haematological malignancies (chronic lymphocytic leukaemia, Mantle 
cell lymphoma, multiple myeloma etc), non-malignant haematological disorders 
(idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, factor VIII 
deficiency etc.), posttransplant lymphoproliferative disorder and other indications200.  
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Since its approval in 1997, numerous off-label uses of rituximab have evolved in 
different therapeutic areas, mostly in the treatment of autoimmune diseases including 
systemic lupus erythematosus, autoimmune thrombocytopenia and haemolytic 
anaemia, dermatologic diseases including coetaneous B-cell lymphoma, 
dermatomyositis. Graft–versus-host disease (GVHD) and Wegener’s granulomatosis 
have been treated with rituximab as well201, 202. 
 
1.8.2.6. Rituximab targeted cancer therapy  
 
Rituximab binds specifically to the antigen CD20 with binding affinity of 8 nM191. CD 
20 antigen, a nonglycosilated hydrophobic transmembrane phosphoprotein with a 
molecular weight approximately 35 kD located on pre-B and mature B-lymphocytes, 
regulates early steps in the activation process for cell cycle initiation and 
differentiation, and possibly it forms or regulates voltage-independent calcium 
channel198. 
B-cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) 
and associated chronic synovitis. In this context, B-cells may be acting at multiple 
sites in the autoimmune inflammatory process, including through production of the 
Rheumatoid factor (RF) and other autoantibodies;  antigen presentation, T cell 
activation, and/or pro-inflammatory cytokine production. 
On the other hand, CD20 molecule expressed on neoplastic B cells provides a 
promising target for therapy of B-cell lymphomas and leukemia. This antigen is 
especially suitable as a target for antibody mediated therapy because the CD 
antigen: 
 
a. is expressed on  more then  90 % of B-cell- non-Hodgkin’s lymphomas 
but not found on hematopoietic stem cells, pro-B-cells, normal plasma 
cells or other normal tissues 
b. is not normally shed from the cell surface, and there are no detectable 
serum levels of soluble CD20, which might block targeting of antibody 
to lymphomas 
c. it remains on the cell surface without substantial internalization after 
cross-linking with antibodies 
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d. is not expressed in non-haematopoietic tissues, where it could interfere 
with antibody therapy 
Moreover of hematopoietic tumors are accessible and sensitive to lyses by way of 
immuneeffector mechanisms recruited by human Fc domain of this chimeric 
antibody191, 199, 202.   
 
 
1.8.2.7. Mechanism of Action 
 
The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the 
Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible 
mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and 
antibody-dependent cell mediated cytotoxicity (ADCC). Furthermore, rituximab is able 
to induce the death of CD20+ cells in the absence of complement or effector cells 
with number of other pathways, including apoptosis203-205.  
Rituximab is an CD20 depleting agent, therefore during its clinical application it can 
produce numerous adverse reactions.  Due to its immunosupressive effect, during 
anthireumatoid therapy serious infections can occur. Infusion reactions wich may be 
related to cytokine release must be reduced with appropriate premedication. These 
reactions could be worsened in the presence of human antichimeric antibodies 
(HACA). In the NHL patients with high tumor burden severe cytokine release 
syndrom can occur. This syndrome which may be associated with some features of 
tumor lysis syndrom can have fatal outcome.  
Following off-label use of MabThera for the treatment of certain autoimmune 
diseases, cases of fatal Progressive Multifocal Leukoencephalopathy have been 
reported206. 
 
1.8.2.8. Second generation anti CD20 
 
The efficacy and success of Rituximab has led to a few other anti CD20 monoclonal 
antibodies being developed. Currently a humanized version of rituximab, 2H7 
ocrelizumab, is being developed by Genentech Inc., F. Hoffmann-La Roche and 
Biogen Idec Inc. Its evaluation for rheumatoid arthritis and lupus nephritis is under 
Phase III Clinical trials and a Phase II clinical trial for relapsing remitting multiple 
sclerosis is ongoing207.  A fully human anti CD20 rmAb, ofatumumab (HuMax-CD20) 
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is being developed by Genmab A/S in cooperation with Medarex. Phase III clinical 
trials are ongoing evaluating ofatumumab for Non-Hodgkin's lymphoma and 
Refractory Chronic lymphocytic leukaemia (CLL). Drug candidate, modified antibody, 
DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma is being 
developed by InNexus Biotechnology Inc. DXL625 a humanized anti-CD20 
monoclonal antibody enhanced with Dynamic Cross Linking (DXL™) technology may 
afford greater potency and binding affinity then parent antibody208-210. 
 
1.8.3. Abatacept 
 
1.8.3.1. Nomenclature 
 
CTLA4-Ig, rDNA [BIO]; Orencia [TR]; Abatacept [TR USAN INN]; cytototoxic T-lymphocyte-associated 
antigen-Immunoglobulin G1 fragment fusion protein, recombinant; 1-25-Oncostatin M (human 
precursor) fusion protein with CTLA4 (antigen)(human) fusion protein with immunoglobulin G1 (human 
heavy  chain fragment), bimolecular (146→146’)-disulfide [CAS]; 332348-12-6-[CAS RN]; BMS-
188667 [SY]. 
Abatacept is a fusion protein produced by recombinant DNA technology in Chinese 
hamster ovary (CHO) cells211. It is soluble homodimer consisting of two identical 
subunits covalently linked by one disulphide bond. Each subunit consists of the 
modified amino acid sequences of: 
1. the extracellular domain of human cytotoxic lymphocyte associated 
antigen 4 (CTLA-4),  
2. modified sequence of the human IgG1 Fc region. The human IgG1 
sequence is derived from  hinge, CH2 and CH3 domain (Fig. 1.9.) 
 
      1 MHVAQPAVVL ASSRGIASFV CEYASPGKAT EVRVTVLRQA DSQVTEVCAA  
     51 TYMMGNELTF LDDSICTGTS SGNQVNLTIQ GLRAMDTGLY ICKVELMYPP  
    101 PYYLGIGNGT QIYVIDPEPC PDSDQEPKSS DKTHTSPPSP APELLGGSSV  
    151 FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK  
    201 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK  
    251 GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN  
    301 YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 
    351 LSLSPGK 
 
 
Two cysteine residues in the hinge region and one cysteine residue in the CH2 region 
were substituted with serines by mutation of the human IgG1 gene sequence (C→S, 
at positions 130, 136 and 139). Furthermore, amino acid glutamine (Q) was 
Fig.1.9. Amino acid sequence of abatacept.  ECD of human CTLA-4 is indicated by boldface, 
modified sequence of the human IgG1 Fc region is highlighted, and hinge region underlined.   
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introduced between aspartic acid (D) from the ECD of CTLA-4 and glutamic acid (E) 
from the hinge region of the immunoglobulin heavy chain. There is one interchain 
disulphide bridge between the subunits in the CTLA-4 derived regions (Cysteine at 
position 120) and four intrachain bridges within each chain of abatacept (Cysteines at 
positions: 21, 93 and 48, 66 respectively). In addition, one proline (P) was 
unintentionally substituted by serine (S) in the CH2 region (P→S, position 148, Fig. 
1). For secretion into the medium, abatacept is expressed with an upstream signal 
sequence that is cleaved as the protein is secreted (oncostatin). In the Fig. 1.10 a 
scheme of construction and expression of CTLA4-IG has been presented. 
 
 
 
 
 
 
 
 
 
Modifications to the original sequences were introduced to avoid unintended 
disulphide bridge formation and to reduce constant region-mediated biological 
effector functions and complement activation212.  The binding of the immunoglobulin 
to Fcγ receptor and C1q involves residues in the hinge-CH2 region 
(…141APELLGGS148…) and CH2 domains (228E,230K,232K) respectivly213, 214. These 
functions should be avoided since abatacept is not intended to have T-cell depleting 
function. 
Extracellular domain (ECD) of CTLA-4, amino acid sequence from +1-1 to 125 of 
CTLA4-Ig (Fig 1.9) is responsible for interaction with CD80 and CD86 (B7) receptors 
of T-lymphocyte. CTLA-4 is a member of immunoglobulin (Ig) superfamily. The ECD 
of CTLA4 shares homology with immunoglobulins and this part corresponds to the 
variable domain215- 217. 
Crystallographic data have shown that binding surfaces of CTLA-4 and CD80 exhibit 
high degree of shape similarity. The interaction is dominated by hydrophobic 
sequence 97MYPPPYY103 and all residues of this motif except P99 are in direct 
contact with CD80. Amino acid changes in this domain reduce ore abolish binding218. 
Fig.1.10 Construction and expression of CTLA4-Ig. A cDNA construct encoding Signal peptide (SP), 
CTLA-4 (V), and human IgCγ1 (Hinge, CH2 and CH3).  The Amino acid glutamine (D) in parentheses 
was introduced during construction. Asterisks denote C→S mutations. Junctions between CTLA-4 
(capital letters) and the SP of oncostatin M,  and the hinge region are presented as well, Reference 
[217]. 
CH3CH2HingeVSignal peptideOncostatin M
...smasmAMHVA...     ...PCPDSD(Q)epkssdkthtsppsp...* * *
CTLA4-Ig
 - 72 -
On the other hand, IgG1 portion (hinge, CH2 and CH3) endows prolonged circulating 
half life of abatacept molecule219. In addition, abatacept comprises an Fc region, and 
it is therefore amenable to purification by protein A chromatography during the 
downstream processing220. 
Abatacept is produced by fermentation in a transfected genetically engineered CHO 
cell line. For secretion into the medium, abatacept is expressed with an upstream 
signal sequence that is cleaved as the protein is secreted (oncostatin). The fusion 
protein gene contains the coding sequence for the CTLA-4 prepared from the H38 
cell line and the Fc-region (CH2 and CH3 domains) gene derived from a murine 
myeloma cell line producing mouse-human chimeric L6 antibody212. 
 
1.8.3.2 Mechanism of action 
 
Abatacept is the first representative of a new class of drugs known as selective T-cell 
co-stimulation modulators. It selectively modulates a key co-stimulatory signal 
required for full activation of T lymphocytes expressing CD28. Full activation of T 
lymphocytes requires two signals provided by antigen presenting cells (macrophages 
or dentritic cells): recognition of a specific antigen (MHC complex found on antigen-
presenting cells) by a T cell receptor (antigen-specific, signal 1), and a second, 
antigene-indipendent, costimulatory signal. A major costimulatory pathway involves 
the binding of CD80 and CD86 molecules  (B7 molecules) on the surface of antigen 
presenting cells to the CD28 receptor on T lymphocytes (antigene-indipendent signal 
2). The antigen-specific signal is not sufficient to generate a full response, and in the 
absence of a second signal may lead to clonal inactivation or anergy, T-cells may be 
poorly responsive to stimuli and apoptosis may occur. Abatacept selectively inhibits 
the costimulatory pathway by specifically binding to CD80 and CD86, resulting in 
immunosupression and decrease in T-cell activation. 
Studies demonstrate that abatacept modulates T lymphocyte-dependent antibody 
responses and inflammation. Abatacept attenuates human T lymphocyte activation 
(decreased proliferation and cytokine production) and decreases antigen specific 
TNFα, interferon-γ, and interleukin-2 production by T lymphocytes211, 217. 
In the case of abatacept molecule, the binding specificity is achieved using entirely 
human components (human ECD of CTLA-4 and human hinge and Fc fragment), 
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hence it is expected minimal immunogeneicity to the patient and safety for chronic 
use. 
 
1.8.3.3. Clinical formulation 
 
Abatacept (Orencia®, Britol-Myers Squibb) is supplied as a sterile, white, 
preservative-free, lyophilized powder for parenteral administration. Each single-use 
vial of ORENCIA provides 250 mg abatacept, 500 mg maltose, 17.2 mg monobasic 
sodium phosphate, and 14.6 mg sodium chloride. Following reconstitution with 10 mL 
of Sterile Water for Injection (SWFI), the solution of Orencia®  (25 mg/ml) is clear, 
colorless to pale yellow, with a pH range of 7.0 to 8.0211,212.  
 
1.8.3.4. Therapeutic indications 
 
Abatacept (Orencia® Bristol-Myer-Squibb) in combination with methotrexate is 
indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in 
adult patients who have had an insufficient response or intolerance to other disease-
modifying anti-rheumatic drugs including at least one tumor necrosis factor (TNF) 
inhibitor211. 
In USA and Canada abatacept is approved for the treatment of moderate to severe 
RA in patients with an inadequate response to methotrexate and/or TNF-antagonist 
therapy. Therefore, abatacept may be used as monotherapy or concomitantly with 
DMARDs other than TNF antagonists221, 222. 
On August, 2007 FDA accepted for filing  a supplement BLA for Orencia for the 
treatment of paediatric patients with juvenile idiopathic arthritis223, and for this 
indication it was approved on the July, 2008224. 
The studies of the use of abatacept for the treatment of psoriasis and solid organ 
transplant Graft-versus-host disease (GvHD) are in the phase I of clinical tryal225. 
Furthermore, abatacept is being investigated for the treatment of lupus (SLE), 
Crohn’s disease, ulcerative colitis, and multiple sclerosis223.   
Adverse events related to abatacept include hypersensitivity reactions and infections 
and the use of use of abatacept with concomitant biologic RA therapy, i.e., TNF 
blockers, etanercept-Enbrel®, infliximab-Remicade®, adalimumab®; IL-1-blocker 
anakinra-Kineret® may be associated with a greater incidence of infections212. 
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1.8.3.5. Chemical information 
 
Abatacept is comprised of two homologous glycosylated polypeptide chains of 357 
amino acids each forming a covalent homodimer (referred as abatacept “monomer”) 
linked through disulfide bond (120, 120’). The apparent molecular weight of 
abatacept is 92.300 kDa (determined by MALDI/TOF mass spectrometry) of which 15 
% (13.500 kDa) is composed of carbohydrates. The measured molecular weight is 
greater than the theoretical value predicted by the cDNA-derived amino acid 
sequence (39.448 kDa, average mass in reduced form), owing to post-translational 
glycosylation. 
Abatacept is produced in the CHO cells, and therefore as all other proteinic 
molecules it is a complex molecule containing many variants and forms which arise 
during the cell culture. They can be posttranslational modifications and/or 
modifications resulting from subsequent degradation of the molecule. Through the 
recombinant production process various forms of CTLA4-Ig can be produced, i.e. 
glycoforms, conformational isomers, and primary sequence variants226. 
 
1.9. Analytical methodology used for the quality assessment of recombinant 
biological products, trastuzumab, rituximab and abatacept 
 
1.9.1 Trastuzumab analysis 
 
Chemical-physical and biological parameters of trastuzumab have been 
characterized by a number of modern analytical techniques and multiple 
complementary assays have been used for the evaluation of its identity, potency, 
strength and stability.   
Antibody dependent cellular cytotoxicity (ADCC) of trastuzumab was determined by 
51-Cr release, using interleukin-2 activated peripheral blood mononuclear cells as 
effectors and either WI-38 or Her2(+) (SKBR-3) target cells. However this assay is 
not appropriate for potency release testing since it requires fresh donor cells. 
Therefore, antiproliferation activity potency test, able to indicate loss of biological 
activity under conditions of thermal, mechanical, light exposure, oxidative and pH 
stress is used instead167, 227.  
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For quantitative analysis of trastuzumab, capillary isoelectric focusing (cIEF) and 
SDS-capillary gel electrophoresis (SDS-cGE) have been evaluated, demonstrating 
adequate sensitivity, precision and linearity for the use in a quality control 
environment. cIEF and IEF of trastuzumab showed five charge isomorphs (estimated 
pI 8.6-9.1). With both, SDS-CGE and SDS-PAGE the nonreduced trastuzumab 
migrated as a single major peak (band) with six minor peaks (bands) in the 
aggregate and clip regions. After reduction, the electropherogram and the slab gel 
showed the expected heavy chain and light chain fragments with minor peaks 
(bands) in the aggregate, clip regions. When using SDS-CGE for analysis of antibody 
molecules, the method appeared to be precise and compares favorably to analysis 
by Coomassie blue stained SDS-PAGE but was less sensitive than silver stain228. 
Glycosylation and protein modifications are important not only for drug stability and 
efficacy, but also may have consequences for the patient, for example incorrect 
modifications including aggregation may lead to an immune response to therapeutic 
monoclonal antibody229.   
Deamidation of asparagine residue to form aspartic acid and iso-aspartic acid is a 
cause for protein degradation, particularly during long term storage. Most of 
deamidated asparagine forms iso-aspartate, which is not a natural amino acid and 
can potentially be immunogenic. Seven deamidated forms of trastuzumab were 
resolved by cation-exchange chromatography, validated method used for the release 
of trastuzumab production lots. 
Structure differences were assigned by trypsin and endopeptidase Asp-N peptide 
mapping and hydrophobic interaction chromatography (HIC) after papain digestion, 
isoelectric focusing in polyacrylamide gels and Edman degradation. MALDI-TOF 
analysis and Edman degradation were used for the assignment of peptide fractions. 
Deamidation reactions occurred at the light chain (LC) Asn30, and heavy chain (HC) 
Asp102 and Asn55, including: deamidation of LC Asn30 to aspartate (Asp30) in one or 
both LCs, responsible for 2 acidic forms; isomerisation of HC Asp102 to isoaspartate, 
responsible for low potency form, Asp succinimide was also detected; forms with both 
LC Asn30 deamidation and HC Asp102  isomerization modification and deamidation of 
HC Asn55 to isoaspartate165. 
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Deamidation process of peptides and proteins proceeds via a succinimide 
intermediate, followed by partial hydrolysis of succinimide ring to produce 
isoaspartate (the major product) and aspartate (the minor product), Fig . 1.11. The 
sole conversion of Asn30 to aspartate (not isoaspartate) in trastuzumab molecule, 
suggests that the deamidation mechanism in cell culture may be different from that 
during storage229, 165. The form with one deamidated light chain was slightly reduced 
in potency; whereas the form with isoAsp102 in one heavy chain CDR is greatly 
affected (activity of the isomerized species is only 9–21%of the major species). 
All modifications were found in complementarity determining regions) of heavy and 
light chain suggesting that for trastuzumab surface accessibility and flexibility, both of 
which are relatively high in the CDR regions, is more predictive of polypeptide 
degradation sites than the primary sequence165. 
In the trastuzumab terminal lysine processing study, cyanogenbromid (CNBr) 
cleavage after Met431 liberated C-terminal peptides that were isolated by RP-HPLC 
and characterised230.  
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Fig. 1.11. Non-enzymatic damidation of asparagine to aspartic acid ( the minor product) and 
iso-aspartic acid (the major product). According reference [229]. 
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Major product was des-Lys450 peptide (residues 432-449: HEALHNHYT QKSLSLSPG) 
and expected C-terminal peptide (residues 432-450: HEALHNHYT QKSLSLSPGK) 
was the minor product.  
Charge variants resulted due to the trastuzumab incomplete terminal lysine removal 
were resolved with cation-exchange chromatography. Trastuzumab showed five 
charge species: major product had no Lys450 residue, two more basic species had 
one or two Lys450(1) residues, respectively. Two more acidic species were 
deamidated variants at Asn30 in one light chain. One of them had no terminal Lys450 
residue, whereas the other had the terminal lysine residue Lys450.  
Published data suggest that the absence of the C-terminal lysine residues appears to 
be due to the action of carboxipeptidases and plasma-derived antibodies typically 
lack the terminal Lys residues. Therefore the absence C-terminal residues (Lys or 
Arg) is not usually a regulatory concern, as plasma-derived proteins are similarly 
processed230.  
Although oxidation is not as prevalent as deamidation and isomerization in 
antibodies, it can easily occur during their storage175. Trastuzumab methionin 
oxidation was studied by cleaving the Fab and Fc fragments by papain digestion and 
detection of oxidized Fc fragment by hydrophobic interaction chromatography. In 
liquid formulations, trastuzumab underwent oxidation when exposed to intense light 
and elevated temperatures (30-40°C). The rate of oxidation was formulation 
dependent. Trastuzumab single and multiple dose formulation thermo- and 
photostability studies revealed that heavy chain Met255 was the primary site of 
oxidation. Met431, on the other hand, could be as well oxidized, but only under 
extreme conditions231. 
Profiling analysis of oligosaccharides in recombinant antibodies trastuzumab (and 
rituximab) was performed by CE-LIF174,232.  For the derivatisation of PNGaseF 
released N-linked oligosaccharides, derivatization reagent 2-aminobenzoic (2-AA) 
acid was used. CE-LIF analysis of 2-AA labeled oligosaccharides showed that apart 
from typical asialo-biantennary complex type oligosaccharides (major 
oligosaccharide component), sialo-biantennary complex type and high mannose type 
oligosaccharides, in minor amounts were detected, as well.  Their structure was 
assigned by HPLC and MALDI-TOF-MS.  
Asialo-biantennary complex type oligosaccharides, major oligosaccharide 
component, are typical core fucosilated oligosaccharides of mAbs (G0, G1, G1’ and 
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G2). G0 refers to agalacto structure, G1, G1’ monogalactosylated and G2 
digalactosylated structure. The isomeric oligosaccharides G1 and G1’ have one 
galactose residue attached to either of the branches (Fig. 1.12.).  
Sialo-biantennary complex type and high mannose type oligosaccharides were 
present less than 3 % of the total oligosaccharide amount. Monosialidated, 
disialidated and sialohybrid type of minor sialo-oligosaccharides were efficiently 
resolved with CE-LIF. In addition complex profile of high mannose type 
oligosaccharides in minor amounts was detected, as well. 
 
 
  
Peptide mapping was used to assess genetic heterogeneity of recombinant cell lines. 
Detailed structural characterization of trastuzumab revealed heavy chain 
heterogeneity by recovery of two forms of tryptic peptide, with either glutamine (Q) or 
the expected tyrosine (Y) (see Fig 1) at residue 376. Peptide mapping experiments 
indicated that low-level Y376Q variant developed during transfection of the antibody 
heavy and light chain genes into CHO cells233.  
Fig. 1.12. Trastuzumab N-linked oligosaccharide profile. According reference [174].  
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The impact of lyoprotectants, sucrose, and trehalose, alone or in combination with 
mannitol on the stability of trastuzumab at 40°C was assessed234.   
Molar ratios of sugar to protein were used, and the stability of the resulting 
lyophylised formulations was determined by measuring aggregation, deamidation, 
and oxidation of the reconstituted trastuzumab and by infrared (IR) spectroscopy 
(secondary structure) of the dried trastuzumab. Size exclusion chromatography 
(SEC) was used to determine distribution of intact antibody and soluble aggregate 
and/or fragments of trastuzumab. Cation-exchange chromatography was used to 
determine deamidation cyclic imid (Asp succinimid) product. Hydrophobic interaction 
chromatography (HIC) of Fab and Fc fragments of trastuzumab obtained after 
carboxypeptidase and papain treatment was used to detect trastuzumab oxidized 
species. IR spectroscopy and differential scanning calorimetry were used for the 
study of secondary structure of antibody in solution and lyophilized formulations. 
Same study demonstrated that lyophilization of trastuzumab, in the absence of 
sugars, led to a slight increase in aggregate (less than 1.2%). However, at 
accelerated conditions the extent trastuzumab aggregation increased from about 1% 
to >10% after 3 months at 40°C234.  
 
1.9.2. Rituximab analysis 
 
The main source of the antibody heterogeneity results from differences in protein 
glycosylation which is one of the most common post-translational modifications of 
proteins in eukaryotic cells provided that, primary structure variations, deamination, 
deamidation, lysine truncation, methionine oxidation, sulfation and phosphorilation 
create additional IgG variants235. 
Glycosylation of IgG has no effect on antigen binding; however it is critical for effector 
functions including complement fixation, Fc receptor binding on macrophages and 
ADCC.  Moreover, rapid elimination of IgG-antigen complexes from circulation is 
strongly influenced by IgG glycosylation and increase in G0 glycan level is 
associated with reduction in biological activity as measured by a complement 
dependent cytotoxicity (CDC) assay236. Glycosylation of hybridoma produced IgG 
varies with culture age, medium pH or proliferation state237. 
Predominantly, N-linked oligosaccharides present in rituximab belong to asialo, 
neutral complex bianntenary oligosaccharide type, with zero (G0), one (G1 and G1’) 
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and two (G2) terminal galactose residues, as determined CE-LIF, after the PNGase F 
release and derivatization with 2-aminobenzoic acid. With this method minor 
amounts of terminal sialylated oligosaccharides have been detected as well174, 232. 
Manufacturer of pharmaceutical product MabThera® (rituximab) as primary assay for 
characterization and lot release of N-linked glycans on glycoprotein products 
employs CE-LIF based assay wherein  PNGase F release glycans are labeled with 8-
aminopyrene-1,3,6-trisulfonate (APTS) fluorogenic reagent. Additionally, a method 
for direct characterization of major and minor glycan species using capillary 
electrophoresis with on-line LIF detection coupled with mass spectrometry (CE-LIF-
MS), has been reported, as well. Apart from major glycan components this method 
allowed accurate identification of minor glycan such are asialo (0.045 mol of 
sialylated oligosaccharide /mol of protein) and afucosylated species. Since the 
fucosilation affects ADCC and sialylation affects the clearance of therapeutic 
proteins, the identification of these species is of particular importance to the overall 
characterization of rmAbs 88. 
Analysis of rituximab and trastuzumab glycosylation by RP-LC coupled to ESI-MS 
and porous grafit carbon, PGC-LC -MS was reported, demonstrating that neutral and 
sialylated N-glycans of rituximab and trastuzumab could be simultaneously measured 
by LC-ESI-MS. Tryptic glycopeptides were used for the N-glycan profiling by RP-LC-
MS, while porous grafit carbon, PGC-LC -MS of free oligosaccharides delivered 
qualitative structural assignment of antibody glycosilation238. 
A simple and rapid method for the determination of relative amounts of rituximab 
glycoforms differing in terminal galactose was reported. Samples taken from 
recombinant antibody cell culture process were reduced and injected directly into the 
HPLC system for the separation of heavy and light chain antibody fragments, and 
host-cell protein contaminants. Most abundant ions corresponding to the glycoforms 
found on the rituximab heavy chain were monitored by mass selective detection in 
the selected-ion monitoring (SIM) mode40. Charged variants of recombinant 
monoclonal antibodies can be studied with different methods such as Ion-exchange 
chromatography, isoelectric focusing, capillary zone electrophoresis etc235, 239. 
From the amino acid sequence of rituximab molecule is seen that, in both, heavy and 
light chain the first amino acid N-terminal residue is glutamine (Q), for example, the 
first nine residues of heavy and light chains are: 1Q V Q L Q Q P G A… (HCn) and 1Q 
I V L S Q S P A…(LC). Lysine K451 and cysteine C213 are the C-terminal residues of 
 - 81 -
heavy and light chain, respectively. After papain cleavage, two types of IDEC-C2B8 
(rituximab) charge variants have been identified.  
 
1. Inherent charge variants arising during cell culture from the enzymatic 
removal of the C-terminal lysine from one or both heavy chains to reveal a C-
terminal glycine (Fc-0Lys; Fc-1Lys, and Fc-2 Lys) collectively known as Fc-
Lys variants.   
2. Additional charge variants which arise from the sequential cyclization of basic 
amino N-terminal glutamine (Q) of both the heavy and light chains to produce 
neutral pyroglutamate, a deamination reaction: Fab-pEpE -pyroglutamate at 
both N-termini; Fab-pEQ-pyroglutamate at heavy chain N-terminus and the 
glutamine at the light chain N-terminus; Fab-QpE- glutamine at the heavy 
chain N-terminus and the pyroglutamate at the light chain N-terminus and 
Fab-QQ-glutamine at both N-termini. These variants are collectively termed 
Fab pE/Q variants. At the lower temperatures predominant are cyclized 
species and at the higher partially cyclized species. Since the exposure of 
elevated temperatures decreases the activity of rmAb, product quality could 
be controlled by monitoring of the ratio of Fab pE/Q variants. 
These charge variants can occur in a random combination at the four N-termini and 
the two heavy chain C-termini of the antibody leading to a possibility of 15 different 
species240. 
Extensive stability data were provided by manufacturer of rituximab. Numerous 
stability parameters including pH, color and appearance, SDS-PAGE, UV 
spectroscopy, Size exclusion chromatography (SEC), Ion exchange chromatography 
(IEC), rabbit cellular mediated cytotoxicity (CMC), were examined. Short term 
exposure (24 hours) of the product to intense light showed no effect on the product 
stability. However, increased fragmentation and loss of biological activity was caused 
upon to long-term exposure (3 days). The characterization of the rituximab is 
extensive and requires a large battery of different techniques as amino acid analysis, 
amino-terminal sequence analysis, peptide mapping, and analysis of 
oligosaccharides, ion-exchange chromatography, cIEF, SDS-PAGE, and Circular 
Dichroism. The oligosaccharide structure was investigated by capillary zone 
electrophoresis (CE) and MALDI-TOF after isolation from HPAEC-PAD241. 
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Immunoreactivity of rituximab was tested by radiolabeling antibody with 125I or with 
fluorescein isothiocyanate (FITC). They were tested by direct binding to CD20+ target 
cells and detected either by gamma counter or by flow cytometry using a FACScan 
analyzer. Binding of human complement C1q and CDC was determined by 
fluorescein conjugation191.  For the determination of rituximab serum levels flow 
cytometry and ELISA-based assays have been described242, 243.  
Rituximab lot release testing included physicochemical and biological methods such 
are: color and appearance, SDS-PAGE, peptide mapping, fragment IEC-HPLC, SEC-
HPLC, Glycan content, cIEF, complement dependent cytotoxicity CDC, UV- VIS 
spectroscopy scan, sterility, endotoxin testing, osmolality and polisorbat 80 
concentration. Validated human CDC assay was used for the determination of 
potency. Galactose content on the heavy chain oligosaccharide is found to be critical 
parameter for biological activity, therefore another release test for glycan content was 
developed (CE-LIF). It was demonstrated that while galactose content did not 
influence rituximab binding it influenced biological activity measured with CDC assay. 
Validated UV-VIS spectroscopy is used as protein concentration release test. cIEF 
was used to positively identify rituximab from other recombinant monoclonal 
antibodies made by the Manufacturer244. 
 
1.9.3. Abatacept analysis  
 
Multiple charged isoforms in the native abatacept drug substance ranging from pI 4.5 
- 5.5 are detected using isoelectric focusing (IEF) 224. Literature data revealed that the 
drug substance is a mixture of different iso- and glycoforms of the protein and in 
addition to heterogeneity derived from different glycoforms, there is N-terminal and C-
terminal heterogeneity245. Abatacept contains N-linked and O-linked oligosaccharides 
in each chain.Three N-linked glycosylation sites are confirmed by peptide mapping to 
occur at Asn76, Asn108 (both at CTLA4 region) and Asn207 (Fc region) and two O-
linked glycosylation sites have been identified at Ser129 and Ser139245. 
Glycosilation differences have been shown to impact the pharmacokinetics and the 
clearance of product and terminal sialic acids of the carbohydrate moieties are said to 
be important for pharmacokinetics of the protein246. Published data have documented 
the presence of N-land O-linked oligosaccharides in the CTLA4-Ig molecule. It was 
shown that N-linked oligosaccharides are neutral asialo bianntenary complex type, 
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while O-linked oligosaccharides have different degree of sialidation: monosialidated 
and disialidated being the predominant type. CHO derived CTLA4-Ig has α2,3-linked 
sialic acids and the terminal sialic acids are important for its in vivo activity247, 248. 
Underivatised oligosaccharide mixture of CTLA4-Ig (abatacept) has been examined 
by CE and HPAEC-PAD under normal and thermally stressed conditions. Both 
methods indicated CTLA4-Ig derived oligosaccharides being predominantly neutral, 
disialidated (one specie) and monosialidated species (three species) 249 (Fig. 1.13). 
Oligosaccharide composition of different lots of CTLA4-Ig has been examined by 
electrophoresis of fluorophore-conjugated carbohydrates. It was indicated that 
CTLA4-Ig oligosaccharides are predominantly of N-linked biantennary complex-
type247 and in vivo clearance profiles of CTLA4-Ig showed that the clearance rate is 
inversely proportional to the oligosaccharide N-acethylneuraminic content.  
 
 
 
 
 
 
 
 
 
For the demonstration of abatacept quality, numerous release testing have been 
provided by the Manufacturer of this biological drug substance: peptide mapping 
(which can be used as stability indicating assay, as well), to demonstrate molecular 
identity of abatacept, capillary electrophoresis, to discriminate abatacept from related 
molecule belatacept, isoelectric focusing to show the distribution of different 
glycoforms, IEX HPLC, monosaccharide analysis, to show the consistency of 
glycosylation. Bioassay has been used for the release and stability testing245. 
 
 
 
 
 
disialidated O-linked olygosaccharide
NeuNAcα-(2-3)Galβ-(1-3)GalNAc-Ser
monosialidated O-linked olygosaccharide
GlcNAcβ(1-2)Manα1
GlcNAcβ(1-2)Manα1
63Manβ(1-4)GlcNAcβ(1-4)GlcNAc-Asn
asialo complex biantennary olygosaccharide
NeuNAcα-(2-3)Galβ-(1-3)GalNAc-Ser
NeuNAc
α-(2-6)
Fig.1.13. Oligosaccharide profile of abatacept. According reference [247] 
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2. The aims of study 
 
 
1. Evaluation of a reliable 2-DE method for identification and purity assessment 
of therapeutically relevant rDNA derived biological medicinal products: 
humanized monoclonal antibody trastuzumab, chimeric monoclonal antibody 
rituximab and fusion protein abatacept. 2-DE method should be able to assess 
product charge heterogeneity, isomorf pattern and posttranslational 
modifications. This method should allow demonstration of product identity and 
structural integrity comparing 2-DE patterns of the product and reference 
preparation.   
 
2. Development and optimization of a 2-DE method for the separation of rDNA 
medicinal products complemented with MALDI-TOF MS analysis of resulting 
peptides generated after in gel tryptic digestion aiming the product identity 
confirmation. The suitability of peptide mass fingerprinting analysis as a 
routine technique for the rapid detection of these products should be 
investigated. Method should allow rapid identification of heavy and light chains 
of antibodies and both fusion partners of fusion proteins, therefore specific 
discrimination of antibodies of different origin, i.e. chimeric, humanized and 
antibody related substances i.e. fusion proteins should be achieved.    
 
 The suitabilities of aforementioned analytical methodologies as official   
 pharmacopoeia methods of quality testing of recombinant biological medicinal 
 products should be assessed as well.       
 
3. Forced degradation study of recombinant monoclonal antibody trastuzumab 
and the assessment of the stability indicating power of 2-DE method.  
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3. Working objectives 
 
This work focuses on the evaluation of new analytical methodology for quality study 
and the exploring of new quality parameters of rDNA derived biological medicinal 
products.  
1. Planar electrophoresis techniques, SDS-PAGE and IEF have been widely used for 
the quality control of rDNA derived medicinal products such are recombinant 
monoclonal antibodies (rmAbs): 
 
- Purity and structural integrity characterization 
- Stability characterization: due to their stability indicating power, these 
techniques are used to detect  antibody fragmentation and aggregation 
under accelerated conditions and the appearance of extra bands is criterion 
of  purity and stability. 
However, SDS-PAGE and IEF performed separately provide limited information 
related to the rmAbs heterogeneity. Since charge and other variants define the 
quality of these products, establishment of suitable methods to monitor their 
heterogeneity would be of great importance for their overall quality assessment. 
Logically, as 2-DE combines separation in two dimensions, according molecular 
weight (SDS-PAGE) and isoelectric point, more comprehensive information related to 
the heterogeneity of rmAbs products can be obtained. 
 
2. MALDI-TOF MS analysis has been used for the quality assessment of recombinant 
biological medicinal products. MALDI-TOF MS analysis of peptides obtained after in 
gel tryptic digestion of proteins separated by SDS-PAGE and 2-DE and peptide mass 
fingerprint analysis has been used in proteomic studies for the identification of 
proteins from SDS-PAGE and 2-DE gels, therefore, fast and simple identification of 
therapeutic rmAbs and their related pharmaceutical products using peptide mass 
fingerprinting could be achieved.   
 
In order to achieve objectives of this work, three therapeutically relevant medicinal 
products obtained by rDNA technology will be studied:  
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1. Humanized monoclonal antibody (rmAb),  trastuzumab (Herceptin®, Roche)  
2. Chimeric monoclonal antibody, rituximab (MabThera®, Roche), and  
3. Fusion protein, abatacept (Orencia®, Bristol-Mayers) 
In order to develop a suitable gel electrophoresis method complemented with MALDI-
TOF MS analysis for the assessment of quality of rDNA derived biological medicinal 
products, performances of the following analytical techniques will be investigated: 
 
1-D electrophoresis analysis under reducing and non-reducing conditions  
 
• Molecular weight estimation 
• Purity assessment 
• Deglycosilation monitorization and optimization  
• Forced degradation testing of trastuzumab  
• Optimization of staining procedure: linearity, sensitivity of staining, 
reproducibility. Coomassie and Silver staining procedures will be performed. 
 
2-D electrophoresis analysis 
• Estimation of molecular weight and pI 
• Charge heterogeneity and isomorph pattern study (2-DE patterns) 
• The study of posttranslational glycosylation. N-glycosidase F, sialidase and O-
glycosidase will be used to remove N-linked glycans, terminal sialic acids and 
O-linked glycans, respectively. Reduction of sample complexity for subsequent 
MALDI-TOF MS analysis will be attempted as well 
• The study of lysine truncation using carboxypeptidase B  
• In order to assess the effects of severe conditions on the stability of 
reconstituted solutions and to validate the stability indicating power of 2-DE, 
forced degradation testing of trastuzumab will be undertaken. The rate of 
chemical degradation will be increased by subjecting the reconstituted 
pharmaceutical formulation, Herceptin® to exaggerated conditions. Forced 
degradation, including thermal stability study (4-8°C, room temperature, 37,  
and 50°C), oxidation (hydrogen peroxide solution 1 and 3 %), low  pH 
influence (trifluoroacetic acid 1 %),  and shear stress testing will be performed. 
Testing frequency: weekly, 2 months and daily, 1 week.  
 - 87 -
• For 2-DE method development the following parameters and procedures will 
be optimized: sample dialysis, optimization of IEF procedure, application of 
different IPG strips (3-11 NL, 6-9 L, 4-7 L, and 3-6 L); optimization of gel 
concentration, application of gradient gels.  For the visualization of gel spots, 
Silver and Coomassie staining procedures will be optimized.  
• Optimization of electric parameters: voltage and current intensity, during the 
first (IEF) and the second dimension (SDS PAGE). 
 
In gel tryptic digestion  
 
In gel tryptic digestion of sample proteins form selected 2-DE gel positions and the 
extraction procedure of resulting peptides will be optimized.  
 
MALDI-TOF-MS sample preparation and presentation 
 
Optimization of sample preparation and deposition, selection of appropriate 
concentrations of matrix and sample for optimal cocrystalization will be tested as well.  
 
Peptide mass fingerprinting analysis 
 
For the identification purpose, experimental peptide masses will be compared with 
peptide masses obtained by in-silico trypsin digestion using different search engines 
and databases.  
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4. Material and Methods 
 
4.1. Materials and reagents 
 
1. Acetonitrile, use tested for MALDI-MS (Sigma -Aldrich Chemie GmbH, 
Steinheim, Germany) 
2. Acetic acid, conc. 99-100%, HPLC grade (Merck KGaA, Darmstadt, Germany) 
3. Acrylamide 2X, research grade (Serva Electrophoresis GmbH, Heidelberg, 
Germany) 
4. Agarose SERVA Standard low EEO, research grade (Serva Electrophoresis 
GmbH, Heidelberg, Germany) 
5. Ammonium hydrogen carbonate, purum, p.a. (Fluka Chemie GmbH, Buchs 
Switzerland) 
6. Ammonium persulfate, analytical grade (Serva Electrophoresis GmbH, 
Heidelberg, Germany) 
7. Angiotensin II Mass Spec. Standard (Sigma -Aldrich Chemie GmbH, 
Steinheim, Germany) 
8. Aqua bidestillata (Mayrhofer Pharmazeutika GmbH & Co KG, Leonding, 
Austria 
9. Aqua purificata PhEur (Elisabeth Schubert Ges.m.b.H, Vienna Austria) 
10. Bradykinin fragment 1-7, Mass Spec. Standard (Sigma -Aldrich Chemie 
GmbH, Steinheim, Germany) 
11. Bromphenol Blue, Na-salt, research grade (Serva Electrophoresis GmbH, 
Heidelberg, Germany) 
12.  1-Butanol zur Synthese, (Marck Schuchardt, Hohenbrunn, Germany) 
13. Carboxypeptidase B, from pig pancreas, (Roche Diagneostics GmbH, 
Mannheim, Germany).  
14. CHAPS, research grade (Serva Electrophoresis GmbH, Heidelberg, Germany) 
15. Chorhydric acid, p.a. (Donauchem GmbH, Vienna Austria) 
16. Coomassie Brilliant Blue G 250, pure (Serva Electrophoresis GmbH, 
Heidelberg, Germany) 
17. α-Cyano-4-hydroxy- cinnamic acid, desiccate (Sigma -Aldrich Chemie GmbH, 
Steinheim, Germany) 
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18. Dithiothreitol, research grade (Serva Electrophoresis GmbH, Heidelberg, 
Germany) 
19. DryStrip Cover Fluid (Amersham Biosciences AB, Uppsala, Sweden)  
20. Ethanol 96 %, HPLC grade (Merck KGaA, Darmstadt, Germany) 
21. Formic acid 99% pure (Acros Organics, Geel, Belgium) 
22. Formaldehyde sol. 37 %, puriss, p.a. (Fluka Chemie GmbH, Buchs 
Switzerland) 
23. Glycerol, plant  (Serva Electrophoresis GmbH, Heidelberg, Germany) 
24. Glycine, analytical grade (Serva Electrophoresis GmbH, Heidelberg, 
Germany) 
25. Hydrogen peroxide,  35 % v/v (Merck KGaA, Darmstadt, Germany) 
26. ImmobilineTM DryStrip pH 3-6 L; 6-9 L, 4-7 L, 3-11 NL (GE Healthcare Bio-
Sciences AB Uppsala, Sweden) 
27. Insulin oxidized beta chain Mass Spec. Standard (Sigma -Aldrich Chemie 
GmbH, Steinheim, Germany) 
28. Iodoacetamide, research grade (Serva Electrophoresis GmbH, Heidelberg, 
Germany) 
29. IPG Buffers (pH 4-7; 6-11; 3-11), (GE Healthcare Bio-Sciences AB Uppsala, 
Sweden) 
30. Methanol, HPLC grade (Fisher Scientific UK Ltd. Loughborough, UK) 
31. MilliQ Water, Resistivity 18.2 MΩcm at 25 °C (Millipore, Bedford, USA) 
32. Neuraminidase (Sialidase), from Arthrobacter ureafaciens, (Roche 
Diagneostics GmbH, Mannheim, Germany) 
33. N-Glycosiadase F  (PNGase F) from Flavobacterium meningosepticum, 
recombinant-E.coli , (Roche Diagneostics GmbH, Mannheim, Germany) 
34. N,N,N’,N’-Tetramethylene diamine, research grade (Serva Electrophoresis 
GmbH, Heidelberg, Germany) 
35. N,N’-Methylenebisacrylamide 2X, research grade (Serva Electrophoresis 
GmbH, Heidelberg, Germany) 
36. O-glycosidase from Diplococcus pneumoniae (Roche Diagneostics GmbH, 
Mannheim, Germany) 
37. Precision Plus Unstained ProteinTM Standards, (Bio-Rad Laboratories, USA) 
38. Silver nitrate analytical grade (Serva Electrophoresis GmbH, Heidelberg, 
Germany) 
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39. Sodium carbonate anhydrous, pro analysi (Riedel de Haën, Seelze, Germany) 
40. Sodium dihydrogen phosphate monohydrate 99% (Sigma -Aldrich Chemie 
GmbH, Steinheim, Germany) 
41. Sodium dodecylsulfate for biochemical application (Serva Electrophoresis 
GmbH, Heidelberg, Germany) 
42. Sodium hydroxide, 2 M (Merck KGaA, Darmstadt, Germany) 
43. Sodium thiosulfate anhydrous, purum p.a. (Fluka Chemie GmbH, Buchs 
Switzerland) 
44. 2-Propanol “baker analysed” (J.T. Baker B.V., Deventer Holland) 
45.  Potassium hexacyanoferrate III, (Neuber GmbH, Austria) 
46. Trifluoroacetic acid 1 %, for MALDI MS (Sigma -Aldrich Chemie GmbH, 
Steinheim, Germany) 
47. Tris(hydroxymethyl)aminomethane, research grade (Serva Electrophoresis 
GmbH, Heidelberg, Germany) 
48. Triton X-100 pure (Serva Electrophoresis GmbH, Heidelberg, Germany) 
49. Trypsin, sequencing grade (Roche Diagnostics GmbH, Mannheim, Germany) 
50. Urea, analytical grade (Serva Electrophoresis GmbH, Heidelberg, Germany) 
 
Pharmaceutical formulations of recombinant monoclonal antibodies (rmAbs) 
trastuzumab (Herceptin®) and rituximab (MabThera®) were kindly provide from 
Rudolfstiftung Hospital in Vienna, and recombinant fusion protein abatacept 
(Orencia®) was bought in a Pharmacy Shop.  
 
4.2. Apparatus 
 
Kompact Seq, Kratos Analytical, Manchester UK.  (MALDI-TOF MS) 
Hoefer® SE1200 Easy BreezeTM Gel Dryer, Cat Nr: 80-6290-71, (Amersham 
Biosciences Inc). 
Freeze Dryer  Christ Alpha 2-4 LSC, Cat Nr: 102042; Rotations-Vakuum-
Konzentrator RVC2-18, Cat Nr: 100218. (Martin Christ Gefriertrockungsanlagen 
GmbH, Osterode am Harz, Germany) 
Heraeus Biofuge Stratos Cat Nr: 282026 (Kendro Laboratory Products, Osterode 
am Kalkberg, Germany) 
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Mini-PROTEAN® 3 Cell, Cat Nr: 165-3301. Components: Spacer Plate [10.1 cm (W), 
8.3 cm (H)]; Short Plate [10.1 cm (W), 7.3 cm (H)], Gel size [8 cm (W), 7.3 cm (H)]; 
Casting Frame; Combs; Buffer Dam; Electrode Assembly; Clamping Frame; Mini 
Tank and Lid (Bio-Rad Laboratories, USA). 
PROTEAN® II Xi Cell for vertical electrophoresis. Components: Lower Buffer 
Chamber, Central Cooling Core, Lid with electrical leads, Casting Stand, Sandwich 
Clamps, Casting Stand, Long plates (20 X 20 cm), Short plates (22.3 X 20 cm), 
Spacers (22.3 cm X 1 mm) (Bio-Rad Laboratories, USA) 
Hoefer SG 500 Gradient Maker Catalogue Number: 11238-2/28/89 (Hoefer 
Pharmacia Biotech, San Francisco, USA) 
IPGPhorTM Isoelectric focusing system, Catalogue Nr: 80-6415-35 (Ge 
Healthcare, Biosciences AB, formerly Amersham Pharmacia Biotech, Uppsala, 
Sweden) 
PowerPac 1000 (Power Supply), Catalogue Nr: 165-5055 (Bio-Rad Laboratories, 
USA) 
MultiTemp III Thermostatic circulator, Product code: 18-1120-77, (GE Healthcare 
Biosciences AB, Uppsala, Sweden) 
Cellulose dialysis tube Φ21.4 mm X 33.3 mm X 25 m Cut off: 12000-14000, (AS 
ONE, Japan Medical Science, Japan) 
Thermomixer comfort, Catalogue Number: 5355 000.011(Eppendorf AG, Hamburg, 
Germany) 
Ultrasonic bath 
Applied Software  
PDQuest 6.2.1. (Bio-Rad Laboratories, USA) 
Kompact MALDI Software Version 1.2.2 Kratos Analytical, Manchester UK. 
 
4.3. Isoelectric focusing 
 
For 2-DE electrophoresis analysis in the first dimension the Immobiline DryStrip gels 
(length 18 cm ±2 mm) of following pH intervals have been used: 
 
- 3-6 L (abatacept) 
- 4-7 L (abatacept) 
- 6-9 L (trastuzumab, rituximab and abatacept) 
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- 3-11 NL (trastuzumab, rituximab and abatacept) 
 
4.3.1. Sample preparation 
 
In 1 ml aliquot of Rehydration solution (A1), 5 mg/ml DTT and 5 μl/ml IPG Buffer 
were added just prior to use. The pH of IPG Buffer was selected according the pH 
interval of Immobiline DryStrip gels: 
 
- IPG Strips 3-11 NL, IPG Buffer 3-11 NL 
- IPG Strips 6-9 L, IPG Buffer 6-11 L  
- IPG Strips 3-6 L and 4-7 L, IPG Buffer 4-7 L   
 
The given amount of sample was mixed with Prepared rehydration solution A2 (A1 
plus DTT and IPG Buffer) and shortly vortexed. 10 μl (1 μg/μl) of sample solution 
were pipetted into 340 μl Prepared rehydration solution A2, for 2-DE electrophoresis 
optimization and Deglycosylation experiments, while for MALDI-TOF analysis of 2-D 
gel electrophoresis separated proteins 10 μl ( 5 μg/μl) sample were pipetted into 340 
μl Prepared rehydration solution A2. For 18 cm long strips total volume of 350 μl 
mixture is obtained. The mixture was allowed to stay 1 hour at room temperature with 
occasional vortexing (3 X 2 s) followed by centrifugation (15 000 g, 5 min) to remove 
eventual insoluble components. 
 
4.3.2. Rehydration and Isoelectric focusing 
 
Required number of Strip Holders was put onto cooling plate/electrode contact area 
of IPGphor strip holder platform. 
350 μl of sample-containing rehydration solution was carefully pipetted into the Strip 
Holder base. The solution was evenly distributed over the channel length. The cover 
foil was carefully removed from the Immobiline dry strip, starting from the anodic (+ 
end), and using forceps the strip was slowly placed onto rehydration solution, gel 
side-down. Trapping air bubbles under the Immobiline dry strip gel should be 
avoided.  
To ensure that the rehydrated IPG strip gels do not dry out during rehydration and 
the focusing process they are overlaid with 1-1.5 ml Cover Fluid and covered with 
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plastic closure. Finally, after closing the IPGphor cover, the selection of instrument 
program and entering desired run parameters the run was started. Temperature was 
set at 20°C and current limited to 50 μA per IPG strip. After the IPG strips have been 
rehydrated (11-13 hours), IEF started according the programmed parameters (Table 
4.7). 
    
 
 
Temperature 20°C   
Current limit 50 μA per IPG strip   
Sample volume 350μl (18cm long and 
3mm wide strips) 
  
Step Voltage Mode  Time 
Rehydration 0 V  11-13 hours 
IEF S1 1000 V Gradient 1 hour 
IEF S2 2000 V Gradient 0.5 hours 
IEF S3 4000 V Gradient 0.5 hours 
IEF S4 8000 V Gradient 0.5 hours 
IEF S5 8000 V Step-n-hold 72000 Vhrs 
IEF S6 (optional) 2000 V Step-n-hold 0-3 hours 
 
The IPGphor can handle up to 12 Strip Holders (length, 7, 11, 13 or 18 cm). For the 
rehydration and IEF the program was set to allow loading of Strip Holders with 
sample dissolved in rehydration buffer in the afternoon, followed by automatic start of 
IEF during the night so that IEF was finished the next day.After IEF process, 
IPGstrips are taken from Strip Holders and using a clean paper towel residual cover 
fluid is carefully removed from the IPG strips. In this point, there are two possibilities: 
IPG strips can be used immediately for the second dimension or, they can be kept at 
lower temperature. In this work, for reproducibility purposes, IPG strips are stored 
between two sheets of plastic film at -80°C.  
 
4.3.3. Preparation and cleaning of Strip Holders 
 
In order to remove residual proteins after each first dimension IEF-run, Strip Holders 
have been cleaned with a neutral pH detergent (Strip Holder Cleaning Solution®)  
using a toothbrush for vigorous agitation, and rinsed with deionised water.  
Table 4.7. IPGphor running conditions 
 - 94 -
For the efficient protein removal Strip Holders were baked at 250°C for 2.5 hours. 
In order to prevent contamination of clean Strip Holders they are always handled with 
gloves.  
 
4.4. Second dimension. SDS-PAGE 
 
After the IEF, the second-dimension SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) has been performed on vertical system, consisting on four steps: 
 
1. Casting of discontinuous vertical SDS gels  
2. Equilibration of the IPG gel strips 
3. Placing of the equilibrated IPG gel strip on top of the SDS gel 
4. Electrophoresis 
 
Discontinuous gels consist of a resolving or separating (lower) gel and a stacking 
(upper gel). 
 
4.4.1. Preparation of resolving gel 
 
Gels are cast into assembled glass plate sandwiches in a casting stand.  
Single percentage resolving gels (%T 10%, 12.5 % and 15 %) are made combining 
all reagents presented in Table 4.8 leaving out ammonium persulfate and TEMED. 
The monomer solution obtained is degassed 5 minutes in Ultrasonic Bath. TEMED 
and ammonium persulphate are added after degassing and the flask is gently 
swirled, being careful not to generate bubbles. After mixing, the monomer solution is 
poured down the spacer into each sandwich to a level about 4 cm from the top of the 
shorter plate.  For this purpose a 25 ml pipette was used. Immediately after pouring 
each monomer solution was overlaid with a layer of water-saturated 1-butanol (1.0 
ml) to minimize gel exposure to oxygen and to create a flat gel surface. After ca 10-
20 min a sharp liquid gel interface was visible. After allowing a minimum of 1 h for 
polymerization, water-saturated 1-butanol overlay was removed and the gel surface 
was rinsed with deionized water.  
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 Resolving gel Stacking gel 
Final gel conc. (% Acrylamide) 10 % 12.5 % 15 % 4 % 
Acrylamide Stock Solution (Sol B1) 32.47 ml 40.58 ml 48.70 ml 0.65 ml 
Resolving gel buffer (Sol B2) 25 ml 25 ml 25 ml - 
Stacking gel buffer (Sol B3) - - - 1.25 ml 
MilliQ water 42 ml 33.88 ml 25.77 ml 3.05 ml 
APS (Sol B4) 62.50 μl 62.50 μl 62.50 μl 5 μl 
TEMED 468.75 μl 468.75 μl 468.75 μl 50 μl 
Total volume 100 ml 100 ml 100 ml 5 ml 
 
4.4.2. Preparation of stacking gel 
 
In this work, stacking gels were cast just before use. Volume and concentration of 
monomer solution of stacking gels is lower than of resolving gels (Table 4.8). All 
reagents needed for the preparation of stacking gel except APS and TEMED were 
mixed and degassed 5 min in Ultrasonic Bath. TEMED and ammonium persulphate 
were added after degassing and the flask is gently swirled, being careful not to 
generate bubbles. Before pouring the Stacking gel the area above separating gel 
was completely dried with the use of filter paper. Using a 5 ml pipette tip the stacking 
gel was poured into each sandwich to a level about 1 cm from the top of shorter plate 
and immediately overlaid with the layer of water-saturated 1-butanol. After allowing a 
minimum of 1.5 h for polymerization, water-saturated 1-butanol overlay was removed, 
gel surface was rinsed with deionized water and area above the stacking gel was 
dried with the use of filter paper. In order to prevent contamination of glasses and 
other working surface with hand and due to acrylamide neurotoxicity, plastic glows 
were used in all phases of electrophoresis analysis.   
 
4.4.3. Equilibration of the IPG gel strips 
 
The second-dimension gels were prepared and ready to accept the Immobiline 
DryStrip gel before beginning the equilibration protocol.  
4.4.3.1. Preparatory steps 
 
Table 4.8. Single-percentage gel recipes for discontinous SDS gels 
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- 10 ml DTT Equilibration solution (1 %) was prepared dissolving 100 mg DTT 
in 10 ml SDS Equilibration Buffer, Sol C1.  
- 10 ml Iodoacetamide (IAM) Equilibration solution (2.5 %) was prepared 
dissolving 250 mg IAM in 10 ml SDS Equilibration Buffer, Sol C1.  
The volume of 10 ml for each solution was necessary for equilibration of 2 strips (18 
cm long). This amount was divided in two parts of 5 ml for the equilibration of each 
strip. 
 
4.4.3.2. Equilibration step 
 
Focused IPG strips were removed from the plastic foil from -80 °C freezer and 
allowed to warm to room temperature for 1-2 min.  The IPG strips were equilibrated 
twice, each time for 15 min. The first equilibration step is performed in DTT 
Equilibration solution followed by the second equilibration in IAM Equilibration 
solution. IPG strips (gel side-up) were equilibrated in equilibration tray by gently 
shaking on a rocker. 
During the first step, DTT preserves fully reduced state of denatured proteins, while 
IAM in the second step, alkylates thiol groups on proteins and residual DTT. 
Unwanted reactions of Cys residues for subsequent MALDI-TOF MS analysis are 
minimized as well.  
 
4.4.3.3. Placing of the equilibrated IPG gel strip on top of the SDS gel 
. 
Molecular weight standards (1 μl for silver stained gels and 4 μl for Coomassie 
stained gels) were applied to a section of filter paper and placed at the anodic end 
the SDS-PAGE gel.  
Already equilibrated IPG strips were lubricated immersing them in the Diluted 
cathode buffer for few seconds. For easier application on the stacking gel IPG strips 
were cut in both ends (about 5 mm each side) and using forceps positioned between 
the plates on the second-dimension gel surface with the plastic backing against 
shorter glass plate. With a thin spatula, the IPG strip was gently pushed down to 
achieve complete contact with the top surface of the stacking gel ensuring no 
trapping of air bubbles. After that IPG strips (and molecular weight standards) were 
overlaid with about 1.5 ml of Agarose sealing solution, Sol C2 cooled to 40-50°C.  
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Agarose sealing solution, Sol A7 was always prepared during the IPG strip 
equilibration because of the time needed for agarose melting (about 10 min in 100 °C 
heat block) and cooling it to 40-50°C.  After allowing a 2-3 min for agarose to solidify, 
gel cassette was inserted in the electrophoresis unit. Temperature controller was 
switched on and temperature adjusted to 15 °C.  
Into the tank of electrophoresis unit are poured 3 l of diluted anode (lower) buffer 
whereas 500 ml diluted cathode (upper) buffer are pored into the upper buffer 
chamber. Diluted anode and cathode buffers are obtained diluting 10 X Anode Buffer, 
Sol C3 and 10 X Cathode Buffer, Sol C4, respectively, with deionised water.  
 
4.5. Electrophoresis  
 
Second dimension electrophoresis run (gels 10, 12.5 and 15 % T, homogenous, 2.6 
% C; 200 X 200 X 1mm3) was performed under constant current of 45 mA per gel, 
electrophoresis time about 3.5 hours. The run was terminated when the 
Bromophenol Blue dye has migrated off the lower end of the gel.  
 
4.6. One-dimensional, SDS-PAGE gels 
 
The preparation of gels for the one dimensional electrophoresis is essentially same 
as for the two dimensional electrophoresis analysis. Since this setting precludes the 
first dimension (isoelectric focusing) there are some differences in the casting of 
stacking gel and sample loading. 
In mini-gel system [ (8 cm (W), 7.3 cm (H)] the stacking gel solution was pipetted into  
sandwich (on the top of resolving gel) until the top of the short plate and 10 well 
comb was inserted between the plates taking care not to trap air bubbles below the 
teeth of the comb. The stacking gel was allowed to polymerize (about 1 hour). After 
gel polymerization the comb was gently removed and the wells were rinsed and filled 
with diluted cathode buffer. The samples were placed briefly on ice until ready for 
use. Samples are dissolved in Laemmli buffer C5 in which just prior to use are added 
6.2 mg/ml DTT. The reduction/ denaturation of sample is performed by heating the 
sample and DTT-containing Laemmli buffer C5 solution in termocycler, 10 min at  
95°C.  
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Using Hamilton ™ syringe 15 μl of denatured/reduced sample solution were gently 
loaded beneath the buffer in specified well. No adjacent well was left empty, if the 
well was not needed; it was loaded with Laemmli buffer containing no sample. In this 
work 1 or 2 wells were loaded with the mixture of protein standards (1 μl for silver 
stained gels). After the filling the lower and upper buffer chambers with the same 
buffers as those used in 2-DE, and assembling electrophoresis unit, electrophoresis 
run was started and performed under constant voltage 125 V, for about 1 hour.  
Gels were run at room temperature and the run was terminated when the tracking 
dye reached the bottom of the gel. 
 
4.7. Gel fixing 
After termination of electrophoresis run, 1-DE and 2-DE gels were carefully removed 
from plates, the stacking gel was cut out and discarded and the gels were immersed 
on Fixing solution B1 with gentle shaking overnight.  
 
4.8. Silver staining protocol according of Blum et al.250 
 
Silver staining procedure was performed by gently shaking gels immersed in about 
400 ml of needed reagent (volume for two gels, 20 X 20 cm), always using reagent 
grade chemicals. The conductivity of deionised water was less than 2 μS and to 
prevent the contamination, powder free latex glows were always used.  
Silver staining protocol employed in this work has been presented in Table 4.9.  
 
Step Reagent Duration 
Fixing Fixing reagent D1 > 1hour, overnight 
Washing Wash-solution D2 2 X 20 min 
Washing Deionised water 20 min 
Sensitizer Thiosulfate reagent D3 1 min 
Washing Deionised water 3 X 20 sec 
Silver  Silver nitrate reagent D4 20 min 
Washing Deionised water 3 X 20 sec 
Development Developer reagent D5 2-5 min 
Washing  Deionised water 1X 20 sec 
Stop Glycine stop reagent D6 5 min 
Washing Deionised water 3X 10 min 
Table 4.9. Silver staining protocol.
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4.9. Coomassie staining  
 
Coomassie staining procedure, compatible with subsequent MALDI-TOF analysis, 
included gel fixing, staining and destaining steps. It was performed according Table 
4.10.    
 
 
 
Step Reagent Duration 
Fixing Fixing reagent E1 1 hour 
Washing Deionised water 2 X 1 min 
Staining Coomassie staining reagent  E2 until spot/band is visible 
Destaining I Destaining reagent I, E3 30 min 
Destaining II Destaining reagent II, E4 change solution  
until clear background 
 
4.10. Gel scanning  
 
After the gel staining procedure, gels were placed on the scanner plate of Biorad 
Densitometer GS 710. Each gel was placed at the same position on the scanner 
plate and all gels were scanned using the same orientation. Gel analysis was done 
using PDQuest 6.2.1. (Bio-Rad Laboratories, USA). 
 
4.11. Gel drying 
For permanent storage gels were dried in the air gel-drying system. The inner part of 
the Gel Frame was placed on the loading platform; a wetted cellophane sheet was 
laid down, then the gel, and finally another cellophane sheet.  The outer frame was 
set down and locked with quarter turns of the knobs. Finally the Gel Frames were 
placed into the open air drying oven, and dried 2-3 hours. 
 
4.12. In-gel digestion of excised protein spots of silver-stained gels. 
 
In this work for the tryptic digestion of proteins from a silver-stained spots, procedure 
based on the method developed by Gharahdaghi et al. was emplyed131.  
Table 4.10. Mass spectrometry compatible Coomassie staining protocol.  
 - 100 -
In order to reduce the background interferences and improve detectability for MALDI-
TOF MS analysis, gel spots were destained prior to enzymatic digestion.  
 
Washing /destaining  
 
a. Gel slab was washed with Milli-Q water 2 X 15 min 
b. Using a clean scalpel the spots of interest were excised from the gel (as close 
to the spot as possible to minimize the amount of background gel), cut into 
roughly 1 mm cubes and placed in an clean 500 μl Eppeddorf tube in 
approximately 50-100 μl Milli-Q.  A gel piece of roughly the same size was 
excised from a gel region which does not carry any protein (control). 
c. Stained gel pieces are destained in approximately 100 μl mixture of 1:1 30 mM 
Potassium ferricyanide solution F1 and 100 mM Sodium thiosulfate solution F2 
for 5-10 min (until silver stain disappears). After destaining gels were rinsed 
with Milli-Q water until yellow color disappears (3-4 X 15 min). The solution 
was pulled off and discarded and the gel pieces were washed with acetonitrile 
50 % (v/v) 2 X 15 min. Solvent volumes used in the washing step were roughly 
same as the gel volume.  
d.  The liquid was removed and gel particles were covered with acetonitrile 
(dehydration). After the gel pieces have shrunk (they become milky and stick 
together, after 2-3 min) acetonitrile was removed and gel pieces were 
rehydrated with 50-100 μl, 50 mM Ammonium bicarbonate buffer solution F3 
for 5 min followed by the addition of an equal volume (50-100 μl) of acetonitrile 
and incubation for 15 min. Solution was pulled off and discarded, and gel 
particles were dried in vacuum centrifuge. 
 
 Reduction and alkylation 
  
a. Samples were removed from the speed vacuum and let cool. 
b. For the reduction of protein disulfide bonds gel particles were swollen in 50μl 
freshly prepared 10 mM DTT in 50 mM Ammonium bicarbonate buffer solution 
F3 and incubated at 56 °C in thermocycler for 45 min. Tubes were removed, 
chilled to room temperature and excess liquid was removed. 
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c. For alkylation, 50 μl of freshly prepared solution of 55 mM IAM in 50 mM 
Ammonium bicarbonate buffer solution F3 were immediately added and 
incubated at room temperature for 30 min in the dark. 
d. IAM solution was removed and gel particles were washed with 50 μl 50 mM 
Ammonium bicarbonate buffer solution F3 and incubated at room temperature 
for 5 min. After incubation, 50 μl of acetonitrile are added to make 1:1 solution 
of acetonitrile: 50 mM Ammonium bicarbonate buffer solution F3, then 
incubated at room temperature for 15 min. Solution was pulled off and 
discarded, and gel particles were dried in vacuum centrifuge. 
 
Tryptic digestion 
 
a. Gel particles were rehydrated by adding Digestion buffer F4.  50 μl or enough 
digestion buffer was added to completely cover gel pieces and incubated at 
4°C for 45 min. If gel pieces absorbed all the liquid more solution was added 
taking care to avoid formation of air bubbles. After that, the excess of liquid 
was removed, and 50 μl (or enough to cover gel pieces) of same buffer 
without trypsin were added and incubated at 37°C for 16 hours (overnight).  
 
 Extraction 
 
a. The digestion mixture was briefly centrifuged (2 min, 15 000g) to gather 
evaporated liquid, condensed on the side and/or on the lid of tube. 
Supernatant is recovered in the new tube and saved at 4°C.  Extraction was 
repeated two times with 20-30 μl solution 5 % Formic acid Sol F5: Acetonitril 
1:1 with 15 min incubation each.  
b. All digestion extracts are pooled and completely dried in vacuum centrifuge. 
 Sample redissolution and MALDI-TOF sample presentation 
 
Dry pellets of digestion extracts were resuspended in 5 μl of solution of 0.1 % 
Trifluoroacetic acid Sol F6.  
Application of sample onto MALDI target is performed according the method which 
eliminates the mixing of sample with matrix prior to application to the Maldi target159. 
0.5 μl of Saturated matrix solution F7 ( 8mg α-Cyano- 4-hydroxycinnamic acid 
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dissolved in 1 ml mixture of 70 % Acetonitrile and 30% of the 0.1% Trifluoroacetic 
acid  Sol F6) were applied onto the well of the Maldi target. After 1-2 seconds excess 
matrix was removed and target surface allowed to dry. After drying, 0.5 μl of sample 
solution was applied to the sample deposit area. While sample deposit was still wet, 
further 0.5μl of Saturated matrix solution were added and allowed to dry passively. In 
the same way were applied solutions of molecular mass standards.  
All mass spectra were acquired on Compaq SEQ, Kratos Analytical, Manchester, UK 
MS instrument operated in positive reflectron mode, peptides were observed as 
[M+H]+  ions.  
For external calibration were used bradykinin fragment 1-7, angiotensin II, ACTH 
fragment 18-39 and insulin oxidized beta chain. 
 
4.13. Deglycosylation experiments 
 
The solutions of pharmaceutical preparations (23.8μl trastuzumab (Herceptin®), 150 
mg/7.2 ml; 50 μl rituximab (Rituxan®),150 mg/10 ml and 20 μl abatacept (Orencia®) 
250 mg/10 ml) were dialyzed against MilliQ-water for 3 days at 4 °C using cellulose 
membrane tubing (cut off value 12000-14000). Water was changed several times. 
After dialysis, solutions were freeze dried and lyophilised samples of pharmaceutical 
preparations (0.5 mg each) were dissolved in 49 μl of Phosphate buffer pH 7.5 (Sol. 
G1) to obtain final concentration 500 μg/50 μl. In this study four methods of 
enzymatic deglycosilations were evaluated: 
 
1. Deglycosylation under reduced and denaturating conditions (Method 1) 
For the reduction of proteins, prior to enzymatic digestion, 10 μl of  
sample solution (100 μg of each pharmaceutical substance), were 
mixed with 69 μl of the solution of 25 mM Phosphate buffer pH 7.5 
containing 0.1 % SDS, 1 μl 2-ME was added and mixture was boiled at 
97 °C for 5 min. After reduction/denaturation step 10 μl 10% CHAPS in 
0.1 % SDS (Solution G2) and 10 μl (10 units) enzyme PNGase F were 
added and the mixture (total 100 μl) was incubated at 37 °C for 24 or 
48 hours (see discussion section).  
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2. Deglycosylation under nonreducing conditions employing nonionic 
surfactant (Method 2) 
 
In this method immunoglobulin was not subjected to reduction with 2-
ME neither it was boiled. Therefore in this case no denaturation has 
taken place. In order to increase deglycosylation efficiency non-ionic 
surfactant 0.5 % Triton X-100 (Solution G3) was added.  
15 μl of sample solution (150 μg of each pharmaceutical substance) 
were mixed with Solution G3 and the required volume of enzyme(s) 
(PNGaseF, Sialidase,  O-Glycosidase) (Table. 4.11) and the mixture 
was incubated at room temperature for 24 hours. 
 
 
3. Deglycosylation under reducing conditions, with no surfactants and no 
previous boiling (Method 3) 
 
15 μl of sample solution (150 μg of each pharmaceutical substance) 
were mixed with 1μl 2-ME, the required volume of enzyme(s) 
(PNGaseF, Sialidase,  O-Glycosidase) and Phosphate buffer pH 7.5 
(Solution G1) to obtain total volume of 100 μl and the mixture was 
incubated at room temperature for 24 hours. 
 
4. Deglycosylation under non-reducing conditions, no surfactants added 
and no denaturation (Method 4). 
 
15 μl of sample solution (150 μg of each pharmaceutical substance) 
were mixed with the required volume of enzyme(s) (PNGaseF, 
Sialidase,  O-Glycosidase) and Phosphate buffer pH 7.5 (Sol. G1) to 
obtain total volume of 100 μl and the mixture was incubated at room 
temperature for 24 hours. 
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Sample 
Nr. 
Enzyme treatment Sample 
(μl)* 
Enz 1 
(μl) 
Enz 2 
 (μl) 
Enz 3 
(μl) 
Digestion 
 buffer (μl) 
Total 
 (μl) 
1 PNGase-F 15 μl 15 μl   70 μl 100 μl  
2 Sialidase 15 μl  3 μl  82 μl 100 μl 
3 Sialidase 
O-Glycosidase 
15 μl  3 μl 9 μl 73 μl 100 μl 
4 PNGase-F 
Sialidase 
15 μl 15 μl 3 μl  67 μl 100 μl 
5 PNGase-F 
Sialidase 
O-Glycosidase 
15 μl 15 μl 3 μl 9 μl 58 μl 100 μl 
 
Enzyme 1. N-Glycosidase F 
 
PNgase F of Flavobacterium meningosepticum, rec. from E. coli, lyophilizate, 100 U.  
Cat. Nr. 113 651 85.  Content dissolved in 100 μl MilliQ water results in a 
concentration of 100 mM sodium phosphate buffer, 25 mM EDTA, pH 7.2 and N-
Glycosidase F 100 U/100 μl. 
 
Enzyme 2. Neuraminidase (Sialidase)  
 
Cat Nr. 10 269 611 from Arthrobacter ureafaciens 1 U (100 μl).  
 
Enzyme 3.O-Glycosidase  
 
O-Glycan peptide hydrolase (Cat.No. 11 347 101 from Diplococcus pneuminiae 25 
mU (50 μl). 
After finishing the digestion samples were stored at - 80 °C. 
Table 4.11. Deeglycosilation of dialysed pharmaceutical formulations of trastuzumab, rituximab, 
and abatacept.  
Digestion buffer: 0.5 % Triton X-100 (Solution G3)(Method 2)  
Phosphate buffer pH 7.5 (Solution G1)(Methods 3 and 4) 
For Method 3, the volume of Digestion buffer was for 1μl lower (as much was the volume of 
added 2-ME). Volumes of enzymes and samples are the same. 
*Trastuzumab: enzymatic deglycosilation study (PNGase-F and Sialidase) and lysin truncation 
study (Carboxypeptidase B). Rituximab: enzymatic deglycosilation study (PNGase-F) and lysin 
truncation study (Carboxypeptidase B). Abatacept: enzymatic deglycosilation study (PNGase-
F, Sialidase, O-Glycosidase) and lysin truncation study (Carboxypeptidase B). 
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4.13.1. Carboxypeptidase B treatment 
 
For the study of lysine truncation Carboxypeptidase B, 5 mg/ml (specific activity: 
150 U/mg) from pig pancreas Cat. Nr 101 032 33, was used.  
15 μl of sample solution (150 μg of each pharmaceutical substance) were mixed with 
1 μl Carboxypeptidase B and 84 μl Phosphate buffer pH 7.5 (Sol. G1) to obtain total 
volume of 100 μl and the mixture was incubated at 37 °C for 24 hours. 
Simultaneous treatment including Carboxypeptidase B and deglycosilation enzymes 
(Table 10) was carried out adding 1 μl Carboxypeptidase B, required volumes of 
other enzymes and digestion buffer to adjust total volume to 100 μl.   
 
4.13.2. N-Linked oligosaccharide release and storage  
 
For the release of N-linked oligosaccharides slightly modified methods described by 
Kamoda et al174, 272 were used.   
 
1. A freeze dried samples of studied recombinant therapeutic proteins (1 mg), 
were dissolved in 100 μl of Phosphate buffer pH 7.5 (Solution  G1) followed by 
addition of PNGase F (10 U, 10 μl). After the incubation at 37°C overnight, the 
digestion mixture was boiled for 5 min and centrifuged (15000 X g for 15 min) 
and the supernatant containing released N-linked oligosaccharides was dried 
in centrifugal vacuum evaporator.  
2. A freeze dried samples of studied recombinant therapeutic proteins (0.5 mg), 
were dissolved in 50 μl of Phosphate buffer pH 7.5 (Solution G1) followed by 
addition of 1 μl 2-ME and PNGase F (10 U, 10 μl). After the incubation at 37°C 
overnight, 150 μl ethanol were added into the digestion mixture.  After 
centrifugation (15000 X g for 15 min) the supernatant containing released N-
linked oligosaccharides was dried in centrifugal vacuum evaporator.  
 
Lyophilised samples containing released N-linked oligosaccharides were stored at - 
80°C. N-deglycosilated trastuzumab and rituximab, precipitated after 5 min boiling 
(Method 1) and addition of 150 μl ethanol (Method 2). However precipitation of N-
deglycosilated abatacept was achieved only when Method 2 was employed.  
 - 106 -
5. Results and discussion 
 
5.1. Gel electrophoresis analysis of trastuzumab 
 
One-dimensional gel electrophoresis (1D-SDS-PAGE) under reducing and non-
reducing conditions, and two-dimensional gel electrophoresis (2-DE) are used for the 
examination of quality related aspects of recombinant monoclonal antibody, 
trastuzumab (Herceptin®).  
This study involved the examination of different factors influencing electrophoretic 
behavior of this complex molecule. 1-DE and 2-DE experiments run under different 
conditions were used not only to estimate its molecular weight and isoelectric point, 
but they served to study its isomorf and charge heterogeneity pattern. In addition, 
stability study involving stressed degradation and long-term conditions has been 
addressed, as well. The aim was to assess the capability of planar electrophoresis 
methods to detect the changes which arise upon different storage conditions of the 
drug product, and to assess its degradation profile. 
For assessment of the influence of glycosylation in trastuzumab charge 
heterogeneity pattern, and preparation of sample for subsequent MALDI-TOF 
analysis, enzymatic deglycosilation study has been performed in 1- and 2-De setting 
involving the use of different enzymes.  
 
5.1.1. One dimensional (1D-SDS-PAGE) gel electrophoresis analysis of 
trastuzumab 
5. 1.1.1. Molecular weight estimation and sensitivity of staining  
 
 
 
 
 
 
 
 
 
 
 
 
A B 
    1        2    3   4    5     6        7         1        2   3    4   5    6       7    
150 kDa 
50 kDa 
25 kDa 
50 kDa 
25 kDa 
 
Fig. 5.14 A) 1-DE analysis of trastuzumab under reducing conditions. Acrylamid 12.5 %, 
%C 2.6%.  Silver staining. Lanes 2-6: Trastuzumab 1.3-20.5 μg., Lanes 1, 7 MW 
standards. B). 1-DE analysis of trastuzumab under non-reducing conditions.Lanes 2-6: 
Trastuzumab, 1.3-20.5 μg Lanes 1, 7 MW standards 
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SDS-PAGE gels of trastuzumab under reducing and nonreducing conditions are 
presented in  Fig. 5.14. 
Under reducing conditions (Fig 5.14.A) trastuzumab is resolved in two distinct 
molecular weight species which migrated in two bands, upper band at about 50 kDa 
and lower band at about 23 kDa, confirming the migration behavior typical for IgG 
antibodies which are composed of two identical subunits each composed by two 
polypeptide chains, two heavy and two light chains, linked via disulfide bonds.  
Trastuzumab is an antibody molecule and therefore its basic monomer structure 
upon reducing conditions is cleaved in 4 polypeptide chains. Its heavy chains contain 
450 amino acids and in SDS-PGE gel migrated at about 50 kDa. Light chains contain 
214 amino acids and as seen in Fig 20 migrate at about 23 kDa. 
This migration behavior matches with the molecular weights of trastuzumab heavy 
and light chains, calculated from their corresponding cDNA derived amino acid 
sequences (49.285 kDa and 23.443 kDa, respectively). The apparent molecular 
weight of the heavy chain is about 50 kDa and this difference is due to the co 
translational attachment of N-linked glycans which contribute in the increase of its 
molecular weight for about 3-5 %174.  
Under non-reducing conditions, migration behavior of trastuzumab monomer was 
different. It migrated at molecular weight about 150 kDa, and in contrast with 
reducing conditions, the band sharpness was reduced (Fig 5.14.B). The molecular 
weight of ~150 kDa is the sum of 2 heavy chains, each ~50 kDa and two light chains 
each ~23.5 kDa.  
From Fig. 5.14.A is seen that band intensity was proportional to sample amount, 
provided that lower sample concentrations generated sharper bands. 
To assess the sensitivity of silver and Coomassie staining procedures lower 
concentration of trastuzumab were subjected to 1-D electrophoresis under reducing 
conditions. 
As shown in the Fig 5.15.A bands of heavy and light chains are detected even at very 
low sample amount, 0.005 μg trastuzumab (Fig 5.15.A, lane 6). Comparing with silver 
staining Coomassie staining resulted to be less sensitive. As seen in Fig 5.15.B and 
5.15.C, trastuzumab light and heavy chain bands were detected in both gels. 
However, for trastuzumab amount 0.01 μg, bands of both chains are detected only in 
silver stained gels  (Fig 5.15.B, lane 1) and not in the Coomassie stained gel (Fig 
5.15.C, lane 1).  
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5.1.1.2. 1-DE. Deglycosilation optimisation study 
 
N-glycosidase F was used for the removal of N-linked glycans from the trastuzumab 
molecule. In order to optimise the deglycosilation conditions, the influence of various 
factors such are reduction of sample, temperature, amount of enzyme, digestion 
time, and the use of different surfactants have been studied.  
 
1. Deglycosilation under reducing and denaturating conditions (2ME, 
97°C, SDS 0.1%, CHAPS 10 % 
 
2. Deglycosilation under nonreducing conditions. Nonionic surfactant, 
Triton X-100, 0.5 % 
 
3. Deglycosilation under reducing conditions, 2-ME, with no surfactants 
and no previous boiling 
 
4. Deglycosilation under non-reducing conditions, no surfactants and no 
previous boiling 
  1         2   3   4    5     6   7  8       1   2   3   4    3   2    1         4     
25 kDa 
25 kDa 
50 kDa 50 kDa 
A B C 
Fig 5.15 A) 1-DE analysis of trastuzumab under reducing conditions. Silver staining. Lanes 
2-6: Trastuzumab 0.52; 0.26; 0.1; 0.05; 0.005 μg. Lane 7: 2 μg. Lanes 1, 8: MW standards.  
B). 1-DE analysis of trastuzumab under reducing conditions Silver staining. Lanes 1-3: 
Trastuzumab, 0.01; 0.2; 1 μg. Lane 4: MW standards.  C). 1-DE analysis of trastuzumab 
under reducing conditions. Coomassie staining. Lanes 1-3: Trastuzumab, 0.01; 0.2; 1 μg. 
Lane 4: MW standards. 
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*In all studied methods phosphate buffer pH 7.2 was used. For the detailed 
information see experimental section (4.13. Deglycosylation experiments, page 102) 
Deglycosilation efficiency was monitored by comparison of deglycosilated and 
glycosilated (native) samples separated with 1-DE and 2-DE.  
 
5.1.1.3. Preliminary deglycosilation experiments 
In Fig. 5.16. 1-DE gels of trastuzumab treated with N-glycosidase F under different 
conditions are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gels bands from Fig. 5.16 show that deglycosilation performed under condition of 
Method 1 (2-ME, with the denaturation of the sample 97 °C/10 min), brought about 
only partial deglycosilation. Splitting of heavy chain bands are split indicating non-
efficient deglycosilation process (lanes B and F, Fig 5.16.A and B and D, Fig 5.16B, 
respectively). 
On the other hand, lane C in both gels showed no splitting, with additional increase of 
the migration of heavy chain to lower molecular weight, comparing to glycosilated 
sample (lanes D, Fig 5.16.A and F, Fig 5.16.B, respectively). On the basis of these 
observations it is evident that the second deglycosilation method, which employs 
surfactant Triton X-100, without reduction and denaturation, is more efficient than the 
first method. The role of the surfactant is to increase the deglycosilation efficiency.  
     A   B          C            D           E     F     A           B          C            D          E      F
50 kDa 
25 kDa 
50 kDa 
25 kDa 
Fig 5.16. Deglycosilation monotorization. Trastuzumab 2 μg. Silver staining 
A) Digestion time 24 h. Lanes A and E Molecular weght standards. Lane B and F: Method 1, 10 I.U.and 
20 I.U. NGF, respectively. Lane C. Method 2, 10 I.U NGF. Lane D. Glycosilated sample/control.  
B) Digestion time 48 h. Lanes A and E Molecular weght standards. Lane B and D: Method 1, 10 I.U.and 
20 I.U. NGF, respectively. Lane C. Method 2, 10 I.U NGF. Lane F. Glycosilated sample/control.  
A  B 
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Actually, in native conformation the immunoglobulin G molecules are water soluble, 
provided that some interior regions of the molecule are highly hydrophobic. The 
possible cause for only partial deglycosilation in cases when 2-ME and boiling where 
employed is that upon denaturation, heavy chains of trastuzumab/and rituximab 
become insoluble. Hence, complete deglycosilation of glycans N-linked to amino acid 
asparagine N300 (trastuzumab) and N301 (rituximab) is difficult under denaturing 
conditions.  
According the results from Fig. 5.16.A and B digestion time (24 and 48 hours) did not 
influence significantly the deglycosilation efficiency.   
Monitorisation of deglycosilation efficiency for Methods 3 and 4 is depicted in the Fig. 
5.17. The comparison of heavy chain bands of glycosilated trastuzumab (lane B) with 
the lines of heavy chains of deglycosilated trastuzumab according Methods 3 and 4 
(lanes C and D, respectively) reveals that the molecular weights of both 
deglycosilated samples are substantially lower. Furthermore 1-DE data from Fig. 5.16 
and Fig. 5.17 indicate that deglycosilation Methods 3 and 4 result as more efficient 
than Method 2. The first method, results the one with the lowest deglycosilation 
efficiency. These observations confirm that reduction and denaturation of 
immunoglobulins has negative impact in the deglycosilation efficiency which is in 
accordance with the literature data251. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A   B        C         D       
25 kDa 
50 kDa 
Fig 5.17. Deglycosilation monitorization. Trastuzumab 2 μg. Silver staining. Digestion time 
24 h. 10 I.U. NGF. Lane A: Molecular weight standards. Lane B: Nondeglycosilated 
sample/control, Lane C: deglycosilated, Method 3, Lane D: Deglycosilated, Method 4  
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On the basis of deglycosilation optimization experiments, for both monoclonal 
antibodies trastuzumab and rituximab, Methods 3 and 4 resulted as optimal. 
However, in the case of abatacept, all deglycosilation methods, except the Method 1 
were of similar efficiency. This could be explained taking into consideration 
solubilities of recombinant monoclonal antibodies (trastuzumab and rituximab) heavy 
chains and abatacept. The solubility of latter is better.  
 
5.1.2. Two-dimensional (2-DE) gel electrophoresis analysis of trastuzumab 
 
Preliminary two-dimensional gel electrophoresis 2-DE experiments are performed 
using immobiline gradients of pH 3-11 NL and pH 6-9 L. The study of trastuzumab 
charge heterogeneity, deglycosilation optimization and stability has been carried out 
employing different 2-DE conditions. For the optimization purpose different factors 
such are concentration of sample, immobiline pH gradient, gel concentration and 
staining procedure were evaluated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 On the bases of 2 DE experiments (Fig 5.18), results that after reduction of disulfide 
bonds trastuzumab subjected to 2-DE, demonstrated typical complex spot pattern of 
recombinant monoclonal antibodies. Its heavy chains in 2 DE gel migrated at 
molecular weight ~ 50 kD with the pI value between 6.5 and 8.7. The theoretical pI 
value of the trastuzumab heavy chain is 8.49 and its theoretical molecular weight 
 3                                               11  6                                          9 
50 kDa 
25 kDa 
Fig. 5.18. 2-DE analysis of trastuzumab, 10 μg, Silver staining. A)  IPG 3-11 NL, B) 6-9 L 
A B 
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49.285 kDa. Trastuzumab light chain migrated at molecular weight ~23 kDa and pI 
ranged 5.7 to 8.1. Theoretic pI derived from its cDNA sequence is 7.76252.  
Trastuzumab spot pattern shows high degree of complexity which is typical for 
electrophoretic behavior of all antibody molecules. Like rituximab, another rmAbs 
studied in this work, the spot pattern of trastuzumab consists on numerous poorly 
resolved and overlapped spots tending to spread as bands. The degree of heavy 
chain complexity is apparently higher than of the light chain suggesting the 
contribution of the heavy chain glycosylation in the additional complexity. 
As noted in Fig. 5.18., for the same sample concentration, the resolution of heavy 
and light chain spots is higher when immobilized pH gradient 3-11 NL is employed. 
The superior resolution comparing to the immobilized pH gradient 6-9 L was 
observed in all trastuzumab (and rituximab) studied gels.  
Another factor which affected the spot resolution was the amount of applied sample. 
In the gels studied so far, independently from the type of immobilized pI gradient, 
reduction of sample concentration generally brought about improvement in the spot 
resolution, (Fig. 5.19.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 DE of trastuzumab at the acrylamide concentration of 10 %, 12.5 % and 15 % has 
been studied, as well. 
 
 
A 
B 
Fig 5.19. 2-DE analysis of trastuzumab, 10 μg, Silver staining. A)  IPG 3-11 NL, 5.2μg, B) 
6-9 L, 5.2 μg. 
 3                                               11 6                                               9 
50 kDa 
25 kDa 
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As expected, the mobility of both chains in more concentrated gels was lower than in 
the more diluted gels (Fig. 5.20). The intermediate gel concentration of 12.5 % was 
selected as optimal and all analysis were performed at this acrylamide concentration 
hereof. 
 
 
 
 
 
 
 
 
 
 
 
5.1.2.1. 2-DE. Deglycosilation optimization study 
 
N-Glycosidase F treatment of trastuzumab employing Method 1 provided 2-DE 
results similar with 1-DE experiments: trastuzumab heavy chain split in two parts, the 
lower part tending toward the lower pI values (Fig. 5.21.). 
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, 2-DE gels offered no possibility to assess the molecular weight 
difference between glycosylated and deglycosilated trastuzumab heavy chains 
according Methods 2,3 and 4 (Fig. 5.22). 
A 
B C 
Fig. 5.20 2-DE analysis of trastuzumab, 10 μg, Silver staining. A) 10 %; B) 12.5 %; C) 15 % 
50 
25 
 3                               11  3                               11 3                               11 
 3                                  11 
50 kDa 
25 kDa 
Fig. 5.21. Deglycosilation monitorization. Trastuzumab 10 μg. Silver staining. Method 1 
 kDa 
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In Fig. 5.22 (A and B) 2-DE gels obtained from deglycosilated trastuzumab are 
presented. For the N-glycan release Method 2 employing nonionic surfactant, Triton 
X-100 was employed. 
As mentioned above, the difference between molecular weight of trastuzumab heavy 
chain in glycosilated and its native form is only about 3-5 % therefore this small 
difference is difficult to notice in 2-DE gels 
In the first dimension immobiline pH gradients 6-9 L and 3-11 NL were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were two principal reasons why Methods 3 and 4 were used for the 
deglycosilation of recombinant antibodies trastuzumab and rituximab, which after 2-
DE separation and in gel tryptic digestion were subjected to MALDI-TOF analysis: 
first, because 1-DE data confirmed their superior efficiency in comparison with 
Methods 1 and 2, and second, the detergent absence facilitates subsequent MALDI-
 3                                  11 6                                       9 
50 kDa 
25 kDa 
 3                                  11 3                                  11  
50 kDa 
25 kDa 
Fig 5.22. Deglycosilation monitorization. Trastuzumab 8.3 μg. Silver staining. Method 2. 
Non-reduced, Triton X-100, 10 I.U. NGF A) 3-11 NL, B) 6-9 L, C) Trastuzumab 100 μg, 
Method 4. D) Trastuzumab 100 μg, Method 4, Coomassie staining. 
A B 
C D 
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TOF analysis. Literature data report that many detergents have negative impact on 
the MALDI-TOF process 251.  In Fig. 5.22. silver and Coomassie stained 2-DE gels of 
deglycosilated trastuzumab employing deglycosilation Method 4 are presented. 
2-DE experiments showed no significant difference in the charge heterogeneity 
between deglycosilated and glycosilated trastuzumab samples.  
As a consequence of N-glycosidase F action asparagine N300 on the trastuzumab 
molecule is converted to aspartic acid D300, and the polypeptide chain remains intact. 
The conversion of N to D adds a negative charge to proteins. For small proteins 
which are highly glycosilated and have large charge differences between glycosilated 
and deglycosilated forms (i.e. abatacept, EPO etc) the process of deglycosilation 
may be monitored on 1-DE and 2-DE gels, respectively117. For recombinant 
monoclonal antibodies like trastuzumab and rituximab, however, 2-DE results are 
equivocal. This is due to the fact that the mass of glycans in trastuzumab and 
rituximab heavy chains counts only 3-5 % of total polypeptide molecular mass. In 
addition, pI difference between deglycosilated and glycosilated forms of trastuzumab 
and rituximab heavy chains is very low (theoretically calculated about 0.13)253 and 
this is obviously difficult to be assessed with 2-DE gels. 
 
 
5.1.2.2. Charge heterogeneity study of trastuzumab   
 
 
In order to study the contribution of N-linked glycans and the C-terminal terminal 
lysine truncation in the spot complexity of rmAb pharmaceutical trastuzumab, three 
selected enzymes have been employed:  N-glycosidase F; sialidase and 
carboxypeptidase B.  
Since published data indicate that IgG molecules (trastuzumab and rituximab) 
contain only N-glycans, O-deglycosilation study has been omitted253. 
For the first dimension, IEF, immobiline pH gradients 3-11 NL and 6-9 L have been 
employed. Deglycosilation efficiency was monitored with 1-DE. 
 
5.1.2.3. Trastuzumab charge heterogeneity IPG 3-11 NL 
 
2-DE experiments provided similar charge heterogeneity patterns for both 
recombinant monoclonal antibodies addressed in this study, trastuzumab and 
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rituximab. Numerous poorly resolved spots were observed in both chains, particularly 
in heavy chain.   
Since the glycan composition of these two antibodies is similar174, it was expected 
that enzymatic deglycosilation experiments would provide similar results in terms of 
their molecular weight, pI and spot complexity. After comparison of the 2-DE 
experimental data both studied rmAbs, this assumption resulted to be correct.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As in other IgG1 isotype antibodies, in trastuzumab molecule oligosaccharides are 
attached at asparagine N300. 1-DE experiments comparing native and N-glycosidase 
F treated trastuzumab prove the presence of N-linked glycan molecules, however for 
the charge difference assessment 2-DE was needed. 
After N-linked glycan release for each molecule of trastuzumab only one carboxylic 
acid of asparagic acid is released, therefore a low change in the pI is expected. 
Calculated from cDNA derived sequence this difference should be only 0.13 (ΔpI= 
pINg-pID= 8.49-8.36= 0.13). 
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Fig. 5.23. Trastuzumab, 2-DE, 3-11 NL, 10 μg. Silver staining. 
A. Control; B. Sialidase; C. Carboxypeptidase B, Sialidase, N-Glycosidase F;  
D. N-Glycosidase F; E. Carboxypeptidase B; F. Carboxypeptidase B, Sialidase  
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As shown in Fig. 5.23, pI  and MW difference between the control, native sample (gel 
29A) and gels obtained from the N-deglycosilated, desialinated and 
Carboxypeptidase B treated samples is very low. The high value of gel to gel 
variation in the spot intensity, does not allow detecting this small changes. After 
sialidase treatment no change has been observed, suggesting that the N-linked 
sugars of trastuzumab pertain to complex biantennary type but without terminal sialic 
acid residues which is in accordance with the literature data174, 232.  
On the other hand, heavy chain terminal lysine truncation can be a source of charge 
heterogeneity. Again, comparing calculated theoretical pI  values of trastuzumab and 
its truncated variant with no lysine at the position 450, the difference in pI is very low 
(ΔpI=0.13) to be detected with this method. 
 
5.1.2.4. Trastuzumab charge heterogeneity IPG 6-9 L 
 
In order to more accurately assess trastuzumab heavy chain pI changes, after its 
deglycosilation, narrower immobiline pI gradient was used in the first (IEF) 
dimension. However, experimental data showed that no pI differences between 
control and digested samples could be noticed (Fig 5.24, 5.25.). 
In Fig. 5.25, 2-DE gels of controlled sample (A) and with different enzymes treated 
trastuzumab are shown. The sample amount of sample was increased to 50 μg. 
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Fig. 5.24. Trastuzumab, 2-DE, 6-9 L. Silver staining.; A. Control; B. Carboxypeptidase B; C. Sialidase;  
D. N-glycosidase F, Carboxypeptidase B Sialidase; E. Sialidase, Carboxypeptidase B; F. N-Glycosidase 
F. Gels: ABCF, 25 μg trastuzumab. Gels: DE, 10 μg trastuzumab. 
Fig. 5.25. Trastuzumab, 2-DE, 6-9 L, 50 μg. Silver staining. A: Control; B: Sialidase;  
C: N-Glycosidase F; D: Carboxypeptidase B, Sialidase, N-Glycosidase F; E: Carboxypeptidase B;  
F: Carboxypeptidase B, Sialidase  
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5.2. Stability study of trastuzumab 
 
 
Recombinant monoclonal antibodies are biological products produced by the r DNA 
technology, therefore, like other protein pharmaceuticals; they also require extensive 
and stringent characterization of purity, structural integrity and stability158. A major 
obstacle in the development of protein drug formulations is the need to maintain the 
native, active protein structure both during the formulation process and upon long 
time storage254.   
Antibodies like other proteins are prone to a variety of physical and chemical 
degradation pathways. These products are particularly sensitive to environmental 
factors such as temperature changes, oxidation, light, ionic content and shear. All 
these factor can affect their potency, purity and quality255.   
Two major pathways of physical instability are denaturation and degradation. 
Precipitation and surface adsorption occur as well. Chemical degradation pathways 
include cross linking, deamidation, isomerisation, oxidation, and fragmentation25. 
Additionally, the glycosylation state of an antibody can significantly affect its 
degradation rate256. 
This study addressed thermal degradation of trastuzumab under accelerated storage 
conditions. 1-DE and 2-DE analyses were evaluated for their ability to monitor 
possible changes in electrophoretic pattern of trastuzumab upon forced degradation 
conditions, detect possible degradation products and assess the effect of other 
severe conditions (oxidation, low pH and shearing in the stability of this drug product. 
The rate of chemical degradation was increased employing exaggerated conditions: 
higher temperature (room temperature, 40ºC); oxidation: H2O2 1 and 3 %, TFA in 
different concentrations and shearing. 
 
5.2.1. Termo-degradation study 
 
Freshly prepared reconstituted formulations of the drug substance were stored at the 
different conditions (room temperature, 4-8°C, 37°C, and 50°C) and after storage up 
to given time were analyzed with 1-DE and 2-DE. In Fig. 5.26, termodegradation 
study of trastuzumab solution stored at different temperatures is presented. 
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Fig. 5.26. Trastuzumab. 3-11 NL. Forced Degradation study. 3-11 NL. Silver staining 
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In order to assess long term stability of trastuzumab, its reconstituted solution was 
stored up to 90 days at the room temperature. For this analysis sample of different 
production series, has been used (Fig. 5.27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immobilized pH gradient strips pI 6-9 L were used for the first dimension in the 
following stability monitoring experiment (Fig. 5.28.). 
However, experimental data revealed similar results with 2-DE with immobilized pH 
gradient 3 -11 NL. 
 
 
 
 CONTROL
31 DAYS 60 DAYS 90 DAYS 
Fig. 5.27. Trastuzumab. Forced Degradation study.  
Room temperature. 3-11 NL. Silver staining 
3                              11 
 3                              11  3                              11 3                              11 
 - 122 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As seen from Figures 5.26, 5.27 and 5.28, 2-DE gels obtained from trastuzumab 
subjected to elevated temperatures (RT, 37°C and 50°C) could not reveal specific 
change (s) in the pI and MW of  resulting spots even for aged samples (to 90 days). 
The situation was different upon sample exposure to oxidation and lower pH values 
(Figures 5.29 and 5.30). 
Significant differences in pI and MW of trastuzumab 2-DE spots are observed upon 7 
day sample storage in the solution of 1 % trifluoroacetic acid, at room temperature, 
provided that elevated temperatures substantially accelerated degradation eventually 
leading to completely degradation and denaturation of sample ( Fig. 5.29). 
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Fig. 5.28. Trastuzumab. Forced Degradation study.  
Different temperatures/Shearing. 6-9 L. Silver staining 
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In Fig. 5.30., 2-DE gels of trastuzumab subjected to 1 and 3 % hydrogen peroxide 
solution are presented. After 7 day storage under these conditions, significant 
changes are observed, both in pI and MW of resulting spots. In Fig 5.30 B and 5.30 
C numerous spots at pI 6-7 and around 30 kDa are noted in both gels. 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
An opened vial of trastuzumab was stored at room temperature, for 7, 14 and 30 
days, respectively. Resulting 2-DE gels showed an interesting pattern of degraded 
sample, heavy chain spot size progressively reduced its size and new spots emerged 
 3                                    11 3                                 11 3                                11    kDa 
   50 
   25 
Fig. 5.29. Trastuzumab. 3-11 NL. Forced degradation study.Acidic conditions  
A) Control, B) TFA 1 %, Room temperature, 7 days; C) TFA 1 % 50°C, 7 days 
  A  B C
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Fig. 5.30. Trastuzumab. 3-11 NL. Forced Degradation study. H2O2 A) Control,  
B) H2O2 1 %, Room temperature, 7 days; C) H2O2 3 % Room temperature 7 days 
  A B  C
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at about 30 kDa and pI around 6-7. A drastic change in shape of light chain spots 
was observed as well (Fig 5.31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-DE analysis of termodegradated trastuzumab employing immobiline pH gradient 3-
11 NL showed that the elevated temperatures influenced the spot pattern of the 
antibody. This influence is remarkable upon longer time storage. Storage for 30 and 
45 days at room temperature resulted in change of the shape of both heavy and light 
chain spot pattern.  In samples stored 45 days at  37°C new spots located above light 
and heavy chain are noted and in those stored 7 days at 50 °C new spots can be 
seen at pI 7.5-8 at molecular weights about 55, 75 and 100 kDa, suggesting possible 
aggregation of antibody molecule (Fig. 5.27).  
On the other hand, no significant difference in spot pattern has been noted in gels 
stored shorter time even at 37 °C. Neither MW nor pI of spots changed significantly 
and consistently. This suggests that, degradation pathway of trastuzumab involves 
chemical reactions such are asparagine deamidation, asparagine and aspartate 
isomerisation and methionine oxidation, which does not cause  bigger differences in 
molecular weight and isoelectric points of resulting species, to be detected with 2-DE.  
 
 5.2.2. 1-DE. Accelerated degradation study of trastuzumab 
Although from SDS-PAGE gels no information regarding pI can be obtained, 
molecular weight changes of trastuzumab under different storage conditions in these 
   3                                 11   3                               11   3                               11     kDa 
   50 
   25 
Fig. 5.31. Trastuzumab. 3-11 NL. Forced Degradation study. Room temperature. 
Opened vial A) 7 days B)  14 days; C)  30 days 
  A  B  C
 - 125 -
gels are evident. Samples stored at room temperature for period of 1 month, 
provided gels with additional bands at higher molecular masses (Fig. 5.32, Gels B, C 
and D). In contrast to control sample (Fig. 5.32, Gel A), in gel D, trastuzumab sample 
stored 1 month at room temperature,  there is a sharp band at molecular weight 100 
kDa which has almost same intensity with heavy chain band (50 kDa). Additional 
bands are present at molecular weights 150 and 200 kDa, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
These additional bands are observed in trastuzumab samples stored 1 month at 4-
8°C, as well. (Gel   A).  
  A         B      C     D     E     F          G      A   B             C    D            E      F    G    
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Fig. 5.32.Trastuzumab. 1-DE Forced degradation study. Silver staining.  
A) Control gel. Lanes A, G: MW standards. Lanes B-F: trastuzumab, 1.3-20.5μg. 
B) 31 days, 4-8°C. Lanes A, G: MW standards. Lanes B-F: trastuzumab, 20.5-1.3 μg 
C) 31 days. Lanes A, H: MW standards. Lanes B-D: 4-8°C. Lanes E-G: Room temperature. 
Trastuzumab: 20.5-1.3 μg 
D) 31 days, Room temperature.Lanes A, G: MW standards. Lanes B-F: trastuzumab, 20.5-1.3 μg 
RT RT4-8°C 
4-8°C A
D
B
C
     A   B    C     D            E     F    G    H      A   B             C     D           E    F    G    
kDa 
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Different lot of trastuzumab sample was loaded onto Gel C.  Left part of this gel, 
(lanes B, C and D, trastuzumab stored at 4-8°C, 1 month) show the same molecular 
weight pattern as gel B. The same holds for lanes E, F, G and gel D (room 
temperature, 1 month).  Fig. 5.32. shows that bigger number of protein bands is 
observed when samples were stored at room temperature (Gel D and Gel C, lanes E, 
F and G) comparing to samples stored at 4-8°C (Gel B and Gel C, lanes B, C and D). 
This observation may suggest trastuzumab aggregation as physical degradation 
pathway. 
SDS-PAGE gels of trastuzumab stored under oxidation and acidic conditions are 
presented in Fig. 5.33.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
As noted in Fig 5.33, severe storage conditions, employing TFA 1 % (Gel A lanes D 
and E) and H2O2 1 and 3 %, 19 days, (Gel B, lanes D, E and B, C, respectively) 
brought about a significant change in the protein band pattern comparing to control 
gel (Fig. 5.32A). Interestingly, additional protein bands above and below 50 kDa have 
been observed in H2O2 exposed samples. However, samples stored in the solution of 
TFA 1 % provided additional bands predominantly below 50 kDa (Gel A, lanes d and 
E). On the other hand, sample stored 19 days at 37°C, provided additional bands 
above 50 kDa, similarly as in Fig 5.32. (Gel D). 
Fig. 5.33. Forced degradation study. Trastuzumab 0.2 and 0.8 μg, 19 days. Silver staining.  
Gel A. Lanes A, F: MW standards, Lanes B, C: 37°C, Lanes D, E: TFA 1 % , RT 
Gel B: Lanes A, F: MW standards, Lanes B, C H2O2 3 %,  RT,  Lanes D, E: H2O2 1 %, RT 
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5.3. Matrix assisted laser desorption ionization time of flight mass 
spectrometric (MALDI-TOF MS) analysis of trastuzumab 
 
5.3.1. Primary sequence confirmation. Peptide mass fingerprinting  
 
MALDI-TOF spectrum of generated peptides from deglycosilated and in-gel tryptic 
digested trastuzumab heavy chain is presented in the Fig. 5.34. 
As discussed above, recombinant monoclonal antibody trastuzumab contains two 
heavy and two light chains linked via disulfide bridges. It is composed of 1,328 amino 
acids:  heavy chain contains 450 and light chain 214, amino acids, respectively (Fig 
1.7.). 
 
Trastuzumab is humanised antibody obtained by grafting murine complementarity 
determining regions (CDR regions) into the human framework. CDR regions are 
located in the antigen binding domains of the antibody, which comprise variable 
domains of both chains, CH1 domain of heavy and constant domain of light chain, 
respectively. Trastuzumab Fab domains therefore have human and murine nature. 
On the other hand, heavy chain hinge region, CH2 and CH3 domains are fully human. 
On the basis of peptide mass fingerprint data  it was possible to identify both heavy 
and light chains of trastuzumab, to confirm their humanised origin, and to confirm  
mutations in CH3 domain of heavy chain: E359D and M361L which were installed to 
convert the antibody from the naturally rare A allotype to much more common non-A 
allotype. MALDI-TOF peptide mass 1905.97 (1922.38) specific for the ...359EEM361... 
sequence, was not observed in the MALDI-TOF spectra of abatacept and rituximab 
heavy chain, since their corresponding positions have (... DEL...) sequence (non-A 
allotype) instead. 
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5.3.1.1. Identification of heavy chain 
 
For primary sequence confirmation and identification of the trastuzumab heavy chain, 
the list of 29 peptide masses (Fig. 5.35.) generated by MALDI-TOF MS  of peptides 
obtained from corresponding positions of silver and Coomassie stained gels (Fig. 
Fig. 5.34. MALDI-TOF spectrum of deglycosilated heavy chain of trastuzumab. Up: 
Entire spectrum, Down: Section of spectrum 
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5.22 Gels C and D), were searched with MASCOT and PROFOUND (Prowl) search 
engines using three sequence databases: MSDB, NCBInr and SwissProt.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.35. Trastuzumab heavy chain. List of entered peptide masses 
501.99; 600.99; 657.08; 682.80; 788.15; 818.85;  831.11; 836.12; 839.37; 1086.20; 1090.53; 
1162.60; 1184.12; 1187.35; 1191.23; 1268.17; 1287.61; 1311.28; 1322.68; 1335.84; 1673.61; 
1678.99; 1874.98; 1883.11; 1905.97; 2140.40; 2231.37; 2239.55; 2546.78.
Fig. 5.36. Trastuzumab, heavy chain. Mascot search results. Primary sequence database: 
MSDB. Mas tolerance was set to ± 1.2 Da 
 - 130 -
During Database searching, taxonomy was restricted to Homo sapiens, selected 
enzyme was trypsin. Other search parameters were set to allow up to 1 missed 
cleavage, methionins in oxidized form (variable modification), cysteins in 
carbamidomethylated form (fixed modification), average mass, peptide ions in 
protonated [M+H]+ form, mass tolerance was set ±1, ±1.2 and ±1.5 Da. Protein 
molecular mass was not specified. 
All databases searched in this study generated similar results concerning the 
identified protein and significance of obtained data. 
 
5.3.1.2. MASCOT/MSDB sequence database 
 
 List of searched peptides in this search engine (MSDB primary sequence database), 
generated the top total score 274 for mixture of two peptides at MT±2:  
- CAC21795 (Sequence 3 from Patent WO0069913 (Fragment). - Homo 
sapiens (Human). 
- 1FVEB (Fab fragment of humanized antibody 4d5, version 7, chain B - 
human), (Fig. 5.36) 
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As shown in Figures 5.37 and 1.7, sequences of human protein CAC21795 (1-232), 
and  heavy chain of trastuzumab (humAb4D5-8 ) (218-450), are identical with 
exception that Ser-5 in CAC21795 is replaced with Cys- 223 in trastuzumab heavy 
chain sequence.  Actually, expect this Cys-Ser difference entire sequence of 
CAC21795 corresponds to trastuzumab hinge, CH2 and CH3 regions, which are fully 
human. Additionally, this protein and trastuzumab have the same allotype marker: 
...359EEM361... sequence of trastuzumab, corresponds to...141EEM143... of CAC21795. 
According protein view data (Fig. 5.37), 16 protein masses are matched and 
sequence coverage 65 % has been achieved.    
Fig. 5.37. Trastuzumab, heavy chain. Protein view section. CAC21795. Mascot/MSDB.  
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Fab fragment of humanized antibody 4d5, chain B - human, 1FVEB, was the second 
component of top score mixture (Fig. 5.38). In this instance there are 12 peptide 
matches, and sequence coverage is 55 %. Score value 85 indicates significant 
match. 1 FVEB corresponds to residues 1-223 of trastuzumab, including Fv and CH1 
domains. 
Database output made possible the identification of the antigen binding domain of 
trastuzumab (humAb4D5-8). From the Table 1.6 and published data165-168 is seen 
Fig. 5.38. Trastuzumab, heavy chain. Protein view section. 1FVEB. 
Mascot/MSDB.  
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that the sequences of trastuzumab heavy chain for both versions (humAb4D5-8 and 
humAb4D5-7) are identical. They differ in one amino acid in the light chain CDR2. 
For mass tolerance (MT) parameter set to ±1, the same proteins were reported, with 
same ranking, provided that number of matched masses was lower, and 
consequently their sequence coverages: Total score of mixture was 231, and number 
of queries matched, 25. For CAC21795, reported score was 116, number of queries 
matched, 14, sequence coverage was 55 %; and for humAb4D5, reported score was 
81, number of queries matched, 11, sequence coverage was 51 %. 
By increasing MT value to ±1.5 and ±2, scores dropped slightly, provided that there 
were 17 queries matched for CAC21795. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, at MT ±1, 1,2 and 1.5, as second ranked result, variable fragment of 
humAb4D5-8 (1 FVCB, Fv fragment of humanized antibody 4d5, version 8, chain B - 
human), is reported, with score value 77, sequence coverage 81 % and 10 queries 
Fig. 5.39. Trastuzumab, heavy chain.1FVCB.  Protein view section. 
Mascot/MSDB  
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matched. Variable fragment, 1 FVCB contains only 120 amino acids, and 
corresponds to sequence 1-120 of trastuzumab Fab fragment.  
The section of protein view report for 1 FVCB, (Fv fragment of humanized antibody 
4d5, version 8, chain B - human) is presented in Fig. 5.39. 
Results obtained in Figures 5.37, 5.38 and 5.39; provide confirmation of the 
sequence of trastuzumab heavy chain.  
 
5.3.1.3. MASCOT/ NCBInr sequence database. 
 
Second amino acid sequence database searched was NCBInr.  As in previous 
instance search parameters were set at the same values. 
 
For MT parameter set to ±1.2, Protein Mixture 1 is reported as the highest ranking 
result, with total score value of 276.  
The highest score mixture consisted of two identified proteins: 
 
- gi 226787, immunoglobulin gamma 1. 
- gi 442924, Chain B, X-Ray Structures Of The Antigen-Binding Domains From 
Three Variants Of Humanized Anti-P185-Her2 Antibody 4d5 And Comparison 
With Molecular Modelling. (Fig. 5.40.). 
 
First reported protein, gi 226787, represents sequence of human recombinant 
immunoglobulin G polypeptide, more precisely its CH2 and CH3 regions, and its entire 
amino acid  sequence (except Met-1, because it was produced in E. coli), 
corresponds to trastuzumab heavy chain sequence 228-450, (Fig. 5.41.). 
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There were reported 16 peptide masses to mach with masses obtained from in silico 
tryptic digest, score  value was 137 and sequence coverage 67 %. 
Fig. 5.40. Trastuzumab, heavy chain. Mascot search results. Primary sequence database: 
NCBInr. Mas tolelrance set to ± 1.2 Da 
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Fig. 5.41. shows that this protein and trastuzumab have the same allotype 
marker:...359EEM361... residues of trastuzumab, corresponds to...133EEM135... of gi 
226787. 
 
 
 
Second component of the reported Mixture 1 is gi 442924 protein. This protein 
represents antigen binding domain of trastuzumab (anti p185-HER2antibody 4D5, 
rhumAb4D5-8), heavy chain.  It corresponds to trastuzumab sequence 1-223, 
therefore to its heavy chain variable and CH1 domains. As observed from protein 
view report, in Fig. 5.42., amino acid sequences of the three complementarity 
determining regions (CDR1, 2 and 3 regions) are sequentially covered. From the 
Fig. 5.41. Trastuzumab, heavy chain. Protein view section. 
gi226787.Mascot/NCBInr.  
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analytical perspective, this is very important issue; since these (murine) CDR regions 
were grafted into human heavy chain sequence, to obtain humanized antibody, and 
this fact make possible specific identification and its discrimination from antibodies of 
different origin, i.e. fully human, chimeric, murine and/or fusion proteins. 
The score was significant (85), number of queries matched was 12 and sequence 
coverage 55 % (Fig. 5.42.) 
 
 
 
 
 
Fig. 5.42. Trastuzumab, heavy chain.gi442924. Protein view section. 
Mascot/NCBInr.  
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Similar results were obtained when MT set to ±1, provided that, the number of 
matched peptide masses (PM), score values (S) and sequence coverages (SEQ), for 
gi 226787, immunoglobulin gamma 1 and  gi 442924, Humanized Anti-P185-Her2 
Antibody 4d5, were lower (PM -14, S -118, SEQ-57% and PM-11, S -81, SEQ-51%  
respectively). If MT is set to higher values, then score results for both proteins fall.   
MASCOT/SwissProt sequence database outputted as a top score 137 with 18 
matched peptides, human Ig gamma-1 chain C region protein. 
 
Search results generated by PROFOUND Search engine were similar to those 
obtained by MASCOT (Fig. 5.43.) 
At MT± 1.5 the highest rank protein candidates were: 
- gi 226787, Ig gamma1, same protein as in case with MASCOT search 
engine (Figures 5.41. and 5.43.), corresponds to trastuzumab heavy chain 
sequence 228-450. 
- gi55669886, Fc fragment of Igg1, identical with trastuzumab Fc fragment, its 
entire sequence corresponds to trastuzumab heavy chain sequence 227-
450. 
These results are generated searching after the removal of variable fragment 
matched masses. 
 
 
 
 
 
 
Antigen binding domains of trastuzumab (rhumAb4D5-8, anti-p185-HER2 antibody) were 
second protein candidates to be reported (Fig. 5.44). In this instance, sequence 
Fig. 5.43. Trastuzumab, heavy chain. PROFOUND/Prowl/NCBInr, 
section of protein information and sequence analysis tools. 1T83A 
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coverages were 53 % and 73 %, depending on the reported fragment of antigen 
binding domain: only variable domain (1 FVCB, amino acid sequence 1-120) or 
variable domain and CH1 domain (1 FVEB amino acid sequence 1-223; 1 N8ZB, 
amino acid sequence 1-220). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MALDI-TOF analysis of trastuzumab has been performed measuring masses of 
peptides generated after tryptic digestion of Coomassie and silver stained gels. For 
both staining methods, MALDI-TOF analysis delivered qualitatively similar spectra. 
From Coomassie stained gels number of detected masses was higher (Fig. 5. 45.), 
which reflected on the increase of sequence coverage for identified trastuzumab. 
 
 
 
 
Fig. 5.44. Trastuzumab, heavy chain. PROFOUND/Prowl/NCBInr, 
section of protein information and sequence analysis tools. FVEB. 
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Fig. 5.45. MALDI_TOF Analysis of trastuzumab heavy chain. UP: MALDI -TOF 
Spectra of peptides generated from silver stained gels DOWN: MALDI -TOF 
Spectra of peptides generated from Coomassie stained gels.  
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5.3.1.4. Identification of light chain 
 
For primary sequence confirmation and identification of the trastuzumab light chain, a 
list of 18 peptide masses (Fig. 5.46.) generated by MALDI-TOF MS of peptides 
obtained from corresponding positions of Coomassie and silver stained gels (Figures 
V and Fig 19), were searched with MASCOT and PROFOUND (Prowl) Search 
Engines using three sequence databases: MSDB, NCBInr and SwissProt.  
 
 
 
 
 
 
During Database searching, taxonomy was restricted to Homo sapiens, selected 
enzyme was trypsin. Other search parameters were set to allow up to 1 missed 
cleavage, methionins in oxidized form (variable modification), cysteins in 
carbamidomethylated form (fixed modification), average mass, peptide ions in 
protonated [M+H]+ form, mass tolerance was set ±1, ±1.2,  ± 1.5 and ±2 Da. Protein 
molecular mass was not specified. 
All databases searched in this study generated similar results concerning the 
identified protein and significance of obtained data. 
 
In the Fig. 5. 47 MALDI-TOF spectrum obtained from peptides generated after tryptic 
digestion of light chain from Coomassie stained gel, is presented. 
 
 
 
 
 
 
 
 
 
 
Fig. 5.46. Trastuzumab light chain. List of entered peptide masses 
523.59; 553.61; 560.80; 644.77; 749.79; 869.77; 891.61; 1773.57; 1798.93; 1877.51; 1897.88; 
1947.62; 1992.36; 2103,51; 2142.17; 2289.33; 2611.00; 3623.68 
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Fig. 5.47. MALDI-TOF Analysis of trastuzumab light chain. UP: Entire spectrum, 
DOWN: Detailed view of higher mass range. 
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MASCOT/NCBInr search engine (MT ±1), reported the highest ranking and scores for 
two proteins: 
- The highest score had light chain of trastuzumab.  
- Second highest score had light chain sequence variant of trastuzumab which 
differ from trastuzumab light chain in one amino acid residue, Y55E , 
As seen in protein view report (Fig. 5.48.) for Herceptin Fab (Herceptin is 
commercial name of trastuzumab, such as it was submitted to database257, PDB 
ID. 1n8z) the reported score was 212, there were 16 queries matched and the 
sequence coverage was 65 %.   
 
Fig. 5.48. Trastuzumab, light chain. Mascot search results. Primary 
sequence database: NCBInr. Mas tolerance set to ± 1.0 Da 
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Increasing the MT parameter to ±2, the sequence coverage for light chain increased 
substantially, due to the match of the high mass, 3623.68 Da. Protein view data for 
light chain of trastuzumab (Herceptin Fab) are presented in Fig. 5.49. In this instance 
top score value obtained was 219, 18 masses matched and sequence coverage was 
81 %.  
 
 
 
 
As seen from the amino acid sequence in Fig. 5.49 amino acid residues Y-55 and R-
66, both sequentially covered, are characteristic for trastuzumab (rhumAb4D5-8) light 
chain. Y-55 as part of CDR region, and R-66 as part of FR3 were imported from the 
Fig. 5.49. Trastuzumab, light chain. Mascot search results. Primary sequence database: 
NCBInr. Protein view data/Section. Mas tolerance set to ± 2.0 Da.  
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murine LC sequence into the human LC sequence (See Table 1.6). Therefore, they 
are determinants for humanised antibody. On the other hand, if the light chain 
sequence of trastuzumab is carefully observed (Fig. 5.49), between peptide 
fragments of positions 62-103 and 67-103 and 67-107 respectively there is no lysine, 
neither arginine, therefore their masses are very high to be extracted from the gel 
and subsequently detected by MALDI-TOF MS. Therefore that region of light chain 
sequence remained uncovered.  
Second protein to be reported was variant of trastuzumab humAb4D5-7 which 
contains E instead of Y at position 55. Score and sequence coverage for this protein 
was lower that for trastuzumab though.  
For MT ±1.2 and ±1.5 obtained score results were 201 and 186, respectively. The 
number of queries matched was 16 in both cases. 
 
MASCOT/MSDB search engine (MT± 2) reported as the highest rank mixture 1 of 
two proteins,”separating” the sequence of trastuzumab light chain in two parts:  
1. Protein CAH68665, Score: 106, Molecular mass: 11936, 10 matched queries, 
sequence coverage 97%. From Figures 5.49 and 5.50 is observed that the 
complete sequence of this protein is identical with trastuzumab sequence, 
corresponding to amino acid residues108-214, in other words to constant 
domain of its light chain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.50. Trastuzumab, light chain. Section of protein view from Macot/MSDB 
search results. Sequence of CAH68665, identical with trastuzumab light chain 
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2. Protein 1 FVCC ( Fv fragment of humanised antibody 4D5, version 8, chain  
C with scoring parameter 74, molecular mass 11966, queries matched 8, and 
sequence coverage 65 %, (Fig. 5.51). 
 
 
 
   
 
 
 
 
 
 
This protein represents light chain variable domain of trastuzumab.  It corresponds to 
light chain trastuzumab sequence 1-108 (Figures 1.7, 5.49 and 5.51). 
Narrower mass tolerance parameters i.e. MT±1; MT±1.2 and MT±1.5, delivered 
same sequence coverage for 1 FVCC (65 %), provided that for CAH68665 coverage 
was reduced to 65 %.  
In MASCOT/SwissProt the highest score (90) result was protein IGKC_Human (Ig 
kappa chain C region). There were 9 mass values matched with sequence coverage 
of 97 %. The sequence of IGKC_Human (Ig kappa chain C region) reported here is 
identical with trastuzumab sequence, 109-214. 
 
Finally, PROFOUND/NCBInr generated same results as MASCOT/NCBInr. 
As in the case of heavy chain analysis, for both staining methods, MALDI-TOF 
analysis delivered qualitatively similar spectra. From Coomassie stained gels number 
of detected masses was higher (Fig. 5.52), which reflected on the increase of 
sequence coverage for identified trastuzumab. 
 
 
 
 
 
 
Fig. 5.51. Trastuzumab, light chain. Section of protein view from Macot/MSDB 
search results. 1 FVCC.  
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Fig. 5.52. MALDI_TOF Analysis of trastuzumab light chain. UP: MALDI -TOF 
Spectra of peptides generated from silver stained gels DOWN: MALDI -TOF 
Spectra of peptides generated from Coomassie stained gels.  
 - 148 -
5.4. Gel electrophoresis analysis of rituximab 
 
 
 
In order to assess relevant quality parameters ncluding detection, molecular weight 
estimation and purity, one-dimensional sodium dodecylesulfate polyacrylamide gel 
electrophoresis analysis (1D-SDS PAGE) of rituximab has been performed under 
reducing and non-reducing conditions. 
For the same purpose as above, and additionally for the estimation of the protein pI, 
study of the charge heterogeneity, and isoform pattern, two-dimensional gel 
electrophoresis analysis (2-DE) has been performed. Aiming the efficient resolution 
of protein spots two types of immobilized pI gradients (IPG) have been employed in 
the first dimension, IEF: IPG strips 3-11 NL and IPG strips 6-9 L.  
Obtained 1-DE SDS PAGE and 2-DE gels have been stained with Coomassie and 
silver staining. 
 
5.4.1. One dimensional (1D-SDS-PAGE) gel electrophoresis analysis of 
rituximab 
 
 
5.4.1.1. Molecular weight estimation and sensitivity of staining 
 
In Figures 5.53 and 5.54, 1D-SDS PAGE gels of rituximab under reducing and 
nonreducing conditions are presented. The electropherograms show typical gel 
patterns of IgG. Under reducing conditions, trastuzumab migrated as two sharp 
bands of heavy chain at located at ~ 50 kDa and light chain at ~23 kDa, respectively. 
On the other hand under non-reducing conditions, single band of rituximab has been 
observed at molecular weight higher than 150 kDa, provided that lower molecular 
mass minor protein bands could be observed as well. The obtained molecular 
masses correspond to the masses of rituximab heavy and light chain. Since 
trastuzumab heavy chain is glycosilated observed mass corresponds to the 
glycosilated form which is approximately 3-5 % higher than the mass of heavy chain 
derived from its consensus sequence. Theoretical average molecular weight of 
rituximab heavy chain based on its amino acid sequence in reduced, non-
glycosilated form is 49.214 kDa. On the other hand, the theoretical molecular weight 
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of the rituximab light chain is 23.057 kDa252. Therefore, the molecular weight of non-
glycosilated rituximab is 144.542 kDa.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
In order to assess, linearity and sensitivity of staining, 1D SDS PAGE analysis of 
rituximab under reducing conditions with the sample concentration ranging from 
(0.0067 μg/μl-0.33 μg/μl) was performed (Fig. 5.54.). 
 
 
 
 
 
 
 
 
 
The Gels in Fig. 5.54 showed that in this concentration range, both staining 
procedures enabled detection of rituximab bands, provided that for the lowest sample 
Fig. 5.54. 1-DE analysis of rituximab. Linearity/sensitivity A) silver staining. B) 
Coomassie staining. Lanes 1 and 10 MW standards. Lanes: 4,5, 6, 7 and 8: rituximab in 
increasing amount: 0.1 μg, 0.5 μg, 1 μg,  2.5 μg, and 5 μg 
  
  
Fig. 5.53. 1-DE analysis of rituximab A) silver staining; B) Coomassie staining. 
Lanes 1 and 9: MW standard; lanes 3 and 5: rituximab, reducing conditions, 15 and 1.5 
μg, respectively; lanes 7 and 10: rituximab, non-reducing conditions, 15 and 1.5 μg 
respectively. 
A 
1      3          5       7          9   10
  150 kDa  
1                   4    5    6    7   8         10 1                  4   5    6     7   8          10
1         3       5          7       9    10 
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25 kDa  
50 kDa  
25 kDa  
50 kDa  
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concentration in silver stained gel band intensity. Additionally, upon silver staining 
procedure additional protein bands are detected as well i.e. at the aggregate region. 
  
5.4.1.2.1-DE. Deglycosilation optimisation study. Preliminary experiments 
 
In Fig. 5.55, 1-DE gels of rituximab treated with N-glycosidase F under different 
conditions are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
 
 
  
 
 
 
Performed experiments for deglycosilation of rituximab and trastuzumab generated 
similar results. Gels bands from Fig. 5.55. show that deglycosilation performed under 
reducing and denaturing conditions (Method 1), brought about only partial 
deglycosilation. Heavy chain bands are split indicating non-efficient deglycosilation 
process (Fig. 5.55. lane 2 in both gels, Fig 5.55. C.) 
On the other hand, lane 3 in both gels migrated at slightly lower molecular weight 
comparing to glycosilated band 4, and showed no splitting. On the basis of these 
observations was evident that deglycosilation Method 2, which employs surfactant 
Triton X-100, without reduction and denaturation is more efficient than the first 
Fig. 5.55.1-DE analysis of rituximab. Deglycosilation monitorisation. Rituximab 2 μg. Silver staining 
A) Digestion time 24 hour. B) Digestion time 48 hour. C) Section of gel A. 
Lanes 1, 5: MW standards, Lane 4: glycosilated rituximab, Lane 2: deglycosilated rituximab  Method 1, 
Lane 3: deglycosilated rituximab, Method 2. 
 
 
1        2                3   4       5     1        2         3          4          5 
A
B
C
25 kDa  
50 kDa  
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method. As discussed previously, upon denaturation, immunoglobulin heavy chains 
become insoluble consequently their deglycosilation process is hampered.  
According results from Fig. 5.55.A and B, digestion times (24 and 48 hours) did not 
influence significantly the deglycosilation efficiency.   
Monitorisation of deglycosilation efficiency for Methods 3 and 4 is depicted in the Fig. 
5.56. Comparison of heavy chain bands of glycosilated trastuzumab (lane 2) with the 
lines of heavy chains of deglycosilated trastuzumab according Method 3 and 4 (lanes 
3 and 4, respectively) revealed that the molecular weights of both deglycosilated 
samples were substantially lower. Furthermore 1-DE data from Fig. 5.55 and Fig. 
5.56 indicate that deglycosilation Methods 3 and 4 result as more efficient than 
Method 2. The first method, results the one with the lowest deglycosilation efficiency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1          2       3         4        
Fig. 5.56. 1-DE analysis of rituximab. Deglycosilation monitorization. Optimised conditions. 
Rituximab 2 μg. Silver staining. Digestion time 24 h. 10 I.U. NGF 
Lane 1: Molecular weight standards. Lane 2: Nondeglycosilated sample/control, Lane 3: 
deglycosilated, Method 3, Lane 4: Deglycosilated, Method 4  
 
50 kDa  
25 kDa  
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5.4.2. Two-dimensional (2-DE) gel electrophoresis analysis of rituximab 
5.4.2.1. Immobilized pH gradient IPG 3-11 NL 
 
2-DE experiments of native, glycosilated rituximab revealed very complex two 
dimensional electrophoresis spot patterns characteristic for monoclonal antibodies: 
two sets of characteristic spots, one at ~50 kDa and other ~23 kDa.  
Heavy chain spots appeared as a characteristic band forming spots located in the pI 
range from about  6.3 to 9 provided that the most intense spots are at the basic 
region above pI 8. According to the electrophoresis data, comparing to the heavy 
chain spots, rituximab light chin spots are slightly shifted to the lower pI range, from 
about 6 to about 8.5, the most intense spot(s) being around pI 8.1. Experimentally 
estimated isoelectric points were in accordance with the theoretical pI values derived 
from cDNA amino acid sequences of rituximab heavy and light chains:  8.67 and 
8.26, respectivly252. According published data the pI of immunoglobulins of IgG class 
ranges from 6.4 to 9258. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental data revealed that reduction of sample concentration generally 
delivered spot patterns of higher resolution. Furthermore it is confirmed superior 
sensitivity of silver staining comparing to Coomassie staining procedure. As observed 
in Fig. 5.58, Coomassie staining provided the characteristic spot pattern of rituximab, 
Fig. 5.57. 2-DE analysis of rituximab, glycosilated sample 10 μg. Silver staining 
A) Heavy chain, detailed insight B) Light chain, detailed insight 
 
   3                                          11 
50 kDa 
25 kDa 
A 
B 
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of same pI range. However, as presented in Fig. 5.58A and B, spot intensities of 
silver and Coomassie stained gels are similar even at 10 fold higher sample amount 
loaded to Coomassie stained gel.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.2.2. Immobilized pH gradient IPG 6-9 L 
 
 
As observed in previous experiments, 2-DE gels of rituximab generated extremely 
complex spot pattern for both light and heavy chains and 2-DE gels as poorly 
resolved band forming spots, typical for all IgG are seen. Aiming to reduce spot 
overlapping and achieve better resolution, narrower immobiline pH gradient, 6 -9 L 
was used for the first dimension, isoelectric focusing. However, 2-DE data revealed 
no improvement in isoform resolution after application of narrow immobiline gradient 
(Fig. 5.59). Furthermore, comparing IPG 6-9 L with IPG 3-11 NL gels of rituximab and 
trastuzumab, isoform resolution obtained with IPG 6-9 L seems  to be even worst 
than obtained from IPG 3-11 NL gels.  
 
 
 
 
 
 
Fig. 5.58. 2-DE analysis of rituximab. Sample concentration. 
A) Glycosilated, 1μg, Silver staining. B) Non-Glycosilated, 10 μg. 
Coomassie staining 
      3                                         11  
50 kDa 
25 kDa 
     3                                 11  
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Coomassie stained gels of rituximab afford typical gel electrophoresis pattern of 
rituximab, provided that the band streaking was not as intense as in the case of silver 
staining at the same sample concentration (Fig. 5.59.D). On the other hand the 
superior sensitivity of silver staining vs. Coomassie staining is demonstrated in Fig. 
5.59.C., when 0.1μg sample is applied and both chain spots have been detected 
A B 
C D 
Fig. 5.59. 2-DE Analysis of  glycosilated rituximab. 
A) 10 μg rituximab, Silver staining. Control  
B) 10 μg rituximab. 30 days, 4-8 °C  
C) 0.1μg rituximab, Silver staining 
D) 10 μg rituximab, Coomassie staining 
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In the Fig.  5.59.B 2-DE gel of rituximab aged sample is presented. No significant 
mass or pI changes were observed. For comparison 2-DE gel of control has been 
presented as well (Fig. 5.59.A). 
 
 
 
5.4.2.3. Charge heterogeneity study of rituximab  
 
 
 
After preliminary 1D SDS PAGE and 2-DE experiments, next step consisted in the 
study of the influence of glycosylation and lysine truncation on rituximab charge 
heterogeneity, aiming the reduction of sample complexity and/or optimization of 
deglycosilation as sample preparation procedure for the subsequent immunoglobulin 
identification with MALDI-TOF analysis.  
 
For this study both immobiline pH gradients were applied:  IPG 3-11 NL to assess 
changes at the broader pI range and IPG 6-9 L to eventually have a detailed insight 
in narrower range. Proteins were detected with silver staining. 
 
Since deglycosilation study of rmAb trastuzumab indicated that no significant 
changes occurred in the isomorf pattern of this antibody after sialidase treatment the 
enzymatic desialination study of rituximab was omitted. Rituximab and trastuzumab 
oligosaccharides are mostly asialo neutral type of glycans, therefore desialination of 
sialo negatively charged glycans which are  only minor component ( less than 3 % in 
sugar content), could not be detected with 2-DE.  In addition, according literature 
data rituximab contains no O-linked glycans , therefore, O-deglycosilation study was 
not performed, as well253. 
For the first dimension, IEF, immobiline pH gradients 3-11 NL and 6-9 L have been 
employed. Deglycosilation efficiency was monitored with 1-DE (Fig. 5.55 and Fig. 
5.56). 
 
 
5.4.2.4. N-linked glycans. N-glycosidase F 
 
For the N-linked oligosaccharide removal enzyme N-glycosidase-F has been used. 
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This enzyme specifically hydrolyzes the aspartil glycosilamine bond between 
rituximab heavy chain Asn301 and the innermost N-acetylglucosamine of the 
oligosaccharide. Free carboxylate of aspartic acid, N-acetyl glucosamine which 
spontaneously hydrolizes to ammonia and free oligosaccharide are the reaction 
products. In rituximab (and trastuzumab) heavy chain there is only one 
oligosaccharide binding site Asn301 (Asn300, respectively) therefore the release of only 
one free carboxylate occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data obtained by 2-DE experiments revealed that the influence of N-Glycosidase-F 
glycan release was very small and it could not be detected with this technique. After 
glycan release, expected heavy chain molecular mass decrease is only about  3-5 % 
and pI difference only 0.1 (8.67 N-301; 8.57 D-301) due to the fact that N-linked 
sugars are neutral. Therefore, 1-DE and not 2-DE was able to confirm heavy chain 
A B 
C D 
Fig. 5.60. 2-DE analysis of rituximab. Deglycosilation study. 10 μg rituximab. Silver staining  
A) Glycosilated  6-9 L /Controle B) Deglycosilated, Method 2; 6-9 L  
C) Glycosilated  3-11 NL /Controle D) Deglycosilated, Method 2, 3-11 NL 
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molecular mass reduction, for studied rmAbs, trastuzumab and rituximab. Molecular 
mass of light chain anyway should remain unaffected.   
After deglycosilation, charge heterogeneity remained the same, suggesting that other 
factor, as in case of trastuzumab, and not glycovariants might be relevant to 
determine charge heterogeneity pattern of rituximab.  
In Fig. 5.60. 2-DE gels obtained from deglycosilated trastuzumab are presented. For 
N-linked glycan release, Method 2 employing nonionic surfactant, Triton X-100 was 
employed. Neither gels IPG 3-11 NL (Fig. 5.60. A, B) nor IPG 6-9 L (Fig. 5.60. C, D) 
were able to detect molecular weight and/or pI differences between deglycosilated 
and glycosilated (control) samples.  
Deglycosilation employing Method 1 as in the case of trastuzumab brought about 
horizontal split up of spot bands, indicating incomplete degycosilation, (Fig. 5.61. ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deglycosilation Methods 3 and 4, which on the basis of 1-DE data resulted as 
optimal, were used for trastuzumab N-linked glycan release for the preparation of 
sample for subsequent MALDI-TOF analysis (Fig. 5.62).  
50 kD 
25 kD 
A
B
Fig. 5.61. 2-DE analysis of rituximab. Deglycosilation optimisation study. Silver 
staining. 10 μg rituximab   
A) Deglycosilated, 3-11 NL, Method 1  
B) Heavy chain spot band split suggesting incomplete/partial deglycosilation.  
C) Light chain 
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C
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5.4.2.5. The study of lysine truncation. Carboxypeptidase B 
 
 
For the study of lysine truncation, rituximab solution was digested with the enzyme 
carboxypeptidase B (CPB) which specifically cleaves the terminal lysines from the 
protein backbone. After 2-DE experiments no significant changes in the spot pattern 
of heavy chain upon carboxypeptidase B treatment were observed (Figures 5.63. and 
5.64.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.62. 2-DE analysis of rituximab. Optimised deglycosilation conditions. 100 
μg, 3-11NL, Silver staining Deglycosilated, N-Glycosidase F A) Method 3 B) 
Method 4 
50 kDa 
25 kDa 
Fig. 5.63. 2-DE analysis of rituximab. Carboxypeptidase B. 10 μg, silver 
staining. A) 3-11 NL B) 6-9 L 
A B
25 kD 
50 kD 
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5.5. Matrix assisted laser desorption ionization time of flight mass 
spectrometric (MALDI-TOF MS) analysis of rituximab 
5.5.1. Primary sequence confirmation. Peptide mass fingerprinting  
 
In Fig. 5.65. MALDI-TOF spectrum of generated peptides from deglycosilated and in-
gel tryptic digested rituximab heavy chain, is presented. 
Rituximab is chimeric IgG1- κ antibody obtained by cloning murine light and heavy 
chain variable regions into the human framework.  
Fig. 5.64. 2-DE analysis of rituximab. Carboxypeptidase B plus N-
Glycosidase F. 10μg rituximab. Silver staining. A) 3-11 NL B) 6-9 L 
50 kDa 
25 kDa 
 6                                             9       3                                            11 
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As discussed above, recombinant monoclonal antibody rituximab contains two heavy 
and two light chains linked via disulfide bridges. It is composed of 1,328 amino acids:  
heavy chain contains 451 and light chain 213, amino acids, respectively (Fig. 1.8). 
 
 
 
Fig. 5.65. MALDI-TOF spectra of deglycosilated rituximab heavy chain. Up: Entire spectrum;  
Down: Detailed spectra. 
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5.5.1.1. Identification of heavy chain 
For primary sequence confirmation and identification of the rituximab heavy chain, 
the list of 14 peptide masses (Fig. 5.66) generated by MALDI-TOF MS  of peptides 
obtained from corresponding positions of silver stained gels (Fig. 5.62) were 
searched with MASCOT and PROFOUND (Prowl) search engines using three 
sequence databases: MSDB, NCBInr and SwissProt.  
 
 
 
 
 
 
During Database searching, taxonomy was restricted to Homo sapiens, selected 
enzyme was trypsin. Other search parameters were set to allow up to 1 missed 
cleavage, methionins in oxidized form (variable modification), cysteins in 
carbamidomethylated form (fixed modification), average mass, peptide ions in 
protonated [M+H]+ form, mass tolerance was set ±1, ±1.5 and ±2 Da. Protein 
molecular mass was not specified. The best results were obtained with 
MASCOT/NCBInr and PROFOUND (Prowl)/NCBInr databases. 
 
5.5.1.2. MASCOT/NCBInr sequence database 
 
List of searched peptides at MT±2 at MASCOT/NCBInr primary sequence database 
generated the top score values for human IgG1 constant region (score: 81- 119) and 
Fc fragment of rituximab (score 103) (Fig. 5.67).  
As seen from search results, the highest score had an IgG1 Fc fragment. There were 
12 masses matched and 60 % sequence coverage for this immunoglobulin fragment.  
Chain A, Fc fragment of rituximab bound to minimized version of protein A (Z34c) 
had score 103, 11 matched masses and 57 % sequence coverage (Fig. 5.68). 
 
Due to the fact that in database a version of Fc fragment lacking the last 4 amino 
acid residues at the C-terminus (448-SPGK-451) is registered, peptide mass 788.51 
Da does not match. According in silico digest this peptide mass corresponds to 
heavy chain residue 444-SLSLSPGK-451 (Fig. 1.8.). Furthermore, in MALDI-TOF 
Fig. 5.66. Rituximab heavy chain. List of entered peptide masses. 
2547.32; 2141.74; 1875.21; 1679.57; 1674.77; 1288.44; 1191.86; 1163.22; 878.23; 839.88; 
788.51; 657.28; 559.18; 502.69 
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spectrum peptide mass of 1962.71 Da has been observed. The difference of this 
peptide mass and the peptide mass of heavy chain fragment 1-19 (1978.29 Da) is 
15.6 Da, suggesting possible glutamine (Q) to pyroglutamate conversion. The 
theoretical difference is between two masses is 17 kDa. 
Decreasing Mass tolerance parameter to ±1.5, number of matched masses dropped 
to 9, sequence coverage was lower, however the score parameter although reduced, 
was still significant.  
The observed peptide masses were searched in MSDB and SwissProt search 
engines. At the same search parameters, these two databases generated high score  
 
Fig. 5.67. Rituximab, heavy chain. Mascot search results. Primary sequence database: 
NCBInr. Mass tolerance was set to ± 2 Da 
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results for human IgG1 constant region and human IgG1 Fc fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFOUND (Prowl) search engine generated similar results as MASCOT/NCBInr for 
same peptide fragment masses searched (Fig. 5.69). 
Fig. 5.68. Rituximab, heavy chain. Mascot/NCBInr. Protein view section.  
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On the basis of heavy chain PMF results it is demonstrated that only rituximab Fc 
fragment including CH2 and CH3 domains was identified with sequence coverage of 
57 % and  52 % respectively. 
In the Fig. 5.70 MALDI TOFF Spectra generated from peptide fragments of heavy 
chain of rituximab are presented. 
 
Fig. 5.69. Rituximab, heavy chain. Profound (Prowl)/NCBInr search results. Protein view section.  
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5.5.1.3. Identification of light chain 
 
For primary sequence confirmation and identification of the rituximab light chain, a list 
of 18 peptide masses (Fig. 5.71) generated by MALDI-TOF MS of peptides obtained 
from corresponding positions of silver stained gels (Fig. 5.62, Gel A), were searched 
with MASCOT and PROFOUND (Prowl) Search Engines using three sequence 
databases: MSDB, NCBInr and SwissProt.  
 
 
 
 
 
Fig. 5.70 MALDI-TOF Analysis of rituximab heavy chain.  
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For primary sequence confirmation and identification of the rituximab light chain, the 
list of 13 peptide masses (Fig. 5.71) generated by MALDI-TOF MS  of peptides 
obtained from corresponding positions of silver stained gels (Fig. 5.72), were 
searched with MASCOT and PROFOUND (Prowl) search engines using three 
sequence databases: MSDB, NCBInr and SwissProt.  
 
 
 
 
 
 
 
 
 
 
During Database searching, taxonomy parameter was not specified, selected 
enzyme was trypsin. Other search parameters were set to allow up to 1 missed 
cleavage, methionins in oxidized form (variable modification), cysteins in 
carbamidomethylated form (fixed modification), average mass, peptide ions in 
protonated [M+H]+ form, mass tolerance was set ±1- ±2 Da. Protein molecular mass 
was not specified. The best results were obtained with MASCOT/NCBInr at mass 
tolerance parameter set to ± 1.7 (Fig. 5.73). 
 
 
 
 
 
 
 
 
Fig. 5.71. Rituximab, light chain. List of entered peptide masses  
2142.81  2104.16  1948.50  1878.19  1800.02  1608.56  892.60  870.62  768.44  660.29  
561.46  524.34  503.09 
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Fig. 5.72. MALDI-TOF spectrum of rituximab light chain. Up: Entire spectrum up, Down: Detailed 
spectra  
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Fig. 5.73. Rituximab, light chain. Mascot search results. Primary sequence database: NCBInr. 
Mass tolerance was set to ± 1.7 Da 
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As shown in Fig. 5.73, peptide masses searched at MASCOT/NCBInr, MT±1.7 Da, 
as the highest score results generated two proteins: 
 
- Rituximab Fab 
- Antibody C2H7 Fab 
 
Score parameter for both proteins was 157. For Rituximab Fab, there were 13 
queries matched, and sequence coverage, 45 % (Fig. 5.74.). 
 
 
 
Fig. 5.74. Rituximab, light chain. Mascot/NCBInr. Protein view section.  
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The highest score result of NCBInr database, reported here, Fab fragment of 
rituximab, represents the full sequence of its light chain (murine variable region, 
residues 1-106 and human constant region, residues 107-213).  
As shown in Fig 80, murine variable domain of light chain was sequentially less 
covered as human constant domain counterpart. An explanation would be that 
lysines at position 38 and 44 are followed by proline, therefore not amenable to 
trypsine cleavage. Therefore the majority of other variable region peptide fragments 
generated from in silico tryptic digest have masses higher than 3300 Da and 
consequently, are more difficult to be extracted from gels and eventually to be 
detected by MALDI-TOF MS. 
This search engine generated the highest score results for rituximab Fab (light chain) 
for all MT parameters, provided that for more stringent MT values the sequence 
coverage was reduced e.g. (MT± 1, Score: 100, 9 matched queries; MT±1.5, Score 
141, 12 matched queries). However, if MT parameter is set to ± 2, then score slightly 
dropped (149) due to the fact that the number of matched masses remained 
constant. 
Other sequence databases, MASCOT/MSDB, and SwissProt, generated the highest 
score results for Ig kappa light chain, and fragments of other monoclonal antibodies 
suggesting that in this databases rituximab light chain is not included. 
MALDI-TOF spectra obtained from peptides generated after in gel trypsin digestion of 
rituximab light chain spots (Fig. 5.62, Gel A), are presented in Fig. 5.75.  
 
Fig. 5.75 MALDI-TOF Analysis of rituximab light chain
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5.6. Gel electrophoresis analysis of abatacept 
 
One- dimensional sodium dodecylsulfate polyacrilamid gel electrophoresis (1D-SDS-
PAGE) under reducing and nonreducing conditions, and two-dimensional gel 
electrophoresis (2-DE) pattern of abatacept have been studied, focusing on the 
examination of different factors influencing electrophoretic behavior of this complex 
molecule. Aiming the estimation of molecular weight and pI range, examination of 
charge heterogeneity and the influence of the posttranslational modifications in 
isoform distribution, 1-SDS-PAGE and 2-DE experiments were run under different 
conditions. Optimization of deglycosilation procedure for the study of charge 
heterogeneity and sample preparation for the subsequent MALDI-TOF analysis have 
been addressed as well.  
 
5.6.1. One dimensional (1D-SDS-PAGE) gel electrophoresis analysis of 
abatacept 
 
5.6.1.1. Molecular weight estimation and sensitivity of staining 
 
In the Fig. 5.76 silver stained and Coomassie stained gels of abatacept under non-
reducing and reducing conditions are presented. The amount of applied sample was 
increased from 0.05 μg-5 μg in both gels under reducing conditions and 1 and 5 μg in 
non-reducing conditions, respectively. For both staining procedures, gels show that 
reduced form of abatacept migrated as a sharp band at around 50 kDa. Under 
nonreducing conditions abatacept migrated at about 100 kDa, provided that for the 
highest sample amount shading toward lower molecular weight is observed (Fig. 5.76 
, Lane 8 in Gel A and B). 
 In the gel A the band of the smallest amount of abatacept (0.05μg) is clearly noted 
(Lane 6). On the other hand for the Coomassie stained gel Fig. 5.76B protein band is 
barely noticeable. This observation proves the higher sensitivity of silver staining 
toward Coomassie staining procedure. 
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5.6.1.2. Deglycosilation optimisation study 
 
1D-SDS-PAGE analysis of abatacept was used for the study of deglycosilation 
efficiency, following the application of different enzymes for the cleavage of N-and O 
linked glycans. 
The N-deglycosilation is performed in the similar way as for the rmAbs trastuzumab 
and rituximab. While for trastuzumab and rituximab the preferred deglycosilation 
conditions comprised no-denaturation of the sample prior to the reduction and 
deglycosilation, experimental results from 1D-SDS-PAGE and 2-DE experiments of 
abatacept demonstrated that sample reduction prior the deglycosilation does not 
hamper the deglycosilation process. It is even preferred step for efficient N-
deglycosilation process. The optimal methods resulted methods which employ no 
solubilizator or surfactant (Methods 3 and 4).  
As for trastuzumab and rituximab, for methods of deglycosilation have been studied: 
1. Deglycosilation under reducing and denaturated conditions 
2. Deglycosilation under nonreducing conditions. Nonionic surfactant 
3. Deglycosilation under reducing conditions, with no surfactants and no previous 
boiling 
4. Deglycosilation under non-reducing conditions, no surfactants and no previous 
boiling 
For detailed information see Experimental section.  
Fig. 5.76. 1-DE Analysis of abatacept: A) Silver stained gel B) Coomassie stained gel. 
Lanes 1-6: Abatacept 5 μg-0.05 μg, reducing conditions. 
Lanes 8 and 9: Abatacept 5 and 1 μg, respectively, nonreducing conditions.  
Lanes 7 and 10: MW Standards 
1     2    3    4   5    6   7   8     9   10 1     2    3    4   5    6   7   8     9   10 
A B 
50 kDa 50 kDa 
100 kDa 100 kDa 
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Literature data indicates that abatacept molecule apart from N-linked 
oligosaccharides contains O- linked glycans of different degree of terminal 
sialidation245. Therefore, in contrast to trastuzumab and rituximab, the deglycosilation 
optimization study of abatacept involved the O-deglycosilation and desialination, as 
well. 
 
 
5.6.1.3. Preliminary deglycosilation experiments 
 
In the Fig. 5.77, 1-DE gels of abatacept deglycosilated and control sample under 
reducing and nonreducing conditions have been presented. 
 
 
 
 
 
 
 
 
 
 
 
 
For the preliminary experiments abatacept sample was digested with required 
enzymes according Method 2 (Non-reducing/non-denaturing conditions Triton X-100 
0.5 %) and its modification, where Triton X-100 was replaced with CHAPS 0.5 % and 
SDS 0.1 % (Method 2 M). Abatacept samples were in reduced and nonreduced 
forms (Fig 5.77 A and B, respectively). Method 1 has been studied as well. 
Fig. 5.77 indicates no change in the MW for abatacept sample treated with 
carboxypeptidase B (CPB) under reducing (Fig. 5.77A, lane 4) and non-reducing 
conditions (Fig. 5.77B lane 4). This is normal due to the expected small MW 
difference (146.2 Da) between abatacept and its corresponding truncated 0-Lys or 2-
Lys form. 
A B 
1     2    3    4   5    6   7   8     9   10 1  2    3   4   5    6   7   8     9   10 
50 kDa 
100 kDa 
Fig. 5.77. Abatacept (1μg). Deglycosilation optimisation, silver stained gels: A) Non-
reducing B) Reducing conditions. Lane 2: NGF-Method 2M, Lane 3: Sialidase, Lane 4: 
CPB, Lane 5: NGF, sialidase, Lane 6: NGF, Sialidase, CPB, Lane 7: NGF, Method 2; Lane 
8: NGF, Method 1, Lane 9: Control,  Lanes 1 and10: MW Standards 
 - 174 -
 
N-deglycosilation employing Method 1 (denaturation/reduction) under non-reducing 
conditions (Fig. 5.77A Lane 8) was not optimal. Under reducing conditions the 
molecular weight of abatacept has considerably decreased, comparing with non-
deglycosilated sample (Fig. 5.77B Lanes 8 and 9, respectively) however the 
abatacept band is not sharp. 
On the other hand, molecular weight difference of bands 7 and 9 under non-reducing 
conditions (Fig. 5.77A) is evident. This difference is better noted comparing bands 7 
and 9 under reducing conditions (Fig. 5.77B): the MW of glycosilated abatacept band 
is estimated ~ 50 kDa whereas MW of deglycosilated sample is much lower (~ 42-44 
kDa). These data suggest that the N-deglycosilation employing Method 2 is more 
efficient than the one which employs Method 1. 
As indicated above, modification of the Method 2 consisted on the replacement of 
Triton X-100 with CHAPS 0.5 % and SDS 0.1 %. With this method experiments 
involving sialidase and carboxypeptidase B digestion were performed.  
From the Fig 5.77A and 5.77B, no significant difference in the molecular weight of 
deglycosilated abatacept employing Method 2M an Method 2 was noted (Lanes 2 
and 7 respectively in both gels), provided that, Method 2 provided sharper bands 
than Method 2M. 
Fig. 5.77A and 5.77B shows that abatacept samples treated with N-glycosidase F, 
Sialidase (Lane 5) and N-glicosidase F, Sialidase and carboxypeptidase B (Lane 6) 
employing Method 2M, exhibit no significant differences in the molecular weight 
neither with sample treated with N-glycosidase F Method 2, nor with sample treated 
with N-glycosidase F Method 2M (Lanes 2 and 7), indicating small contribution of 
terminal silaic acids and lysine in the abatacept MW.  
Interestingly, in gels of abatacept digested only with sialidase (Method 2M) small 
difference in MW between sialidase treated abatacept and control has been 
observed (Lanes 3 and 9 in both gels) suggesting small contribution of terminal N-
Acetylneuraminic acid residues (MW 309.27) from O-linked sugars in the MW of 
abatacept. The presence of terminal silaic acid resuidues in abatacept was confirmed 
with 2-DE analysis (see the next section). 
Preliminary deglycosilation experiments confirmed that N-deglycosilation and 
desialination  give rise to the abatacept species with lower molecular weght. 
The deglycosilation procedure hovewer was further optimised. 
 - 175 -
 
5.6.1.4. Optimized experimental conditions 
 
Fig. 5.78 shows that the optimal conditions for deglycosilation of abatacept consist of 
the application of the Method 3 (deglycosilation under reducing conditions, employing 
no surfactant). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
In the Fig. 5.78 substantial decrease in molecular weight under reduced and non-
reduced conditions is observed upon deglycosilation according Method 3 (Lanes 3, 5 
and 8).  
Molecular weight of glycosilated native sample (Lane 2), estimated ~ 100 kDa after 
N-Glycosidase digestion changed to ~ 75 kDa. At the same time, molecular weight of 
glycosilated reduced sample (Lane 7) decreased to ~ 40 kDa provided that 1-DE 
does not make possible exact measurement of molecular difference. Nevertheless, 
significant molecular weight difference after N-deglycosilation suggests that N-linked 
sugars are predominant glycans of abatacept molecule. 
 
     1       2    3   4      5   6     7      8   9   10
50 kDa 
100 kDa 
Fig. 5.78. Abatacept (2 μg) optimised deglycosilation conditions. Silver staining. Lanes 1, 6 and 
10, MW Standards, lane 2 Nonreducing/glycosilated, lane 3 and 5 Deglycosilated, Method 3, lane 
4 Deglycosilated Method 4. Lane 7 Reducing/glycosilated, lane 8 Deglycosilated, Method 3, lane 
9 Deglycosilated, Method 4. 
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Lanes 4 and 9, show that for abatacept deglycosilation procedure employing Method 
4 did not perform as efficiently as Method 3. 
 
5.6.1.5. Optimized electrophoresis conditions. Comparison of biological medicinal 
substances 
 
In order to compare relative extent of glycosylation in two classical rmAbs 
trastuzumab and rituximab with fusion protein abatacept, three substances have 
been run in one SDS-PAGE gel, under reducing and non-reducing conditions (Fig. 
5.79). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two sets of heavy and light chain bands, ~ 50 kDa and ~ 23 kDa respectively, are 
observed for trastuzumab and rituximab. The difference in molecular weight between 
deglycosilated (lanes 6, 7 and 9, 10 for trastuzumab and rituximab respectively) and 
non-deglycosilated samples (lanes 5 and 8 for trastuzumab and rituximab 
respectively) is not large. This difference is noted only in the bands of heavy chains 
since they are glycosilated. Position of light chain bands remains the same. 
  1     2         3     4    5     6    7     8    9  10
       Abatacept          Trastuzumab   Rituximab 
50 kDa 
25 kDa 
Fig. 5.79. Deglycosilation efficiency. Abatacept, trastuzumab and rituximab, 2 
μg each. silver staining. Lane 1: MW Standard, Lanes 2,3,4: abatacept; Lanes 
5,6, 7 trastuzumab; Lanes 8,9,10 rituximab. 
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On the other hand, glycosilated abatacept which has about the same molecular 
weight as trastuzumab and rituximab heavy chains (~ 50 kDa), after deglycosilation 
provides band with considerably lower MW, ~40 kDa. Therefore one the basis of 
these experiments one can conclude that the extent of glycosylation in the fusion 
protein abatacept is substantially higher than in rmAbs trastuzumab and rituximab. 
 
5.6.2. Two-dimensional (2-DE) gel electrophoresis analysis of abatacept 
 
Biologics produced by recombinant DNA technology are complex heterogeneous 
mixtures of posttranslational anticipated forms, i.e. glycoforms or other variants 
produced during manufacture and/or storage, like deamidation, isomerisation etc. 
The characterisation of the degree and profile of the heterogeneity is of the great 
importance from the regulatory point of view since the heterogeneity of these 
products defines their quality161. 
Abatacept is a biological product derived from rDNA technology and produced in 
CHO cells. Therefore it is expected, that like other biological products, to have certain 
degree of heterogeneity and isoforms. 
This study addresses 2-DE electrophoresis behaviour of abatacept aiming to analyse 
its charge heterogeneity, and subsequently with MALDI-TOF analysis to identify and 
characterise the drug substance, its purity and stability. 
For the 2-DE optimisation, electrophoresis experiments are performed using different 
immobiline pH gradients (IPG strips: 3-11 NL, 6-9 L; 4-7 L and 3-6 L). In order to 
have a view on the broader pI range the preliminary experiments are performed with 
IPG gradient 3-11 NL. IPG gradient 4-7 L results the most suitable for charge 
heterogeneity study. 
The influence of glycosylation pattern in the charge heterogeneity of abatacept was 
studied using enzyme N-glycosidase F for the release of N-linked glycans, O-
glycosidase for O-linked glycans and the sialidase for the release of terminal sialic 
acids. In addition carboxypeptidase B was used for the study of lysine truncation. 
Gels were stained with Coomassie Blue and silver staining procedure. 
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5.6.2.1. Preliminary 2-DE experiments. IPG strips 3-11 NL   
 
As expected, 2-DE analysis revealed that abatacept is very complex mixture of 
different isoforms. In the Fig. 5.80 two gels of abatacept developed under different 
conditions with detailed section of gel A are presented. 
The estimated pI of this acidic glycoprotein ranged from 4.5-5.5, and there are 
observed 13-14 spots. Molecular weight is estimated to be higher than 50 kDa. There 
are obvious differences in the 2-DE spot pattern of abatacept and heavy chains of 
classic rmAb studied so far, rituximab and trastuzumab. First, the abatacept’s pI is 
substantially lower. This is in agreement with the difference of sugar composition of 
these two classes of biologics. Namely, abatacept contains acidic O-linked glycans 
which do not occur in molecules of rmAbs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3                                               11 3                                               11 
A B 
C 
Fig. 5.80. 2-DE analysis of abatacept (10 μg). Silver staining A) Development 
time 5 min, B) Development time 2.5 min, C) Detailed section of A. 
 
 50 kDa 
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Second, as seen in the gels from Fig. 5.80, abatacept spots extend  in an oblique 
direction, which proves the presence not only of charged but mass variants, as well, 
suggesting that its not only the type but the quantity of particular attached glycan 
and/or other factor(s) which will determine the mass and charge heterogeneity.  
Third, resolution of abatacept spots was better to resolution of rmAb therapeutics, 
rituximab and trastuzumab.   
In Fig. 5.80 the influence of the time of development phase in gel transparency and 
spot intensity has been depicted. The development time of 2.5 minutes has been 
selected as optimal. 
Aiming to compare the staining sensitivity, 1 μg of abatacept is applied into the gels 
and they are stained with silver staining and Coomassie staining procedure. 
Gel spots could be visualized in both cases however with the large difference in their 
intensities (Fig. 5.81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3                                               11 3                                                 11 
50 kDa 
Fig. 5.81. 2-DE analysis of abatacept (1 μg). Silver versus Coomassie staining. A) 
Silver staining A)Coomassie staining C) detailed section of A.  Arrow indicates 
abatacept spots in gel B. 
 
A B
C 
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Experimental data revealed that the reduction of sample concentration generally 
brought about enhancement in the spot resolution. For illustration, detailed section of 
silver stained gel with 1 μg abatacept applied is presented in Fig. 5.81. 
Improvement in the spot resolution was observed when immobiline pH gradient was 
narrower, as well. In this study IPG gradients of 3-6 L, 4-7 L and 6-9 L have been 
employed. 
Comparing to IPG 3-11 NL, IPG gradients 3-6 L and 4-7 L, afforded better spot 
resolution at the same sample amount, 10 μg abatacept (Fig. 5.82). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4                                              7 3                                             6 
A B
50 kDa 
6                                                   9  
50 kDa 
C
Fig. 5.82. 2-DE analysis of abatacept (10 μg).Optimisation of pH gradient. 
Silver staining A) IPG 3-6 L, B) IPG 4-7 L C) IPG 6-9 L 
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In contrary, immobiline gradient IPG 6-9 L brought about poorly resolved band 
around pI 6, most likely only minor component of the abatacept protein, consequently 
studies with this IPG gradient were not pursued further. 
 
5.6.2.2. The study of charge heterogeneity 
 
From previous 2-DE experiments performed under different IPG gradients it was 
documented that abatacept is very complex molecule, containing 13-14 spots. 
Consequently the charge heterogeneity study should employ the conditions which 
must permit obtaining of the maximal information for the spot pattern complexity of 
abatacept sample. In other words, IPG strips which provide maximally resolved spots 
should be selected for the study. Previous experiments indicated that strips 3-6 L and 
4-7 L might fulfill these requirements.  
Therefore, for the study of the influence of terminal sialic acids in charge variant 
complexity, the first immobiline pH gradient employed was IPG 3-6 L.  
Experimental data revealed that after sialidase digestion due to the cleavage of 
terminal N-acetylneuraminic acid residues, spot complexity was substantially 
reduced, however since pI of resulting variants shifted toward more basic values, 
approaching pI 6, and this pI is the upper pH limit for the strips (3-6 L), the number of 
spots and their position could not be precisely determined Fig. 5.83. 
 
 
 
 
 
 
 
 
 
 
 
 
3 6
50 kDa 
Fig. 5.83. 2-DE analysis of abatacept (10μg) 3-6 L. Sialidase. Silver staining.  
Arrow indicates the position of abatacept spots 
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Nevertheless, from the Fig. 5.83 important information is obtained. The pI of resulting 
spots is more basic comparing to native sample, their number and complexity is 
reduced, and their molecular weight seems to be lower, as well. 
The next step was to study more suitable pI gradient conditions (broader pI range) 
with additional examination of the influence of other factors such are N-linked glycans 
and O-linked glycans on the charge heterogeneity. (In)complete terminal lysine 
processing should be addressed, as well. 
 
5.6.2.3. Immobiline pH gradient 4-7 L 
The study involving IPG 4-7 L tends to answer very important questions related to 
posttranslational modification of abatacept,  primarily to test which is the contribution 
of N-linked and O-linked glycans on its charge heterogeneity, what is their relative 
content in abatacept molecule, which oligosaccharides contain terminal sialic acid 
residues: N-linked, O-linked or both of them? This information, supplemented with 1-
DE and 2-DE experiments of native sample and in conjunction with subsequent 
MALDI-TOF analysis, could represent an important step not only for the elucidation 
and confirmation of isomorf pattern, but for the identity and purity assessment of this 
biological product as well. 
In the Figures 5.84 and 5.85 Gels of abatacept under different digestion conditions 
using N-glycosidase F, O-glycosidase, and Sialidase are presented. 
For the comparison purpose, in both Figures gel obtained from nontreated, control 
sample has been included.  
In the Table 5.12 a list of corresponding pI values is presented. 
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Fig 5.84. shows that in comparison with the spots of control gel A (non-deglycosilated 
sample ), spots of abatacept digested with N-glycosidase F in gel B of the same Fig. 
are displayed as spot pattern of lower molecular weight than control spots. Their pI 
range shifted toward lower pI range although not in greater extent (Table 5.12.). A 
considerable difference in molecular weight confirms that abatacept is extensively N-
glycosilated molecule containing predominantly N-linked glycans. 
On the other hand, pI shift toward lower pI range after N-oligosaccharide release, 
suggests that N-linked glycans of abatacept are neutral molecules containing no 
A 
       4                                                 7 
50 kDa 
37 kDa 
      4                                                 7 
B 
C 
       4                                                 7       4                                                 7 
50 kDa 
37 kDa 
D
Fig. 5.84. 2-DE analysis of abatacept. Charge heterogeneity study I. 4-7 L. Abatacept ( 
10μg) Silver staning.  A) Glycosilated sample, control; B. N-glycosidase F; C. Sialidase; D. 
Sialidase and O-glycosidase  
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sialic acid residues at their non-reducing termini. After the hydrolysis of glycoside 
bond with the release of oligosaccharide and ammonia, for each N-glycosylation site 
one free carboxylate of aspartic acid is released, hence the pI of molecule is lower. 
Larger difference in abatacept spot pattern is observed upon the digestion of sample 
with sialidase (Fig. 5.84C) and with both enzymes together, sialidase and O-
glycosidase (Fig. 5.84D). In these instances, the molecular weight change is not so 
much pronounced as after digestion with N-glycosidase F, but there is a considerable 
change in the abatacept pI and its spot complexity.  
Namely, after sialidase digestion (Fig. 5.84 C) pI range increased in order of 
magnitude 0.5 suggesting that O-linked abatacept glycans contain terminal N-
Acetylneuraminic acid residues which are responsible for acidic nature of abatacept. 
However after sialidase cleavage, they are released, with concomitant release of 
neutral serine residues from protein backbone therefore pI of asialo abatacept is 
shifted toward higher values. In contrast to non-deglycosilated abatacept the spot 
complexity is substantially reduced, as well suggesting that the different degree of 
sialidation and/or different structures of O-linked glycans, are major contributors to 
abatacept charge heterogeneity.  
In order to examine the influence of O-linked glycans in the charge variant 
distribution abatacept was first digested with sialidase followed by O-glycosidase (Fig 
5.84 D). The previous desialination was needed due to the fact that in contrast to N-
glycosidase F, O-glycosidase can not cleave modified (i.e. sialinated) O-linked 
glycans.  
The experimental results show that O-deglycosilated (and desialinated) abatacept 
has lower molecular weight comparing to control and desialinated sample although 
still considerably higher than of N-deglycosilated abatacept form. This observation 
suggests that the size of O-glycans and/or their abundance is lower than of N-linked 
glycans in molecule of abatacept. Fig 5.84 D shows as well that the pI range of 
resulting abatacept has moved toward higher pI values, as in the case when only 
sialidase is employed (Fig 5.84 A, C, D, Table 5.12). 
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In order to cleave both, N-linked glycans and N-Acetyl neuraminic acid termini from 
abatacept molecule N-glycosidase F and sialidase were used simultaneously (Fig 
.5.85B). For the removal of N-linked and O-linked glycans, abatacept sample was 
initially desialinated and subsequently N and O-deglycosilated using slightly different 
deglycosilation procedures which gave similar results (Fig. 5.85C and D).  
Fig 5.85A and B show that asialo and N-deglycosilated abatacept has lower 
molecular weight that control sample with additional reduction in charge 
A 
       4                                                 7 
50 kDa 
37 kDa 
4 7
B 
D
      4                                                 7 
C
50 kDa 
37 kDa 
Fig. 5.85. 2-DE analysis of abatacept. Charge heterogeneity study.II 4-7 L .Abatacept 
( 10μg). Silver staning.  A)  Glycosilated sample, control; B) N-glycosidase F and 
sialidase; C) N-glycosidase F, Sialidase and O-glycosidase, Triton X-100; D) N-
glycosidase F, Sialidase and O-glycosidase.  
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heterogeneity pattern. Its pI range however is similar to control provided that spots 
begin at higher pI values, but end at the approximately same pI values as control. 
Very small difference in pI might be consequence of two opposite processes during 
the N-deglycosilation and desialination. In the first instance pI is decreased due to 
aspartic acid release, and in the second, pI increases due to removal of negatively 
charged sialic acid species (Table 5.11). On the basis of experimental data 
desialination resulted preponderant. 
In the last experiments with IPG 4-7 abatacept was digested with three enzymes 
simultaneously N-glycosidase F, O-glycosidase and sialidase (Fig. 5.85C) and 
initially digested with sialidase and N-glycosdidase F followed by the O-glycosidase 
digestion (Fig. 5.85D). 
Both gels provided similar results. Larger difference in molecular weight between 
resulting abatacept form and control sample has been observed, invoking the 
additive effect in the molecular weight reduction of three enzymes. Charge 
heterogeneity is reduced, provided that the pI range is similar to the one in Fig.5.85B. 
 
 
Deglycosilation 
status 
Glycosilated N-Glycosidase 
F (NGF) 
Sialidase  
(S) 
O-glycosidase 
(OG), sialidase 
S, NGF S,NGF, 
OG 
pI range 4.6-5.5 4.3-5.3 5.4-5.9 5.3-5.9 4.9-5.3 5.0-5.6 
 
 
 
 
5.6.2.4. Immobiline pH gradient 3-11NL 
 
After application of immobiline pH gradient IPG 3-11 NL similar results were obtained 
as in previous cases with IPGs 3-6 L and 4-7 L. Corresponding gels are presented in 
Fig. 5.86. 
 
 
 
 
 
 
Table 5.12. Charge heterogeneity study of abatacept 
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2-DE study of abatacept charge heterogeneity, presented in Fig. 5.86 is possible with 
broader pI gradient 3-11 which in this instance is non-linear. As in previous cases (3-
6 L and 4-7 L) N-deglycosilated abatacept displayed the similar charge complexity as 
non-treated sample. Additionally, its pI range shifted to lower values and molecular 
weight substantially decreased in comparison with control (Fig. 5.86A and C).  
A B
C D
50 kDa 
50 kDa 
37 kDa 
37 kDa 
Fig. 5.86. 2-DE analysis of abatacept. Charge heterogeneity study. 3-11 
NL. Abatacept (10μg). Silver staning.  A) Non-deglycosilated, control; B) 
Sialidase; C) N-glycosidase F, Triton X-100; D) N-glycosidase F, Sialidase. 
       3                                                11 3                                                11 
       3                                                11 3                                                11 
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Desialinated abatacept resulted less acidic, and displayed reduced complexity 
comparing to control sample. Molecular weight decrease was small (Fig 5.86B). 
Finally, abatacept sample digested simultaneously with N-glycosidase F and 
sialidase displayed difference in pI range with considerable molecular weigh and spot 
complexity reduction (Fig. 5.86D). 
The lysine truncation study of abatacept with 2-DE provided no conclusive data. Fig. 
5.87 shows the gel of abatacept treated with enzyme carboxypeptidase B for 
illustration purpose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the basis of experimental data obtained employing three types of IPG gradients it 
can be concluded that 1-DE and 2-DE are suitable methods to detect, estimate 
molecular weight and monitor the charge heterogeneity pattern of abatacept. 
Since the enzymatic deglycosilation is nondestructive technique the resulting 
abatacept peptides could be further analyzed with MALDI-TOF MS in order to confirm 
its identity. 
On the other hand, for the full characterization of abatacept glycoforms, i.e. glycan 
sequencing, a supplementary method is required. 
In summary, as indicated above, charge variants and other variants of this drug 
substance define its quality, the establishment of suitable methods to monitor the 
heterogeneity of this rDNA derived medicinal product would be of great importance 
for its overall quality assessment.  
 
      3                                                11 
50 kDa 
Fig. 5.87. 2-DE analysis of abatacept. Charge heterogeneity study. 
Carboxypeptidase B. 3-11 NL. Silver staning. Abatacept 10 μg. 
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5.7. Matrix assisted laser desorption ionization time of flight mass 
spectrometric (MALDI-TOF MS) analysis of abatacept. 
 
Identification of abatacept was the primary goal of MALDO-TOF mass spectrometric 
analysis which followed the in-gel tryptic digestion of the molecule. 
For analysis, two silver stained gel spots of deglycosilated abatacept (indicated with 
arrows in the Fig. 5.85 gel D) have been selected and with the use of clean scalpel 
excised in pieces of approximately 1 mm3 size. A piece of gel is excised from blank 
region and processed parallel with the sample to serve as control. After destaining131, 
proteins were in-gel reduced (DTT, 45 min. 56°C) and acetamidated (iodoacetamide, 
30 min in the dark).  In- gel tryptic digestion is performed according published 
procedures129, 130 (For details see experimental section). Digestion buffer consisted of 
12.5 ng/μl modified trypsin in 50 mM ammoniumhydrogene carbonate, pH 8.5. 
After extraction (formic acid 5 %, acetonitrile 1:1) and vacuum evaporation, pellet of 
resulting peptides was dissolved in 3-5 μl of 0.1 % trifluoroacetic acid.  
 
5.7.1. MALDI-TOF sample presentation 
 
Application of sample onto MALDI target is performed according the method which 
eliminates the mixing of sample with matrix prior to application to the MALDI target259. 
0.5 μl of saturated matrix solution (8mg α-Cyano- 4-hydroxycinnamic acid dissolved 
in 1 ml mixture of 70 % ACN and 30% of the 0.1% TFA solution) was applied onto 
the well of the MALDI target. After 1-2 seconds excess matrix was removed and 
target surface allowed to dry. After drying, 0.5 μl of sample solution was applied to 
the sample deposit area. While sample deposit was still wet, further 0.5μl of matrix 
solution were added and allowed to dry passively. In the same way were applied 
solutions of molecular mass standards.  
All mass spectra were acquired on Compaq SEQ, Kratos Analytical, Manchester, UK) 
MS instrument operated in positive reflectron mode, peptides were observed as 
[M+H]+  ions.  
For external calibration were used bradykinin fragment 1-7, angiotensin II, ACTH 
fragment 18-39 and insulin oxidized beta chain. 
The identity of abatacept could be confirmed by MALDI-TOF MS by matching the 
measures molecular weights of resulting peptides to a sequence database.  
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5.7.2. Peptide mass fingerprint analysis of abatacept 
 
Experimental peptide masses obtained from MALDI-TOF- MS analysis of in gel 
trypsin digested abatacept, are compared with calculated peptide masses by 
applying the enzyme cleavage rules from three primary sequence databases: MSDB, 
NCBInr and SwissProt using MASCOT search engine.  The closest matches have 
been identified by using the scoring algorithm.  
PeptideMass (http://www.expasy.ch/tools/peptide-mass.html) program was used to in 
silico cleave entered abatacept sequence with trypsine and to compute generated 
peptide masses with their specified modifications252.  
Only peptide masses bigger than 500 Da have been displayed since in mass region 
below 500 Da MALDI-TOF spectrum is obscured by the presence of matrix peaks. 
For the sequence confirmation, list of peptide masses from MALDI-TOF spectrum 
(Fig. 5.88) of deglycosilated abatacept is entered to Mascot search engine and 
corresponding primary sequence database is selected. 
 
MALDI-TOF spectrum of generated peptides from deglycosilated and in-gel tryptic 
digested abatacept is presented in Fig. 5.88. 
 
 
Fig. 5.88. MALDI-TOF spectrum of deglycosilated abatacept. 
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5.7.3. Primary sequence confirmation. Peptide mass fingerprinting. 
 
For primary sequence confirmation and identification of abatacept, the list of  22 
peptide masses (Fig. 5.89) obtained by MALDI-TOF MS were searched with 
MASCOT and Profound (Prowl) search engines using three sequence databases: 
MSDB, NCBInr and SwissProt.  
Taxonomy was restricted to Homo sapiens, selected enzyme was trypsin. Other 
search parameters were set to allowed up to 1 missed cleavages, methionins in 
oxidized form (variable modification), cysteins in carbamidomethylated form (fixed 
modification), average mass, peptide ions in protonated [M+H]+form, mass tolerance 
was set 1, 1.5 and 2 Da. Protein molecular mass was not specified. 
 
 
 
 
 
 
 
All databases searched for given peptide masses generated similar results. Entered 
masses matched with high scores with two components of CTLA4-Ig (abatacept): 
 
1. AAL96263 Fragment of human immunoglobulin gamma-1 heavy chain 
constant region IgG1. 
2. Q9BZK2_HUMAN Fragment of human CTLA-4 V domain region.  
 
For human IgG1 fragment sequence coverage and score values were dependent on 
the entered mass tolerance (MT) parameter. On the other hand, for CTLA-4 V 
domain region, only score values were affected by the MT change. For example, for 
MT ± 1 Da Mascot search results (MSDB sequence database), reported top score 
180 for mixture of AAL96263, human IgG1 fragment and Q9BZK2_HUMAN 
Fragment of human CTLA-4 V domain region. From 22 entered queries, matched 
18(12 for IgG1Fc fragment and for 7 CTLA-4 V domain). Sequence coverages were 
51 % and 41 % for heavy chain IgG1 fragment and CTLA-4 V domain region, 
Fig. 5.89. Abatacept. List of entered peptide masses  
2547.29  2230.59  2141.17  2044.04  1874.96  1674.40  1679.39  1467.17  
1487.35  1288.22  1191.35  1172.98  1162.96  1145.21  839.55  836.30  
819.57  788.34  657.16  588.17  576.18  501.89 
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respectively. With the increase of MT to ±1.5 Da, sequence coverage of IgG1 
fragment was higher i.e. corresponding sequence coverages were 64 % and 41 %. 
From 22 queries matched 20 (14 queries matched for IgG1 fragment and 7 queries 
for CTLA-4 V domain). For MT ± 2 Da the highest sequence coverage was achieved 
for IgG1 fragment (74 %). In the same time this was the maximal number of queries 
matched (16 matched). The sequence coverage of CTLA-4 V domain and matched 
queries remained the same, 41 % and 7 queries matched, respectively. 
Increasing the MT the total score (TS) of mixture increased. For MT ± 1, TS was 180; 
for MT ± 1.5, TS 186 and for MT ± 2, TS was 210. Individual protein reported scores 
were affected inversely:  Scores for IgG1fragment increased and those of CTLA-4 V 
domain decreased because if the number of matched mass values is constant the 
score in a peptide mass fingerprint will be inversely related to the mass tolerance as 
in the case of CTLA-4 V domain.  
In the Fig. 5.90 Mascot search results using MSDB sequence database with MT 
parameter set to ±1 Da are presented. Apart from protein summary report this 
database output contains probability Mowse score histogram and search parameters 
with specified modifications. As seen from Fig. 5.90 the Mixture 1 is the result with 
the highest score, lowest expectation value and with 18 queries matched. 
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 Fig. 5.90. Abatacept (CTLA4-Ig). Mascot search results, section. Mas tolerance ± 1 Da 
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From the histogram of score distribution (Fig. 5.90) is seen that scores grater then 64 
are significant. 
In Fig. 5.91 for mass tolerance parameter MT± 2 histogram of probability based 
mowse score with part of concise protein summary report is presented. 
 
  
 
 
 
The total score is the absolute probability that the observed match is a random event 
and it is reported as -10xlog10 (P), where P is the absolute probability.   
Expectation is the number of matches with equal or better scores that are expected 
to occur by chance alone. The lower the expectation value, the more significant the 
Fig. 5.91. Abatacept (CTLA4-Ig). Mascot search results, section. Mas tolerance ± 2 Da.  
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score. For a score that is exactly on the default significance threshold, (p<0.05), the 
expectation value is also 0.05. 
As indicated above, and documented in Fig. 5.91,  at the MT parameter set to ± 2 
total score for Mixture 1 and AAL96263 increased to 210 and 135 respectively, and 
for Q9BZK2 decreased at the value 47.   
In Figures 5.92 and 5.93, proton view reports for identified proteins are presented. 
 
 
 
 
 
In the AAL96263, amino acids sequence 1-109 correspond to the CH2 domain, and 
sequence 110-216 to C3H domain of immunoglobulin heavy chain fragment. This part 
of CTLA4-Ig (abatacept) molecule sequence is identified with high score and high 
Fig. 5.92. Abatacept (CTLA4-Ig). Macot Protein view report, section. AAL96263. 
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sequence coverage of 74 %. It corresponds to CTLA4-Ig (Fig. 1.9) sequence 142-
357.The rest of the abatacept sequence, 1-141, contains sequences of CTLA-4 
extracellular domain (1-124) and modified hinge region. 
In the Fig. 5.93 sequence of identified CTLA-4 part of molecule is presented. Amino 
acid sequences 1-38 and 84-93 are covered (total 41 % sequence coverage). If  
remaining non-covered amino acid sequences of CTLA-4 and modified hinge region 
are carefully observed, it is noted that from position 39 there are neither arginines (R) 
nor lysines (K) until positions 83, 93 and 128 respectively. Trypsin specifically 
cleaves peptide chains at the carboxyl side of the amino acids  K and R, therefore 
the resulting masses are to high, peptide sizes to large to efficiently diffuse out of gel, 
extracted and eventually measured by MALDI-TOF. Referring the in silico calculated 
masses, peptide masses of sequences 39-93 is 5877.71 Da;  34-83,  5350.57 Da,  
84-128, 5033.36; 39-83 is 4782.20; 94-132, 4355.04. A good mass range for trypsin 
is 1000-3500 Da260 
 
 
Fig. 5.93. Abatacept (CTLA4-Ig). Mascot Protein view report, section. 
Q9BZK2_HUMAN. 
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In summary results obtained from MASCOT/MSDB sequence data base specifically 
made possible identification of abatacept through identification, with high score, low 
expectation and relatively high sequence coverage of the mixture of its extracellular 
CTLA-4 domain and highly conserved CH2 and CH3 domains of human IgG.  
 
The list of peptide masses searched in sequence database MSDB was submitted to 
second sequence database, NCBInr, and the search results provided similar scores 
and sequence coverages as with the MSDB for both identified abatacept sequence 
fragments. 
The search results from the third database, SwissProt reported top scores for: 
IGHG1_HUMAN (Ig gamma-1 chain C region Homo sapiens MASS 36628 Da). 
 
- Top score 84. Expectation 8.4e-05. Queries matched 12 for MT ±1 
- Top score 90. Expectation 2e-05. Queries matched 14 for MT ±1.5 
- Top score 103. Expectation 1e-06.  14 queries matched, MT ± 2 
 
IGHG1_HUMAN (Ig gamma-1 chain C region Homo sapiens with molecular mass of  
36628 Da) is actually the complete sequence of human heavy chain constant region 
(Fig 100) and not of the heavy chain IgG1 fragment which contains 114 amino acids 
less (Protein view Fig. 5.92). Therefore SwissProt reported less sequence coverage 
(48 %).  
 
     1 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV  
    51 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP  
   101 KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS  
   151 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK  
   201 EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC  
   251 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW  
   301 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK  
 
 
 
Abatacept, however, contains only modified sequence of the human IgG1 Fc region, 
hinge, CH2 and CH3 domain (Fig. 1.9).  
 
When only the following MALDI peptide masses: 575.172; 587.162;  1144.202; 
1172.292; 1466.162; 1486.522; and  2042.822, which correspond to in silico 
calculated masses (Peptide mass Expassy) for CTLA-4 variable domain of abatacept 
Fig. 5.94. Amino acid sequence of human IgG1 heavy chain 
constant region. Mached sequences are highlighted. 
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are searched, top scores higher than 100, with low expectations values, were 
obtained. This significant protein identification results were reported from both MSDB 
and NCBInr sequence databases which provided same results with MT set to ± 1 
(Fig. 5.95) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The top score (117) protein gi 13128929 has the same sequence as 
Q9BZK2_HUMAN fragment of human CTLA-4 V domain region (Figures 5.91, 5.93 
and 5.95, Mol. mass 12575 Da).  
Two next two proteins reported are longer sequence variants of CTLA-4 protein.  gi 
184787 is complete amino acid sequence of human CTLA-4 (186 amino acids). As 
indicated in Fig 1 only extracellular domain of CTLA-4 is part of abatacept molecule. 
Additional 62 amino acids of full CTLA-4 sequence compose its transmemrane and 
intracellular domains.  
Interestingly, protein with top score obtained from SwissProt database is a variant of 
human CTLA-4 (precursor), with 223 amino acids therefore 99 amino acids more 
than CTLA-4 ECD. These additional amino acids compose signal peptide 1-35; 
Fig. 5.95 . Abatacept (CTLA4-Ig). Mascot search results, 
section. MSDB/NCBInr 
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transdermal domain 162-182, and 183-223 cytoplasmatic domain of human CTLA-4 
precursor. 
In this case score is 75, and there are only 6 queries matched. MALDI peptide mass 
1466.16 does not much in contrast to 7 matches seen in Figures 5.90 and 5.91. 
Peptide mass 1466.16 covers the sequence of CTLA-4 V region from position 1-14 
(M1 to R14). In the human CTLA-4 precursor, searched in SwissProt database this 
position is occupied with the rest of signal peptide therefore there is no matching. 
 
Measured peptide masses were submitted to the second search engine, Profound 
(Prowl).The proteins of the highest rank were human immunoglobulin G1 Fc fragment 
and human CTLA-4 V domain region. Rank +1, expectation 5.0×10-5, sequence 
coverage 57 %, pI 7 and molecular weight 25.40 kDa are reported for the first and  
Rank +2, expectation 2.8×10-3, sequence coverage 42 %, pI 4.8 and molecular 
weight 12.56 kDa for the latter, respectively. Mass tolerance parameter was set to 
±1.2 Da.  While human CTLA-4 V domain protein is identical with the protein 
Q9BZK2_HUMAN, reported from MASCOT search engine (NCBInr, MSDB and 
Swiss Prot), human immunoglobulin G1 Fc fragment reported in this sequence 
database is identical as well with the one reported from MASCOT, provided that the 
amino terminus here has been extended for additional 7 amino acids, which are part 
of FC fragment (3 amino acids from CH2 and 4 amino acids from hinge region 
respectively).   
In the Fig. 5.96 as illustration, amino acid sequences human immunoglobulin-G 
fragments reported in both search engines are presented.   
       
 
      1 PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG  
  51 VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP  
    101 IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW  
    151 ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA 
    201 LHNHYTQKSL SLSPGK 
 
     
      1 TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK 
  51 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS  
    101 NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP  
    151 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS 
    201 CSVMHEALHN HYTQKSLSLS PGK 
     
 
 
Fig. 5.96 Identified human IgG1 fragment :   
Up: MASCOT: Immunoglobulin gamma-1 heavy chain constant region (Fragment).- Homo sapiens 
Accession: AAL96263 Down: Profound: Immunoglobulin G1 FC fragment.-Homo sapiens. Accession: 
AAD38158 Amino acid difference is highlighted.  
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In Summary, peptide mass fingerprinting results as a suitable method for the 
identification of abatacept. It is also confirmed that this method is successful when 
amino and /or cDNA sequence of searched protein is known and present in 
sequence databases. To document the reproducibility, MALDI-TOF spectra, acquired 
from the abatacept excised from two different 2-DE gel spots are presented in Fig. 
5.97. 
 
 
 
 
 
 
 
 
 
 
Fig. 5.97. MALDI-TOF Analysis of abatacept (CTLA4-Ig). Spectra generated from 
different 2-DE spots. 
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6. Conclusions 
 
The main objective of this work was to evaluate the suitability of 1-DE, 2-DE and 
MALDI-TOF analysis for the demostration of identity, structural integrity and purity of 
therapeutically relevant rmAbs (trastuzumab, rituximab) and fusion protein, 
abatacept. In addition, in order to assess the stability indicating power of 2-DE, 
forced degradation studies of trastuzumab were undertaken. 
Experimental results confirmed that SDS-PAGE analysis can be used as a simple, 
fast and reliable method for the quality assessment of studied biological products. 
This technique enables the estimation of molecular weights and purity of biological 
medicinal products studied, however only limited information regarding the 
heterogeneity of these products could be obtained.  
Recombinant monoclonal antibodies trastuzumab and rituximab, under non-reducing 
SDS-PAGE migrated as single bands at ~150 kDa, while under reducing conditions 
two distinct molecular weight species, corresponding their light and heavy chains, 
migrated at ~23 and ~50 kDa respectively. Fusion protein abatacept migrated at 
~100 kDa under non-reducing conditions, while upon reduction of its disulfide 
bridges, single sharp band was observed at ~ 50 kDa. 
 SDS-PAGE deglycosilation experiments confirmed that the contribution of 
posttranslational glycosilation in abatacept molecular weight is considerably higher ( 
~15%) comparing to trastuzumab and rituximab (3-5%).  
Higher sensitivity of Silver staining over Coomassie staining, restricted linear dynamic 
range and problematic gel-to-gel reproducibility of band intensities, especially for 
silver staining were documented as well. In all cases, reducing SDS-PAGE delivered 
sharper bands comparing to non-reducing conditions.  
This study documented that in contrast to SDS-PAGE, 2-DE analysis delivered more 
comprehensive information regarding identity and structural integrity of studied 
medicinal products. Apart from the estimation of molecular weight and pI, additional 
information related to the charge heterogeneity and posttranslational modifications of 
studied substances has been obtained and on the basis of obtained results it was 
shown that  2-DE is suitable method for the monitoring of charge heterogeneity and 
isomorf patterns of recombinant monoclonal antibodies and fusion proteins. 
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2-DE analysis of rmAbs trastuzumab and rituximab using IPG strips 6-9 L and 3-11 
NL for the first dimension, demonstrated typical antibody glycoprotein complex spot 
pattern consisting on numerous poorly resolved trains of spots tending to spread as a 
bands, for both chains. On the other hand, acidic glycoprotein abatacept migrated as 
a single set of sloping spots with estimated pI ranging from 4.5-5.5.   
Experimentally estimated isoelectric points were in agreement with literature data 
and their theoretical pI values calculated from respective cDNA derived amino acid 
sequences in case of their deglycosilated forms.   
In all cases, an improved resolution was observed upon the reduction of sample 
amount. Optimized 2-DE electrophoresis conditions for deglycosilation experiments 
and subsequent MALDI-TOF MS analysis included IPG strips 3-11 NL (for rituximab 
and trastruzumab) and 4-7 L for abatacept. Linear 12. 5 % polyacrylamide gels (30.8 
%T and 2.6 % C)  were run and more sensitive silver staining procedure was applied  
for gel visualization. 
For the monitorization of trastuzumab, rituximab and abatacept N-deglycosilation 
SDS-PAGE and 2-DE were used. 1-DE experiments comparing native ande N-
deglycosilated samples proved the presence of N-linked glycan molecules and  
delivered straightforward information concerning deglycosilation efficiency. On the 
otherhand,  2-DE could be used only for deglycosilation monitorization of abatacept, 
while for trastuzumab and rituximab due to the small charge difference between their 
N-deglycosilated and glycosilated forms, results were equivocal.  
The contribution of N- linked sugars, terminal sialic acids and C-terminal lysine 
truncation in 2-DE spot pattern of trastuzumab, rituximab and abatacept, was studied 
using N-glycosilade F, sialidase and Caroxypeptidase B . O- glycosidase was used 
for the removal of abatacept O-linked glycans.   
No significant differences were observed in the 2-DE patterns of N-deglycosilated, 
desialynated, and Carboxypeptidase B treated rmAbs and native samples. These 
results were in accordance with published data: since in rmAbs molecules there is 
only one N-glycosilation site containing predominantly neutral oligosaccharides, the 
expected pI and MW differences after N-linked glycan release are very small to be 
unambiguously detected with 2-DE.  
On the other hand, enzymatic deglycosilation experiments of abatacept resulted in 
completely different behavior comparing to rmAbs. After PNGase, silaidase and O-
glicosidase treatment significant changes in molecular weight and isoelectric point 
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with additional reduction in the complexity of spot pattern were observed.  Apart from 
neutral N-linked glycans, 2-DE experiments confirmed the significant presence of 
acidic O-linked sialo-glycans. 
Forced degradation study of trastuzumab was used for the assessment of stability 
indicating power of SDS-PAGE and 2-DE. Experimental data demonstrated stability 
indicating capability for both methods, provided  that for 2-DE results were less 
straightforward. 
Peptide mass fingerprinting (PMF) analysis was used for the identification of 
trastuzumab, rituximab and abatacept.  
PMF analysis resulted as a fast and reliable method for the identification of 
trastuzumab. Confirmation of humanized origin and allotype marker (...359EEM361...) of 
this antibody was possible, as well. For the identification of trastuzumab heavy chain, 
list of entered peptides matched with highest scores with the mixture of two peptides: 
gi 226787, immunoglobulin gamma 1, which corresponds to trastuzumab heavy 
chain residues 228-450, Fc fragment (sequence coverage 67 %) and gi 442924, 
Antigen-binding domains of humanized Anti-P185-Her2 Antibody 4d5- trastuzumab, 
which corresponds to trastuzumab heavy chain residues 1-223, trastuzumab Fab 
(sequence coverage 55 %).  
For trastuzumab light chain, the highest rank protein reported after the entering of the 
list of peptide masses was gi28948772 (trastuzumab light chain, sequence coverage 
81 %). Since the sequence coverage included amino acid residues, parts of light 
chain CDR regions and FR3 which are imported from the murine light chain 
sequence into the human sequence, this method is capable to specifically 
discriminate the humanized antibody from the antibodies of other origin.  
The identification of the light chain of chimeric antibody rituximab was possible using 
PMF analysis. The highest rank protein reported after the entering of the list of 
peptide masses was gi146387638 (Rituximab Fab fragment, light chain entire 
sequence, residues 1-213) with the sequence coverage 45 %.  Concerning rituximab 
heavy chain identification, list of entered peptide masses into MASCOT/NCBInr 
database generated top score values for gi 20664303 (Fc fragment of rituximab), with 
sequence coverage 57 % and other IgG1 Fc fragments.  
With PMF analysis it was possible identification of both fusion partners of fusion 
protein abatacept, CTLA4-Ig. List of entered abatacept masses matched with high 
scores with two components of CTLA4-Ig (abatacept): AAL96263 (Fragment of 
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human immunoglobulin gamma-1 heavy chain constant region IgG1) and 
9BZK2_HUMAN (Fragment of human CTLA-4 V domain region).  Sequence 
coverage for human IgG1 part of molecule was 74 % while for variable domain of 
CTLA4 41 %. 
Presented results suggest that PMF analysis is a suitable method for the fast identity 
confirmation of recombinant monoclonal antibodies and antibody related substances 
such are fusion proteins. In our opinion, apart from its use for in-process control 
purposes, the simplicity, speed and specificity of this method make it suitable for 
regulatory environment as well.  
Other advantage of this method is that previous separation of peptides with HPLC or 
CE like in peptide mapping is not required, and rapid demonstration of molecular 
identity of the product before committing it to protein sequence analysis is possible.  
Furthermore, protein samples subjected to MALDI-TOF analysis are previously 
separated with 2-DE, therefore sample complexity is greatly reduced. On the other 
hand, additional sample information can be obtained during the 2-DE analysis i.e. 
molecular weight, charge heterogeneity, information about the oligosaccharide 
content and posttranslational modifications, before the in gel tryptic digestion.  
Since 2-DE, MALDI-TOF MS and peptide mass fingerprinting analysis have already 
matured, necessary equipment is commercially available and no special personnel 
requirements are needed, this method might be used as routine technique in quality 
control laboratories.  
In addition, PMF analysis might enable the discrimination of rmAbs of different origin 
(murine, chimeric, humanized and human), and the identification of structurally 
related antibody fusion proteins could be possible, as well. This could be of great 
importance for in process control during the production of different products in same 
production platform. 
As seen above, for all studied substances the basic requirement for the success of 
peptide mass fingerprinting strategy is that the searched peptide sequence must be 
present at opened access databases. For instance abatacept was identified as a 
mixture of its constituent fragments and not as an entire sequence. The same holds 
for rituximab and trastuzumab heavy chains. In given databases Fv, Fab, and Fc 
fragments are stored and not entire sequences of their heavy chains.  
Other tasks to be fulfilled in the future remain more detailed optimization of 2-DE-
MALDI-TOF MS with subsequent PMF analysis for identification purposes, i.e. in 
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order to increase the sequence coverage for the PMF analysis of studied biological 
medicinal products, the application of enzymes of different specificity, i.e. 
chymotrypsin, should be studied and a suitable method for the full characterization of 
abatacept glycoforms should be development as well. 
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8. Attachment 
 
Table 8.13. Reagents used for sample preparation 
       Concentration  Amount 
Solution A1   Rehydration Stock solution  
   Urea     8M  48.05 g 
   Thiourea    2M  15.22 g 
   Chaps     4 %  4.00 g 
   TritonX100    0.5 %  0.50 ml 
   Bromphenol blue (Sol 1 %)  0.005 % 0.50 ml 
   Milli-Q water     ad 100.00 ml  
    1ml Aliquots stored at -20°C 
 
Solution A2  Prepared rehydration solution  
   Dithiothreitol     0.5 %  5 mg 
   IPG Buffer    0.5 %  5 μl 
   Rehydration solution (freshly prepared)   1.00 ml 
 
Table 8.14. Reagents used for preparation of the gels 
       Concentration  Amount 
Solution B1  Acrylamide Stock Solution (%T 30.8 %, % C 2.6 %) 
   Acrylamide 2X    30 %  150 g 
   N,N’-Methylene bisacrylamide  0.8 %  4.00 g 
   Milli-Q water     ad 500.0 ml 
   Stored at 4°C 
 
Solution B2  Resolving gel Buffer  
   Tris(hydroxymethyl)aminomethane  1.5 M  90.80 g 
   Sodium dodecyl sulfate   0.4 %  2.00 g 
   6 M Hydrochloric acid     pH 8.8 
   Milli-Q water      ad 500.00 ml 
 
Solution B3  Stacking gel Buffer 
   Tris(hydroxymethyl)aminomethane  0.5 M  6.06 g 
   Sodium dodecyl sulfate   0.4 %  0.40 g 
   6 M Hydrochloric acid     pH 6.8 
   Milli-Q water      ad 100.00 ml 
   Solutions B2 and B3 stored at room temperature. 
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Solution B4  Ammonium persulfate 10 % 
   Ammonium persulfate   10 %  5.0 g 
   Milli-Q water      ad 50.0 ml 
   1 ml Aliquots stored at -20°C     
 
Table 8.15. Reagents used for 1-D and 2-D electrophoresis experiments   
       Concentration   Amount  
Solution C1  Equilibration Buffer 
   Tris(hydroxymethyl)aminomethane  0.05 M  4.84 g 
   Urea     6M  288.28 g 
   Glycerol    30 %  240.00 ml 
   Sodium dodecyl sulfate   2 %  16.00 
   Bromphenol blue (Sol 1 %)  0.005 % 4.00 ml 
   Milli-Q water     ad 800.00 ml 
   20 ml Aliquots stored at -20°C 
 
Solution C1a  Equilibration Buffer with DTT 
   Dithiothreitol    1 %  100 mg 
   Equilibration Buffer    ad 10 ml  
   Freshly prepared 
Solution C1b  Equilibration Buffer with IAM 
   Iodoacetamide    2.5 %  250 mg 
   Equilibration Buffer    ad 10 ml  
   Freshly prepared 
 
Solution C2  Agarose sealing solution 
   Agarose    0.5 %  100 mg 
   Diluted cathode buffer    ad 20 ml 
 
Solution C3  10 X Anode Buffer 
   Tris(hydroxymethyl)aminomethane  0.25 M  30.2 g 
   Sodium dodecyl sulfate   1 %  10.0 g 
   Milli-Q water     ad  1000.0 ml 
 
Solution C3a  Diluted Anode Buffer 
   10 X Anode Buffer     100.0 ml 
   Milli-Q water     ad  1000.0 ml 
 
Solution C4  10 X Cathode Buffer 
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   Tris(hydroxymethyl)aminomethane  0.25 M  30.2 g 
   Sodium dodecyl sulfate   1 %  10.0 g 
   Glycine     14.42 % 144.2 g 
   Milli-Q water     ad  1000.0 ml 
 
Solution C4a  Diluted Cathode Buffer 
   10 X Cathode Buffer     100.0 ml 
   Milli-Q water     ad  1000.0 ml 
 
Solution C5  Laemmli Buffer  
   Tris(hydroxymethyl)aminomethane  0.25 M  3.03 g 
   Glycerol    20 %  20.0 ml 
   Sodium dodecyl sulfate   8 %  8.0 
   Bromphenol blue (Sol 1 %)  0.02 %  20 μl 
   Milli-Q water     ad 100.00 ml 
   1 ml Aliquots stored at -20°C 
   Prior to use 6.2 mg/ml DTT are added. 
 
Table 8.16. Reagents used for silver staining procedure 
       Concentration  Amount 
Solution D1  Fixing reagent 
   Acetic acid conc. 99%   10 %  100.0 ml 
   Methanol    40 %  400.0 ml 
   Milli-Q water     ad 1000.0 ml 
Solution D2  Wash-solution    
   Ethanol conc.    30%  300.0 ml 
   Milli-Q water     ad 1000.0 ml 
 
Solution D3  Thiosulfate reagent 
   Sodium thiosulfate   0.02 % 200.0 mg 
   Milli-Q water     ad 1000.0 ml 
Solution D4  Silver nitrate reagent   
   Silver nitrate    0.2 %  2.0 g 
   Formaldehyde (37 %)   0.002  200 μl 
   Milli-Q water     ad 1000.0 ml 
 
Solution D5  Developer reagent  
   Sodium carbonate   3 %  30.0 g 
   Formaldehyde (37 %)   0.05 %  500 μl 
   Sodium thiosulfate   0.0005 % 5 mg 
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   Milli-Q water     ad 1000.0 ml 
 
Solution D6  Glycine stop reagent 
   Glycine     0.5 %  5.0 g 
   Milli-Q water     ad 1000.0 ml 
 
Table 8.17. Reagents used for Coomassie staining procedure 
       Concentration  Amount 
Solution E1  Fixing reagent 
   Methanol    45 %  450.0 ml 
   Acetic acid conc. 99 %   5 %  50.0 ml 
   Milli-Q water     ad 1000.0 ml 
 
Solution E2  Coomassie staining reagent 
   Coomassie R250   0.025 % 0.25 g 
   Methanol    40 %  400.0 ml 
   Acetic acid conc. 99 %   7 %  70.0 ml 
   Milli-Q water     ad 1000.0 ml 
 
Solution E3  Destaining reagent I 
   Methanol    40 %  400.0 ml 
   Acetic acid conc. 99 %   7 %  70.0 ml 
   Milli-Q water     ad 1000.0 ml 
 
Solution E4  Destaining reagent II 
   Methanol    5 %  50.0 ml 
   Acetic acid conc. 99 %   7 %  70.0 ml 
   Milli-Q water     ad 1000.0 ml 
 
Table 8.18. Reagents used for gel tryptic digestion procedure and MALDI-TOF 
sample preparation and presentation 
       Concentration  Amount 
Solution F1  Potassium ferricianyde solution 
   Potassium ferricianyde   30 mM  0.494 g 
   Milli-Q water     ad 50.0 ml 
 
Solution F2  Sodium thiosulfate solution 
   Potassium ferricianyde   100 mM 0.791 g 
   Milli-Q water     ad 50.0 ml 
Solution F3  Ammonium bicarbonate Buffer 
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   Ammonium bicarbonate   50 mM  0.395 g 
   Ammonium hydroxide 10 %    pH 8.5 
   Milli-Q water     ad 100.0 ml 
 
Solution F4  Digestion Buffer, 
   Trypsine (modified, sequence grade) 12.5 ng/μl 25 μg  
   Hydrochloric acid 1 mM    ad 2.0 ml 
   Aliquots 100 μl after speed drying were stored at -20°C.  
   Just prior to use Aliquots were reconstituted with 100 μl    
   Ammonium bicarbonate Buffer pH 8.5. 
 
Solution F5  Formic acid solution 
   Formic acid    5 %  50.0 μl 
   Milli-Q water     ad 950.0 μl 
 
Solution F6  Trifluoroacetic acid solution 
   Trifluoroacetic acid solution, 1 % 0.1 %   10.0 μl 
   Milli-Q water     ad 100.0 μl 
 
Solution F7  Saturated matrix solution 
   α-Cyano- 4-hydroxycinnamic acid  0.8 %  8.0 μg 
   Solution F6: Acetonitrile (70:30 v/v)  ad 1.0 ml 
 
Table 8.19. Reagents used for deglycosilation experiments 
       Concentration  Amount 
Solution G1  Phosphate Buffer  
   Sodium phosphate monobasic, 
    monohydrate    25 mM  0.345 g 
   Sodium hydroxide 2M     pH 7.5 
   Milli-Q      ad 100 ml 
 
Solution G2  CHAPS in 0.1 % SDS 
   CHAPS     10 %  10.0 g 
   Sodium dodecyl sulfate 0.1 %    0.1 g 
   Milli-Q water      ad 100.0 ml 
 
Solution G3  0.5 % Triton X 100 
   Triton X 100    0.5 %  0.5 ml 
   Sodium hydroxyde      pH 7.2 
   Milli-Q water      ad 100.0ml 
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